Document:

EX-4.3

 Exhibit 4.3 

SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT 

THIS SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT (this “Agreement”) is entered into on October 28, 2020 (the
“Effective Date”), by and among: 
  

	1.	 LianBio, an exempted company organized under the Laws of the Cayman Islands (the “Company”);

  

	2.	 each Group Company listed on Schedule I hereto; 

 

	3.	 each Ordinary Shareholder listed on Schedule II hereto; and 

 

	4.	 each Series Seed Investor and Series A Investor listed on Schedule III hereto (collectively, the
“Investors”, and each an “Investor”). 

 Each of the parties to this Agreement is
referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used herein without definition shall have the meanings set forth in the Subscription Agreement (as defined below).

 RECITALS 
  

	A.	 The Series A Investors have agreed to subscribe for and purchase from the Company, and the Company has agreed
to issue and sell to such Series A Investors, certain Series A Preferred Shares (as defined below) of the Company on the terms and conditions set forth in the Series A Preferred Share Subscription Agreement, dated October 29, 2020, by and among
the Company and such Investors (the “Subscription Agreement”). 

  

	B.	 The Subscription Agreement provides that the execution and delivery of this Agreement shall be a condition
precedent to the consummation of the Initial Closing (as defined in the Subscription Agreement). 

  

	C.	 The Parties desire to enter into this Agreement to amend and restate that certain Amended and Restated
Shareholders Agreement, dated as of October 16, 2019, by and among the Company, the Ordinary Shareholders and the Series Seed Investors (the “Prior Shareholders Agreement”) in its entirety and to make the respective
representations, warranties, covenants and agreements set forth herein on the terms and conditions set forth herein. 

  

	D.	 For the purpose of this Agreement and the Memorandum and Articles (as defined below) of the Company, prior to
the Additional Closing (as defined in the Subscription Agreement), the term “Series A Preferred Shares” shall not include the Series A Preferred Shares issued pursuant to the Subscription Agreement to FIIF (as defined below), and FIIF
shall only become an Investor and may exercise the rights granted to FIIF after the consummation of the Additional Closing. 

WITNESSETH 
 NOW,
THEREFORE, in consideration of the foregoing, the mutual promises hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound hereto hereby
agree as follows: 
  

	1.	 Definitions. 

1.1 Definitions. The following terms shall have the meanings ascribed to them below: 

 “Accounting Standards” means the generally accepted accounting principles
in the United States as in effect from time to time, applied on a consistent basis. 
 “Action” means any charge, claim,
action, complaint, petition, investigation, appeal, suit, litigation, grievance, inquiry or other proceeding, whether administrative, civil, regulatory or criminal, whether at law or in equity, or otherwise under any applicable Law, and whether or
not before any mediator, arbitrator or Governmental Authority. 
 “Affiliate” means, with respect to a Person, any other
Person that, directly or indirectly, Controls, is Controlled by or is under common Control with such Person, including, in the case of any Party, (a) any direct or indirect shareholder or member of such Party, (b) any of such
shareholder’s or member’s or the Party’s general partners or limited partners, (c) the fund manager or investment advisor managing or advising such shareholder or Party (and general partners, limited partners and officers
thereof) and other funds managed or advised by such fund manager or investment advisor, (d) trusts Controlled by or for the benefit of any such Party referred to in (a), (b) or (c), and (e) any fund or holding company formed for investment
purposes that is promoted, sponsored, managed, advised or serviced by the Party or any of their affiliates. 
 “Anti-Corruption
Laws” means all anti-corruption and anti-bribery laws and regulations, including, without limitation, the applicable laws and regulations of the PRC, the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended,
and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. 

“Applicable Securities Laws” means (a) with respect to any offering of securities in the United States, or any other act
or omission within that jurisdiction, the securities Laws of the United States, including the Exchange Act and the Securities Act, and any applicable Law of any state of the United States, and (b) with respect to any offering of securities in
any jurisdiction other than the United States, or any related act or omission in that jurisdiction, the applicable Laws of that jurisdiction. 

“Associate” means, with respect to any Person, (a) a corporation or organization (other than the Group Companies) of
which such Person is a director, officer or partner or is, directly or indirectly, the record or beneficial owner of ten percent (10%) or more of any class of Equity Securities of such corporation or organization, (b) any trust or other estate
in which such Person has a substantial beneficial interest or as to which such Person serves as trustee or in a similar capacity, or (c) any parent, sibling, child or spouse of such Person. 

“Auditor” means the Person for the time being performing the duties of auditor of the Company (if any), who shall be one of
the “Big Four” international accounting firms or such other reputable auditor as approved by the Board in accordance with Section 12.2 hereof. 

“Board” or “Board of Directors” means the board of directors of the Company. 

“Business Day” means any day that is not a Saturday, Sunday, legal holiday or other day on which commercial banks are
required or authorized by Law to be closed in the PRC, Hong Kong, New York, or the Cayman Islands. 
 “Casdin” means Casdin
Private Growth Equity Fund, L.P. 
 “CFC” means a controlled foreign corporation as defined in the Code. 

“Charter Documents” means, with respect to a particular legal entity, the articles of association, certificate of
incorporation, formation or registration (including, if applicable, certificates of change of name), memorandum of association, articles of association, bylaws, articles of organization, limited liability company agreement, trust deed, trust
instrument, operating agreement, joint venture agreement, business license, or similar or other constitutive, governing, or charter documents, or equivalent documents, of such entity. 

  
 2 

 “Code” means the United States Internal Revenue Code of 1986, as amended.

 “Commission” means (a) with respect to any offering of securities in the United States, the Securities and Exchange
Commission of the United States or any other federal agency at the time administering the Securities Act, and (b) with respect to any offering of securities in a jurisdiction other than the United States, the regulatory body of the jurisdiction
with authority to supervise and regulate the offering or sale of securities in that jurisdiction. 
 “Confidential
Information” means all terms and conditions of the Transaction Documents, and all oral, written or tangible technical, financial, business or other information of whatever kind that is confidential, proprietary or not generally available
outside of the Company and its Affiliates, including, without limitation, (a) patents and unpublished patent applications, (b) trade secrets and know-how, (c) proprietary and confidential
information, ideas, gene sequences, cell lines, samples, media, chemical compounds, assays, biological materials, techniques, sketches, drawings, works of authorship, models, inventions, know-how, processes,
apparatuses, equipment, algorithms, software programs, software source documents, and formulae related to the current, future, and proposed products of the Company and its Affiliates (such as information concerning research, experimental work,
development, design details and specifications, engineering, financial information, procurement requirements, purchasing, manufacturing, customer lists, investors, employees, business and contractual relationships, business forecasts, sales and
merchandising, marketing plans and information regarding third parties). Confidential Information shall not include any information or knowledge which: (i) is in the public domain other than by a recipient’s breach of this Agreement;
(ii) is disclosed to a recipient lawfully by a third party who is not under any obligation of confidentiality with respect to such information or knowledge, either by Contract or by Law; or (iii) is now or hereafter becomes generally known
in the industry of the Company other than by a recipient’s breach of this Agreement. 
 “Contract” means a contract,
agreement, indenture, note, bond, loan, instrument, lease, mortgage, franchise, license, commitment, purchase order, and other legally binding arrangement, whether written or oral. 

“Control” of a given Person means the power or authority, whether exercised or not, to direct the business, management and
policies of such Person, directly or indirectly, whether through the ownership of voting securities, by Contract or otherwise; provided, that such power or authority shall conclusively be presumed to exist upon possession of beneficial
ownership or power to direct the vote of more than fifty percent (50%) of the votes entitled to be cast at a meeting of the members or shareholders of such Person or power to control the composition of a majority of the board of directors of such
Person. The terms “Controlled” and “Controlling” have meanings correlative to the foregoing. 

“Director” means a director serving on the Board. 

“Equity Plan” means any equity incentive, purchase or participation plan, employee stock option plan or similar plan of the
Company approved by the Board in accordance with Section 12.2(g). 
 “Equity Securities” means,
with respect to any Person that is a legal entity, any and all shares of capital stock, membership interests, units, profits interests, ownership interests, equity interests, registered capital, and other equity securities of such Person, and any
right, warrant, option, call, commitment, conversion privilege, preemptive right or other right to acquire any of the foregoing, or security convertible into, exchangeable or exercisable for any of the foregoing. 

  
 3 

 “Exchange Act” means the United States Securities Exchange Act of 1934, as
amended. 
 “Farallon” means Zone II Healthcare Holdings, LLC. 

“Form F-3” means Form F-3 promulgated by the
Commission under the Securities Act or any successor form or substantially similar form then in effect. 
 “Form S-3” means Form S-3 promulgated by the Commission under the Securities Act or any successor form or substantially similar form then in effect. 

“FIIF” means Future Industry Investment II (Cayman) Co., Limited. 

“Government Official” means any Person employed by or acting on behalf of a government, government-controlled entity or
public international organization; any political party, party official or candidate; any Person who holds or performs the duties of an appointment, office or position created by custom or convention; and any Person who holds himself out to be the
authorized intermediary of any of the foregoing. 
 “Governmental Authority” means any government of any nation,
federation, province, state or locality or any other political subdivision thereof, any entity, authority or body exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including any
governmental authority, agency, department, board, commission or instrumentality of the PRC or any other country, or any political subdivision thereof, any court, tribunal or arbitrator, and any self-regulatory organization. 

“Governmental Order” means any applicable order, ruling, decision, verdict, decree, writ, subpoena, mandate, precept,
command, directive, consent, approval, award, judgment, injunction or other similar determination or finding by, before or under the supervision of any Governmental Authority. 

“Group Company” means each of the Company and any direct or indirect Subsidiary of the Company, whether established prior to
or after the Effective Date, and “Group” refers to all of the Group Companies collectively. 
 “Holders”
means the Investors and Key Holders, and their Permitted Transferees that become parties to this Agreement from time to time. 

“Hong Kong” means the Hong Kong Special Administrative Region of the People’s Republic of China. 

“Indebtedness” of any Person means, without duplication, each of the following of such Person: (a) all indebtedness for
borrowed money, (b) all obligations issued, undertaken or assumed as the deferred purchase price of property or services (other than trade payables incurred in the ordinary course of business), (c) all reimbursement or payment obligations with
respect to letters of credit, surety bonds and other similar instruments, (d) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced that are incurred in connection with the acquisition
of properties, assets or businesses, (e) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the
proceeds of such indebtedness, (f) all obligations that are capitalized (including capitalized lease obligations), (g) all obligations to purchase, redeem, retire, defease or otherwise acquire for value any Equity Securities of such Person,
(h) all obligations in respect of any interest rate swap, hedge or cap agreement, and (i) all guarantees issued in respect of any indebtedness of another Person where such indebtedness is of the nature described in clauses (a) through
(h) above, but only to the extent of the indebtedness guaranteed. 

  
 4 

 “Initiating Holders” means, with respect to a request duly made under
Section 2.1 or Section 2.2 to Register any Registrable Securities, the Holders initiating such request. 

“Intellectual Property” means any and all (a) patents, patent rights and applications therefor and reissues,
reexaminations, continuations, continuations-in-part, divisions, and patent term extensions thereof, (b) inventions (whether patentable or not), discoveries,
improvements, concepts, innovations and industrial models, (c) registered and unregistered copyrights, copyright registrations and applications, mask works and registrations and applications therefor, author’s rights and works of
authorship (including software, computer programs, source code, object code and executable code, firmware, development tools, files, records and data, and related documentation), (d) technical information,
know-how, trade secrets, drawings, designs, design protocols, specifications, proprietary data, customer lists, databases, proprietary processes, technology, formulae, and algorithms and other intellectual
property, (e) trade names, trade dress, trademarks, domain names, service marks, logos, business names, and registrations and applications therefor, and (f) the goodwill symbolized, associated with or represented by the foregoing. 

“IPO” means the first firm underwritten registered public offering by the Company of its Ordinary Shares pursuant to a
registration statement that is filed with and declared effective by either the Securities and Exchange Commission of the United States under the Securities Act or another governmental authority for a public offering in a jurisdiction other than the
United States. 
 “Key Holders” means Perceptive Life Sciences Master Fund, Ltd., LEV LB Holdings, LP, Perceptive Xontogeny
Venture Fund, LP and BridgeBio Pharma LLC. 
 “Law” or “Laws” means any and all provisions of any
applicable constitution, treaty, statute, law, regulation, ordinance, code, rule, or rule of common law, any governmental approval, concession, grant, franchise, license, agreement, directive, requirement, or other governmental restriction or any
similar form of decision of, or determination by, or any interpretation or administration of any of the foregoing by, any Governmental Authority, in each case as amended, and any and all applicable Governmental Orders. 

“Lien” means any claim, charge, easement, encumbrance, lease, covenant, security interest, lien, option, pledge, or
restriction (whether on voting, sale, transfer, disposition or otherwise), whether imposed by Contract, Law or equity. 

“Memorandum and Articles” means the Second Amended and Restated Memorandum of Association of the Company and the Articles of
Association of the Company, as each may be amended or restated from time to time. 
 “Majority Ordinary Shareholders” means
the holders of more than fifty percent (50%) of the voting power of the then outstanding Ordinary Shares. 
 “Ordinary Share
Equivalents” means any Equity Security which is by its terms convertible into or exchangeable or exercisable for Ordinary Shares or other share capital of the Company, including without limitation, the Preferred Shares. 

“Ordinary Shares” means the Company’s ordinary shares, par value US$0.0001 per share. 

“Perceptive Funds Entities” collectively, means Perceptive Life Sciences Master Fund, Ltd., LEV LB Holdings, LP, Perceptive
Xontogeny Venture Fund, LP and C2 Life Sciences LLC. 
 “Person” means any individual, corporation, partnership, limited
partnership, proprietorship, association, limited liability company, firm, trust, estate or other enterprise or entity. 

“PFIC” means a passive foreign investment company as defined in the Code. 

  
 5 

 “Pfizer” means Pfizer Inc. 

“PRC” means the People’s Republic of China, but solely for the purposes of this Agreement, excluding Hong Kong, Macau
and Taiwan. 
 “PRC Company” means Shanghai LianBio Development Co., Ltd.
(上海联拓生物科技有限公司), a limited liability company incorporated under the Laws of PRC. 

“Preferred Shares” means the Series Seed Preferred Shares and the Series A Preferred Shares. 

“Preferred Shareholders” means the holders of the Preferred Shares. 

“Qualified IPO” shall have the meaning set forth in the Memorandum and Articles. 

“RA Capital” means, collectively, RA Capital Healthcare Fund, LP, RA Capital Nexus Fund II, LP and Blackwell Partners
LLC—Series A. 
 “Recapitalization” means any reorganization, restructuring, reclassification or other similar event
by the Company of its capital structure. 
 “Registrable Securities” means (a) with respect to the demand registration
as provided in Section 2 and the piggyback registrations as provided in Section 3, the Ordinary Shares issued or issuable upon conversion of the Preferred Shares, (b) with respect to the
demand registration as provided in Section 2 and the piggyback registrations as provided in Section 3, any Ordinary Shares issued or issuable upon conversion and/or exercise of any other securities
of the Company, (c) with respect to the demand registration as provided in Section 2 and the piggyback registrations as provided in Section 3, any Ordinary Shares issued or issuable as a
dividend or other distribution with respect to, in exchange for, or in replacement of, the shares referenced in (a) herein, and (d) with respect to the piggyback registrations as provided in Section 3 hereof only,
the issued Ordinary Shares; excluding in all cases, however, any of the foregoing sold by a Person in a transaction other than an assignment pursuant to Section 14.3 and any Registrable Securities which are sold in a
registered public offering under the Securities Act or analogous statute of another jurisdiction, or sold pursuant to Rule 144 promulgated under the Securities Act or analogous rule of another jurisdiction. 

“Registration” means a registration effected by preparing and filing a Registration Statement and the declaration or ordering
of the effectiveness of that Registration Statement; and the terms “Register” and “Registered” have meanings concomitant with the foregoing. 

“Registration Statement” means a registration statement prepared on Form F-1, F-3, S-1, or S-3 under the Securities Act, or on any comparable form in connection with registration in a jurisdiction other than the
US. 
 “Related Party” means any Affiliate, officer, director or shareholder of any Group Company and any Affiliate or
Associate of any of the foregoing. 
 “Requisite Holders” means the holders of a majority of the voting power of the then
total issued and outstanding Shares of the Company that are held by the Preferred Shareholders and the Key Holders (voting together as a single class and not as separate series, calculated on an as-converted
basis). 
 “Requisite Preferred Holders” means both of the Series A Majority Holders and Series Seed Majority Holders, each
voting as a separate class. 
 “Securities Act” means the United States Securities Act of 1933, as amended. 

  
 6 

 “Series A Majority Holders” means the holders of at least sixty percent
(60%) of the voting power of the then outstanding Series A Preferred Shares (calculated on as-converted basis). 

“Series A Preferred Shares” means the Series A preferred shares of the Company, par value US$0.0001 per share, with the
rights and privileges as set forth in the Memorandum and Articles. 
 “Series Seed Majority Holders” means the
holders of at least fifty percent (50%) of the voting power of the then outstanding Series Seed Preferred Shares (calculated on as-converted basis). 

“Series Seed Preferred Shares” means the Series Seed preferred shares of the Company, par value US$0.0001 per share, with the
rights and privileges as set forth in the Memorandum and Articles. 
 “Shareholder” means a holder of any Shares. 

“Shares” means the Ordinary Shares and the Preferred Shares. 

“Sphera” means Sphera Global Healthcare Master Fund. 

“Subsidiary” means, with respect to any given Person, any other Person that is Controlled directly or indirectly by such
given Person. 
 “Tax” means (a) in the PRC: (i) any national, provincial, municipal, or local taxes, charges,
fees, levies, or other assessments, including, without limitation, all net income (including enterprise income tax and individual income withholding tax), turnover (including value-added tax, business tax, and consumption tax), resource (including
urban and township land use tax), special purpose (including land value-added tax, urban maintenance and construction tax, and additional education fees), property (including urban real estate tax and land use fees), documentation (including stamp
duty and deed tax), filing, recording, social insurance (including pension, medical, unemployment, housing, and other social insurance withholding), tariffs (including import duty and import value-added tax), and estimated and provisional taxes,
charges, fees, levies, or other assessments of any kind whatsoever, (ii) all interest, penalties (administrative, civil or criminal), or additional amounts imposed by any Governmental Authority in connection with any item described in clause
(a) above, and (iii) any form of transferee liability imposed by any Governmental Authority in connection with any item described in clauses (i) and (ii) above, and (b) in any jurisdiction other than the PRC: all similar
liabilities as described in clause (a)(i), (a)(ii) and (a)(iii) above. 
 “Transaction Documents” has the meaning set forth
in the Subscription Agreement. 
 “T. Rowe” means, collectively, T. Rowe Price Health Sciences Fund, Inc. and T. Rowe Price
Health Sciences Portfolio. 
 “Tybourne” means Aquila Investments XII. 

“US” means the United States of America. 

“Venrock” means, collectively, Venrock Healthcare Capital Partners III, L.P., VHCP
Co-Investment Holdings III, LLC and Venrock Healthcare Capital Partners EG, L.P. 

“Vida” means, collectively, Vida Ventures II, LLC and Vida Ventures II-A, LLC. 

“Viking” means Viking Global Opportunities Illiquid Investments Sub-Master LP. 

“Wellington” means Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 

  
 7 

 1.2 Other Defined Terms. The following terms shall have the meanings defined for such
terms in the Sections set forth below: 
  

			
	Acting Imporperly	  	Section 13.1(b)
	Agreement	  	Preamble
	Anti-Corruption Policies	  	Section 13.1(a)(i)
	Arbitration Notice	  	Section 14.5(b)
	Bridge	  	Section 11.1(a)
	Bridge Director	  	Section 11.1(a)
	Claimant	  	Section 14.5(d)
	Company	  	Preamble
	Company Representatives	  	Section 13.1(b)
	Co-Sale Notice	  	Section 9.4(a)
	Co-Sale Right	  	Section 9.4(a)
	C-Suite Executives	  	Section 13.9(a)
	Disclosing Party	  	Section 13.8(a)
	Dispute	  	Section 14.5(a)
	Drag-Along Transaction	  	Section 10.1
	Drag-along Selling Shareholder	  	Section 10.1
	Effective Date	  	Preamble
	Exempt Registrations	  	Section 3.5
	HKIAC	  	Section 14.5(c)
	Information Rights	  	Section 8.1(e)
	Inspection Rights	  	Section 8.2
	Investor or Investors	  	Preamble
	New Securities	  	Section 7.3
	Non-soliciting Party	  	Section 13.7
	Observers	  	Section 11.4(c)
	Offered Shares	  	Section 9.2
	Option Period	  	Section 9.3(a)
	Ordinary Director or Ordinary Directors	  	Section 11.1(a)
	Ordinary Shareholders	  	Schedule II
	Participating Investor	  	Section 9.3(a)
	Participating Investor Notice	  	Section 9.3(a)
	Partcipating Rights Holders	  	Section 7.4(a)
	Participation Notice	  	Section 7.4(a)
	Participation Period	  	Section 7.4(a)
	Party or Parties	  	Preamble
	Preemptive Right	  	Section 7.1
	Prior Shareholders Agreement	  	Recital
	Pro Rata Share	  	Section 7.2
	Proposed Transferee	  	Section 9.2
	QEF Election	  	Section 13.2(a)
	RA Capital Observer	  	Section 11.4(b)
	Respondent	  	Section 14.5(d)
	Rights Holder	  	Section 7.1
	Restriction Period	  	Section 12.1(l)
	Series A Investors	  	Schedule III Part B
	Series Seed Director or Series Seed Directors	  	Section 11.1(a)
	Series Seed Investors	  	Schedule III Part A
	Shareholders Agreement	  	Preamble
	Subscription Agreement	  	Preamble
	Transfer	  	Section 9.1
	Transfer Notice	  	Section 9.2
	Transferee	  	Section 9.1
	Transferor	  	Section 9.1
	Venrock Observer	  	Section 11.4(b)
	Violation	  	Section 5.1(a)

  
 8 

 1.3 Interpretation. For all purposes of this Agreement, except as otherwise expressly
herein provided, (a) the terms defined in this Section 1 shall have the meanings assigned to them in this Section 1 and include the plural as well as the singular, (b) all accounting
terms not otherwise defined herein have the meanings assigned under the Accounting Standards, (c) all references in this Agreement to designated “Sections” and other subdivisions are to the designated Sections and other subdivisions
of the body of this Agreement, (d) pronouns of either gender or neuter shall include, as appropriate, the other pronoun forms, (e) the words “herein,” “hereof” and “hereunder” and other words of similar import
refer to this Agreement as a whole and not to any particular Section or other subdivision, (f) all references in this Agreement to designated Schedules, Exhibits and Appendices are to the Schedules, Exhibits and Appendices attached to this
Agreement, (g) references to this Agreement, any other Transaction Documents and any other document shall be construed as references to such document as the same may be amended, supplemented or novated from time to time, (h) the term
“or” is not exclusive and shall be deemed to have the same meaning with “and/or”, (i) the term “including” will be deemed to be followed by “, but not limited to,” (j) the terms “shall,”
“will,” and “agrees” are mandatory, and the term “may” is permissive, (k) the phrase “directly or indirectly” means directly, or indirectly through one or more intermediate Persons or through contractual
or other arrangements, and “direct or indirect” has the correlative meaning, (l) the term “voting power” refers to the number of votes attributable to the Shares (on an as-converted
basis) in accordance with the terms of the Charter Documents, (m) the headings used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement, (n) references to laws include
any such law modifying, re-enacting, extending or made pursuant to the same or which is modified, re-enacted, or extended by the same or pursuant to which the same is
made, (o) the masculine, feminine, and neuter genders will each be deemed to include the others, (p) the term “day” means “calendar day”, and “month” means calendar month, and (q) all references to
dollars or to “US$” are to currency of the United States of America, and all references to RMB are to currency of the PRC (and each shall be deemed to include reference to the equivalent amount in other currencies). 

 

	2.	 Demand Registration. 

2.1 Registration Other Than on Form F-3 or Form S-3. Subject to the terms of this Agreement, at any time or from time to time after the earlier of (a) the fifth (5th) anniversary of the Effective Date
or (b) the date that is six (6) months after the consummation of an IPO, Holders holding forty percent (40%) of the voting power of the then outstanding Registrable Securities held by all Holders may request in writing that the Company
effect a Registration on any internationally recognized exchange that is reasonably acceptable to such requesting Holder. Upon receipt of such a request, the Company shall (x) promptly give written notice of the proposed Registration to all
other Holders and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given pursuant to this Section 2.1, use its commercially reasonable efforts to cause the
Registrable Securities specified in the request, together with any Registrable Securities of any Holder who requests in writing to join such Registration within fifteen (15) days after the Company’s delivery of written notice, to be
Registered or qualified for sale and distribution in such jurisdiction as the Initiating Holders may request. The Company shall be obligated to consummate no more than two (2) Registrations pursuant to this Section 2.1
that have been declared and ordered effective. 
 2.2 Registration on Form
F-3 or Form S-3. At any time after the Company has been subject to the requirements of Section 12 or 15(d) of the Exchange Act for a period
of at least twelve (12) months, the Company shall use its reasonable best efforts to qualify for registration on Form F-3 or Form S-3. Subject to the terms of this
Agreement, if the Company qualifies for registration on Form F-3 or Form S-3 (or any comparable form for Registration in a jurisdiction other than the United

  
 9 

 
States), Holders of at least thirty percent (30%) of the Registrable Securities then outstanding may request the Company to file, in any jurisdiction in which the Company has had a registered
underwritten public offering, a Registration Statement on Form F-3 or Form S-3 (or any comparable form for Registration in a jurisdiction other than the United States),
including without limitation any registration statement filed under the Securities Act providing for the registration of, and the sale on a continuous or a delayed basis by the Holders of, all of the Registrable Securities pursuant to Rule 415 under
the Securities Act or any similar rule that may be adopted by the Commission. Upon receipt of such a request, the Company shall (a) promptly give written notice of the proposed Registration to all other Holders and (b) as soon as
practicable, use its reasonable best efforts to cause the Registrable Securities specified in the request, together with any Registrable Securities of any Holder who requests in writing to join such Registration within fifteen (15) days after
the Company’s delivery of written notice, to be Registered and qualified for sale and distribution in such jurisdiction. Except as otherwise provided herein, there shall be no limit on the number of times the Holders may request Registration of
Registrable Securities under this Section 2.2. 
 2.3 Right of Deferral. 

(a) The Company shall not be obligated to Register or qualify Registrable Securities pursuant to this Section 2: 

(i) if, within ten (10) days of the receipt of any request of the Holders to Register any Registrable Securities under
Section 2.1 or Section 2.2, the Company gives notice to the Initiating Holders of its bona fide intention to effect the filing for its own account of a Registration Statement of Ordinary Shares
within one hundred eighty (180) days of receipt of that request; provided, that the Company is actively employing in good faith its reasonable best efforts to cause that Registration Statement to become effective within one hundred
eighty (180) days of receipt of that request; provided, further, that the Holders are entitled to join such Registration in accordance with Section 3 (other than an Exempt Registration); 

(ii) during the period starting with the date of filing by the Company of, and ending six (6) months following the effective date of any
Registration Statement pertaining to Ordinary Shares of the Company other than an Exempt Registration; provided, that the Holders are entitled to join such Registration in accordance with Section 3; 

(iii) with respect to the registration on Form F-3 or Form S-3
(or any comparable form for Registration in a jurisdiction other than the United States), if such form is not available for such offering by the Holders, or if the Holders, together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than US$5,000,000; or 

(iv) in any jurisdiction in which the Company would be required to be qualified to do business or execute a general consent to service of
process in effecting such Registration or qualification, unless the Company is already subject to service of process in such jurisdiction. 

(b) If, after receiving a request from Holders pursuant to Section 2.1 or Section 2.2
hereof, the Company furnishes to the Holders a certificate signed by the chief executive officer of the Company stating that, in the good faith judgment of the Board, it would be materially detrimental to the Company or its shareholders for a
Registration Statement to be filed in the near future, then the Company shall have the right to defer such filing for a period during which such filing would be materially detrimental, provided, that the Company may not utilize this right for
more than one hundred eighty (180) days on any one occasion or more than once during any twelve (12) month period; provided, further, that the Company may not Register any other Equity Securities during such period (except
for Exempt Registrations). 

  
 10 

 2.4 Underwritten Offerings. If, in connection with a request to Register
Registrable Securities under Section 2.1 or Section 2.2, the Initiating Holders seek to distribute such Registrable Securities in an underwritten offering, they shall so advise the Company as a part of the request, and the
Company shall include such information in the written notice to the other Holders described in Section 2.1 and Section 2.2. In such event, the right of any Holder to include its Registrable Securities in such Registration
shall be conditioned upon such Holder’s participation in such underwritten offering and the inclusion of such Holder’s Registrable Securities in the underwritten offering (unless otherwise mutually agreed by the Initiating Holders and such
Holder) to the extent provided in this Section 2.4. All Holders proposing to distribute their Registrable Securities through such underwritten offering shall enter into an underwriting agreement in customary form with the underwriter or
underwriters of internationally recognized standing selected for such underwritten offering by the Company and reasonably acceptable to the holders of seventy five percent (75%) of the voting power of all Registrable Securities proposed to be
included in such Registration. Notwithstanding any other provision of this Agreement, if the managing underwriter advises the Company that marketing factors (including without limitation the aggregate number of securities requested to be Registered,
the general condition of the market, and the status of the Persons proposing to sell securities pursuant to the Registration) require a limitation of the number of Registrable Securities to be underwritten in a Registration pursuant to
Section 2.1 or Section 2.2, the underwriters may exclude up to fifty percent (50%) of the Registrable Securities requested to be Registered but only after first excluding all other Equity Securities from the Registration and
underwritten offering and so long as the number of shares to be included in the Registration on behalf of the Holders is allocated among all non-excluded Holders in proportion, as nearly as practicable, to the
respective amounts of Registrable Securities requested by such non-excluded Holders to be included; provided, that any Initiating Holder shall have the right to withdraw its request for Registration from the underwriting by written notice to the
Company and the underwriters delivered at least ten (10) days prior to the effective date of the Registration Statement, and such withdrawal request for Registration shall not be deemed to constitute one of the Registration rights granted pursuant
to Section 2.1 or Section 2.2, as the case may be; provided, further, that if any Holder disapproves the terms of any underwriting, the Holder may also elect to withdraw therefrom by written notice to the Company and the
underwriters delivered at least ten (10) days prior to the effective date of the Registration Statement. Any Registrable Securities excluded or withdrawn from such underwritten offering shall be withdrawn from the Registration. To facilitate the
allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to a Holder to the nearest one hundred (100) shares. 

3. Piggyback Registrations. 
 3.1
Registration of the Company’s Securities. Subject to the terms of this Agreement, if the Company proposes to Register for its own account any of its Equity Securities, or for the account of any holder of Equity
Securities any of such holder’s Equity Securities, in connection with the public offering of such securities (except for Exempt Registrations), the Company shall promptly give each Holder written notice of such Registration and, upon the
written request of any Holder given within twenty (20) days after delivery of such notice, the Company shall use its reasonable best efforts to include in such Registration any Registrable Securities thereby requested to be Registered by such
Holder. If a Holder decides not to include all or any of its Registrable Securities in such Registration by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent Registration
Statement or Registration Statements as may be filed by the Company, all upon the terms and conditions set forth herein. 
 3.2
Right to Terminate Registration. The Company shall have the right to terminate or withdraw any Registration initiated by it under Section 3.1 prior to the effectiveness of such Registration, whether or not any
Holder has elected to participate therein. The expenses of such withdrawn Registration shall be borne by the Company in accordance with Section 4.3. 

  
 11 

 3.3 Underwriting Requirements. 

(a) In connection with any offering involving an underwriting of the Company’s Equity Securities, the Company shall not be required to
Register the Registrable Securities of a Holder under this Section 3 unless such Holder’s Registrable Securities are included in the underwritten offering and such Holder enters into an underwriting agreement in
customary form with the underwriter or underwriters of internationally recognized standing selected by the Company and setting forth such terms for the underwritten offering as have been agreed upon between the Company and the underwriters. In the
event the underwriters advise Holders seeking Registration of Registrable Securities pursuant to this Section 3 in writing that market factors (including the aggregate number of Registrable Securities requested to be
Registered, the general condition of the market, and the status of the Persons proposing to sell securities pursuant to the Registration) require a limitation of the number of Registrable Securities to be underwritten, the underwriters may exclude
up to fifty percent (50%) of the Registrable Securities requested to be Registered but in any case only after first excluding all other Equity Securities (except for securities sold for the account of the Company) from the Registration and
underwriting (including all shares held by the Investors and all other employees, directors, officers, etc.), so long as in no event shall Registrable Securities which are held by the Holders be excluded from such underwriting unless all Registrable
Securities that are not held by the Holders are first excluded from such offering, and so long as the Registrable Securities to be included in such Registration on behalf of any non-excluded Holders are
allocated among all non-excluded Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities requested by such Holders to be included. To facilitate the allocation of
shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to a Holder to the nearest one hundred (100) shares. 

(b) If any Holder disapproves the terms of any underwriting, the Holder may elect to withdraw therefrom by written notice to the Company and
the underwriters delivered at least ten (10) days prior to the effective date of the Registration Statement. Any Registrable Securities excluded or withdrawn from the underwritten offering shall be withdrawn from the Registration. 

3.4 No Limitation. There shall be no limit on the number of times the Holders may request registration of Registrable Securities
under this Section 3. 
 3.5 Exempt Registrations. The Company shall have no obligation to Register
any Registrable Securities under this Section 3 in connection with a Registration by the Company (a) relating solely to the sale of securities to participants in a Company share plan or (b) relating to a corporate
reorganization or other transaction under Rule 145 of the Securities Act (or comparable provision under the Laws of another jurisdiction, as applicable) (collectively, “Exempt Registrations”). 

4. Registration Procedures. 
 4.1
Registration Procedures and Obligations. Whenever required under this Agreement to effect the Registration of any Registrable Securities held by the Holders, the Company shall, as expeditiously as reasonably possible: 

(a) Prepare and file with the Commission a Registration Statement with respect to those Registrable Securities and use its reasonable best
efforts to cause that Registration Statement to become effective and effective for the period of distribution contemplated thereby; 
 (b)
Prepare and file with the Commission amendments and supplements to that Registration Statement and the prospectus used in connection with the Registration Statement as may be necessary to keep such Registration Statement effective for the period
specified in Section 4.1(a) above and to comply with the provisions of Applicable Securities Laws with respect to the disposition of all Registrable Securities covered by the Registration Statement; 

  
 12 

 (c) Furnish to the selling Holders the number of copies of a prospectus, including a
preliminary prospectus, required by Applicable Securities Laws, and any other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities covered by the Registration Statement; 

(d) Use its reasonable best efforts to Register and qualify the securities covered by the Registration Statement under the securities Laws of
any jurisdiction, as reasonably requested by the Holders, provided, that the Company shall not be required to qualify to do business that it would not otherwise be required to qualify or file a general consent to service of process in any
such jurisdictions; 
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in customary form, with the managing underwriter(s) of the offering; 
 (f) Promptly notify each selling Holder under the
Registration Statement at any time when a prospectus relating thereto is required to be delivered under Applicable Securities Laws of (i) the issuance of any stop order by the Commission, or (ii) the happening of any event or the existence
of any condition as a result of which any prospectus included in the Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances under which they were made, or if in the opinion of counsel for the Company it is necessary to supplement or amend such prospectus to comply with Law, and at the request of any such
selling Holder, promptly prepare and furnish to such selling Holder a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such securities, such
prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made,
and such prospectus, as supplemented or amended, shall comply with Law; 
 (g) Furnish, at the request of any selling Holder, on the date
that such Registrable Securities are delivered for sale in connection with a Registration pursuant to this Agreement, (i) an opinion, dated the date of the sale, of the external counsel of reputable standing, representing the Company for the
purposes of the Registration, in form and substance as is customarily given to underwriters in an underwritten public offering; and (ii) comfort letters dated as of (x) the effective date of the registration statement covering such
Registrable Securities, and (y) the date of the sale as contemplated in Rule 159 under the Securities Act, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified
public accountants to underwriters in an underwritten public offering; 
 (h) Otherwise comply with all applicable Law and rules and
regulations of the Commission to the extent applicable to the Registration Statement and use its reasonable best efforts to make generally available to its security holders (or otherwise provide in accordance with Section 11(a) of the
Securities Act) an earnings statement satisfying the provisions of Section 11(a) of the Securities Act, no later than forty-five (45) days after the end of a twelve (12) month period (or ninety (90) days, if such period is a
fiscal year) beginning with the first month of the Company’s first fiscal quarter commencing after the effective date of such registration statement, which statement shall cover such twelve (12) month period, subject to any proper and
necessary extensions; 
 (i) Not, without the written consent of the holders of at least two-thirds
(2/3rds) of voting power of the Registrable Securities covered by the Registration Statement, make any offer relating to the Equity Securities that would constitute a “free writing prospectus,” as defined in Rule 405 promulgated under
the Exchange Act; 

  
 13 

 (j) Provide a transfer agent and registrar for all Registrable Securities Registered
pursuant to the Registration Statement and, where applicable, a number assigned by the Committee on Uniform Securities Identification Procedures for all those Registrable Securities, in each case not later than the effective date of the Registration
Statement; and 
 (k) Take all necessary actions necessary to list the Registrable Securities on the primary exchange on which the
Company’s securities are or will be listed or traded. 
 4.2 Information from Holder. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Agreement with respect to the Registrable Securities of any selling Holder that such selling Holder shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities as shall be required to effect the Registration of such Holder’s Registrable Securities. 

4.3 Expenses of Registration. All expenses, other than the underwriting discounts and selling commissions applicable to
the sale of Registrable Securities pursuant to this Agreement (which shall be borne by the Holders requesting Registration on a pro rata basis in proportion to their respective numbers of Registrable Securities sold in such Registration), incurred
in connection with Registrations, filings or qualifications pursuant to this Agreement, including (without limitation) all Registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the
Company and reasonable fees and disbursement of one counsel for all selling Holders, shall be borne by the Company. 
 5. Registration-Related
Indemnification. 
 5.1 Company Indemnity. 

(a) In the event of a Registration under this Agreement, to the maximum extent permitted by Law, the Company will indemnify and hold harmless
each selling Holder, such Holder’s partners, officers, employees, directors, shareholders, members, and legal counsel, any underwriter (as defined in the Securities Act) and each Person, if any, who controls (as defined in the Securities Act)
such Holder, legal counsel or underwriter, against any losses, claims, damages or liabilities (joint or several) to which such Person may become subject under Applicable Securities Laws or otherwise, insofar as such losses, claims, damages, or
liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (each a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact
contained in such Registration Statement, on the effective date thereof (including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto), (ii) the omission or alleged omission to state in the
Registration Statement, on the effective date thereof (including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto), a material fact required to be stated therein or necessary to make the
statements therein not misleading, or (iii) any violation or alleged violation by the Company of Applicable Securities Laws, or any rule or regulation promulgated under Applicable Securities Laws; provided, that the Company will not be
liable in any such case if and to the extent any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by
such Person in writing specifically for use in such Registration Statement (including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto). The Company will reimburse, as incurred, each such
Person for any legal or other expenses reasonably incurred by such Person in connection with investigating or defending any such loss, claim, damage, liability or Action. 

  
 14 

 (b) The indemnity agreement contained in this Section 5.1 shall
not apply to amounts paid in settlement of any such loss, claim, damage, liability or Action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld or delayed), nor shall the Company be
liable in any such case for any such loss, claim, damage, liability or Action to the extent that it arises solely out of or is solely based upon a Violation that occurs in reliance upon and in conformity with written information furnished for use in
connection with such Registration by any such Holder, such Holder’s partners, officers, directors, and legal counsel, any underwriter (as defined in the Securities Act) and each Person, if any, who controls (as defined in the Securities Act)
such Holder or underwriter. 
 (c) The indemnity agreement contained in this Section 5.1 shall be in addition to
any liability the Company may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Holder or any indemnified party under this Section 5.1 and
shall survive the transfer of securities by such Holder or any indemnified party. 
 5.2 Holder Indemnity. 

(a) In the event of a Registration under this Agreement, to the maximum extent permitted by Law, each selling Holder that has included
Registrable Securities in a Registration will, severally and not jointly, indemnify and hold harmless the Company, its directors and officers, any other Holder selling securities in connection with such Registration and each Person, if any, who
controls (within the meaning of the Securities Act) the Company or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any such Person may become subject, under Applicable Securities Laws or otherwise,
insofar as such losses, claims, damages or liabilities (or Actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs solely in reliance upon and in
conformity with information furnished by such Holder in writing specifically for use in such Registration Statement (including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto); and each such
Holder will reimburse, as incurred, any Person intended to be indemnified pursuant to this Section 5.2, for any legal or other expenses reasonably incurred by such Person in connection with investigating or defending any
such loss, claim, damage, liability or Action. No selling Holder’s liability under this Section 5.2 (when combined with any amounts paid by such Holder pursuant to Section 5.4) shall exceed
the net proceeds received by such Holder from the offering of securities made in connection with that Registration. 
 (b) The indemnity
contained in this Section 5.2 shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or Action if such settlement is effected without the consent of the Holder (which consent shall not be
unreasonably withheld or delayed). 
 5.3 Notice of Indemnification Claim. Promptly after receipt by an indemnified party under
Section 5.1 or Section 5.2 of notice of the commencement of any Action (including any governmental Action), such indemnified party will, if a claim in respect thereof is to be made against any
indemnifying party under Section 5.1 or Section 5.2, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate
in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the indemnifying parties. An indemnified party (together with
all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonably incurred fees and expenses to be paid by the indemnifying party, if representation of
such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The
failure to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 5 except to the extent such failure is materially
prejudicial to the indemnifying party’s ability to defend such Actions. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof the giving by the claimant or the plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 

  
 15 

 5.4 Contribution. If any indemnification provided for in
Section 5.1 or Section 5.2 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein,
the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is
appropriate to reflect the relative fault of the indemnifying party, on the one hand, and of the indemnified party, on the other, in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well
as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or
the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement
or omission; provided, however, that, in any such case: (A) no Holder will be required to contribute any amount (after combined with any amounts paid by such Holder pursuant to Section 5.2) in excess of
the net proceeds to such Holder from the sale of all such Registrable Securities offered and sold by such Holder pursuant to the applicable Registration Statement; and (B) no Person or entity guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person or entity who was not guilty of such fraudulent misrepresentation. 

5.5 Underwriting Agreement. To the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

5.6 Survival. The obligations of the Company and Holders under this Section 5 shall survive the
completion of any offering of Registrable Securities in a Registration Statement under this Agreement, regardless of the expiration of any statutes of limitation or extensions of such statutes. 

6. Additional Registration-Related Undertakings. 

6.1 Reports under the Exchange Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the
Securities Act and any comparable provision of any Applicable Securities Laws that may at any time permit a Holder to sell securities of the Company to the public without Registration or pursuant to a Registration on Form F-3 or Form S-3 (or any comparable form in a jurisdiction other than the United States), the Company agrees to: 

(a) make and keep public information available, as those terms are understood and defined in Rule 144 (or comparable provision, if any, under
Applicable Securities Laws in any jurisdiction where the Company’s securities are listed), at all times following ninety (90) days after the effective date of the first Registration under the Securities Act filed by the Company for an
offering of its securities to the general public; 
 (b) file with the Commission in a timely manner all reports and other documents required
of the Company under all Applicable Securities Laws; and 
 (c) at any time following ninety (90) days after the effective date of the
first Registration under the Securities Act filed by the Company for an offering of its securities to the general public by the Company, promptly furnish to any Holder holding Registrable Securities, upon request (i) a written statement by the
Company that it has complied with the reporting requirements of all Applicable Securities Laws at any time after it has become subject to such reporting requirements or, at any time after so qualified, that it qualifies as a registrant whose
securities may be resold pursuant to Form F-3 or Form S-3 (or any form comparable thereto under Applicable Securities Laws of any jurisdiction where the Company’s
securities are listed), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents as filed by the Company with the Commission, and (iii) such other information as may be reasonably requested
in availing any Holder of any rule or regulation of the Commission, that permits the selling of any such securities without Registration or pursuant to Form F-3 or Form
S-3 (or any form comparable thereto under Applicable Securities Laws of any jurisdiction where the Company’s securities are listed). 

  
 16 

 6.2 Limitations on Subsequent Registration Rights. From and after the date of
this Agreement, the Company shall not, without the written consent of holders of at least fifty percent (50%) of the voting power of the then outstanding Registrable Securities held by all Investors (calculated on an
as-converted to Ordinary Share basis), enter into any agreement with any holder or prospective holder of any Equity Securities of the Company that would allow such holder or prospective holder (a) to
include such Equity Securities in any Registration filed under Section 2 or Section 3, unless under the terms of such agreement such holder or prospective holder may include such Equity Securities
in any such Registration only to the extent that the inclusion of such Equity Securities will not reduce the amount of the Registrable Securities of the Holders that are included, (b) to demand Registration of their Equity Securities, or
(c) cause the Company to include such Equity Securities in any Registration filed under Section 2 or Section 3 hereof on a basis pari passu with or more favorable to such holder or prospective
holder than is provided to the Holders of Registrable Securities. 
 6.3 “Market
Stand-Off” Agreement. Each holder of Registrable Securities agrees, if so required by the managing underwriter(s), that it will not during the period commencing on the date of the final
prospectus relating to the Company’s IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days from the date of such final prospectus or such longer period if
required by the managing underwriter) (a) lend, offer, pledge, hypothecate, hedge, sell, make any short sale of, loan, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Equity Securities of the Company owned immediately prior to the date of the final prospectus relating to the IPO (other than those included in such offering),
or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such Equity Securities, whether any such transaction described in clause (i) or (ii) above is
to be settled by delivery of Equity Securities of the Company or such other securities, in cash or otherwise; provided, that (i) the foregoing provisions shall only apply to the IPO, (ii) the forgoing provisions of this
Section 6.3 shall not be applicable to any Holder unless all directors, officers and all other Holders of at least one percent (1%) of the outstanding share capital of the Company (calculated on an as-converted to Ordinary Share basis) are bound by restrictions at least as restrictive as those applicable to any such Holder pursuant to this Section 6.3, and (iii) the lockup
agreements shall permit a Holder to transfer their Registrable Securities to their respective Affiliates so long as the transferees enter into the same lockup agreement. The Investors agree to execute and deliver to the underwriters a lock-up agreement containing substantially similar terms and conditions as those contained herein. In order to enforce the foregoing covenant, the Company may place restrictive legends on the certificates and impose
stop-transfer instructions with respect to the Registrable Securities of each Shareholder (and the shares or securities of every other Person subject to the foregoing restriction) until the end of such period. Any discretionary waiver or termination
of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company Shareholders that are subject to such agreements, based on the number of Shares subject to such agreements. 

6.4 Termination of Registration Rights. The registration rights set forth in Section 2 and
Section 3 of this Agreement shall terminate with respect to any Holder, the date on which such Holder may sell all of such Holder’s Registrable Securities under Rule 144 of the Securities Act in any ninety (90)-day period. 
 6.5 Exercise of Ordinary Share Equivalents. Notwithstanding anything to the
contrary provided in this Agreement, the Company shall have no obligation to Register Registrable Securities which, if constituting Ordinary Share Equivalents, have not been exercised, converted or exchanged, as applicable, for Ordinary Shares as of
the effective date of the applicable Registration Statement, but the Company shall cooperate and facilitate any such exercise, conversion or exchange as requested by the applicable Holder. 

  
 17 

 6.6 Intent. The terms of Sections 2 through 6 are drafted
primarily in contemplation of an offering of securities in the United States of America. The parties recognize, however, the possibility that securities may be qualified or registered for offering to the public in a jurisdiction other than the
United States of America where registration rights have significance or that the Company might effect an offering in the United States of America in the form of American Depositary Receipts or American Depositary Shares. Accordingly: 

(a) it is their intention that, whenever this Agreement refers to a Law, form, process or institution of the United States of America but the
parties wish to effectuate qualification or registration in a different jurisdiction where registration rights have significance, reference in this Agreement to the Laws or institutions of the United States shall be read as referring, mutatis
mutandis, to the comparable Laws or institutions of the jurisdiction in question; and 
 (b) it is agreed that the Company will not
undertake any listing of American Depositary Receipts, American Depositary Shares or any other security derivative of the Ordinary Shares unless arrangements have been made reasonably satisfactory to the Requisite Preferred Holders to ensure that
the spirit and intent of this Agreement will be realized and that the Company is committed to take such actions as are necessary such that the Holders will enjoy rights corresponding to the rights hereunder to sell their Registrable Securities in a
public offering in the United States of America as if the Company had listed Ordinary Shares in lieu of such derivative securities. 
 7. Preemptive
Right. 
 7.1 General. The Company hereby grants to each holder of the Preferred Shares (and/or any of its designated
Affiliates) (each such party, the “Rights Holder”) the right of first refusal to purchase such Rights Holder’s Pro Rata Share (as defined below), of all (or any part) of any New Securities (as defined below) that the Company
may from time to time issue after the Effective Date (the “Preemptive Right”). 
 7.2 Pro Rata Share. A Rights
Holder’s “Pro Rata Share” for purposes of the Preemptive Rights is the ratio of (a) the number of Preferred Shares (calculated on an as-converted to Ordinary Share basis) or any
Ordinary Shares issued up on conversion of any Preferred Shares held by such Rights Holder, to (b) the total number of Ordinary Shares (including the Preferred Shares on an as-converted basis) then
outstanding immediately prior to the issuance of New Securities giving rise to the Preemptive Rights. 
 7.3 New Securities.
For purposes hereof, “New Securities” shall mean any Equity Securities of the Company issued after the date hereof, except for: 

(a) any Equity Securities issued upon conversion or exercise of options, warrants or convertible securities existing as of the Effective Date;

 (b) any Ordinary Shares and/or options or warrants therefor issued (or issuable pursuant to such warrants or options) to the Group
Companies’ employees, officers, directors, consultants or any other eligible beneficiaries qualified pursuant to an Equity Plan duly approved by the Board in accordance with this Agreement and the Memorandum and Articles, including but limited
to the approval of at least one Series Seed Director; 
 (c) any Equity Securities of the Company issued or issuable pursuant to a share
subdivision, share dividend, combination, Recapitalization or other similar transaction of the Company, in each case, as duly approved in accordance with this Agreement; 

  
 18 

 (d) any Equity Securities of the Company issued pursuant to a registered public offering
duly approved in accordance with this Agreement; 
 (e) any Equity Securities of the Company issued in connection with a bank financing,
equipment leasing, licensing or strategic alliance arrangement, research, collaboration, development, OEM or other similar agreement or strategic partnership, in any case, duly approved in accordance with the procedure hereunder; 

(f) any Ordinary Shares issued upon the conversion of the Preferred Shares; and 

(g) any Equity Securities that are otherwise excluded by written consent of the Requisite Preferred Holders. 

7.4 Procedures. 
 (a)
Participation Notice. In the event that the Company proposes to undertake an issuance of New Securities (in a single transaction or a series of related transactions), it shall give to each Rights Holder written notice of its intention to
issue New Securities (the “Participation Notice”), describing the amount and type of New Securities, the price and the general terms upon which the Company proposes to issue such New Securities. Each Rights Holder shall have fifteen
(15) Business Days from the date of receipt of any such Participation Notice (the “Participation Period”) to give written notice to the Company of its intention to purchase up to such Rights Holder’s Pro Rata Share of such
New Securities for the price and upon the terms and conditions specified in the Participation Notice stating therein the quantity of New Securities to be purchased (not to exceed such Rights Holder’s Pro Rata Share) (the Rights Holders who have
given such notice, the “Participating Rights Holders”). If any Rights Holder fails to so respond in writing within such fifteen (15) Business Day period, then such Rights Holder shall forfeit the right hereunder to purchase its
Pro Rata Share of such New Securities, but shall not be deemed to forfeit any right with respect to any other issuance of New Securities. 

(b) Closing. For up to ten (10) Business Days following the expiration of the Participation Period, or such longer period as may be
agreed by the Company and the Participating Rights Holders, the Company and the Participating Rights Holders shall negotiate in good faith and execute and deliver a subscription agreement and other customary documents for the issuance of New
Securities consistent with the price and the general terms set forth in the Participation Notice and providing for the closing of such issuance as of a date not less than ten (10) Business Days’ following the execution and delivery of such
subscription agreement. 
 7.5 Failure to Exercise. Upon the expiration of the Participation Period, the Company shall have
ninety (90) days thereafter to complete the sale of the New Securities described in the Participation Notice with respect to which the Preemptive Rights hereunder were not exercised at the same or higher price and upon non-price terms not more favorable to the purchasers thereof than specified in the Participation Notice. In the event that the Company has not issued and sold such New Securities within such ninety (90) day
period, then the Company shall not thereafter issue or sell any New Securities without again first offering such New Securities to the Rights Holders pursuant to this Section 7. 

7.6 Termination. The Preemptive Right shall terminate immediately prior to the completion of a Qualified IPO. 

  
 19 

 8. Information Rights. 

8.1 Delivery of Financial Statements. The Company shall, and shall cause the Group Companies to, keep proper, complete and
accurate books of account in US Dollars, in accordance with the Accounting Standards. All costs and expenses associated with the Company’s keeping of books of account or other financial records (whether through any third party service provider
or not) will be borne by the Company. The Company shall have its accounts and those of the other Group Companies audited annually by the Auditor, as appointed by the Board from time to time, in accordance with such standards by one of the “Big
Four” accounting firms. All costs and expenses associated with the activities of the Auditor will be borne by the Company. The Company shall deliver to each Shareholder (together with its Affiliates) holding at least five percent (5%) of the
issued and outstanding Series Seed Preferred Shares of the Company and each Shareholder holding at least five percent (5%) of the issued and outstanding Series A Preferred Shares of the Company (or Ordinary Shares issued upon conversion of Preferred
Shares) (other than any Investor that the Company reasonably believes to be a competitor of the Company, provided, that none of the Perceptive Fund Entities, Venrock, RA Capital, FIIF, Viking, Tybourne, Pfizer, Wellington or Vida shall be
deemed to be a competitor of the Company for any reason) the following documents or reports: 
 (a) within one hundred and twenty
(120) days after the end of each fiscal year of the Company, a consolidated income statement and statement of cash flows for each Group Company for such fiscal year and a consolidated balance sheet, including a comparison between (x) the
actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined below) for such year, with an explanation of any material differences between such amounts and a schedule
as to the sources and applications of funds for such year, for each Group Company as of the end of the fiscal year, audited and certified by an Auditor, all prepared in English and in accordance with the Accounting Standards consistently applied
throughout the period; 
 (b) within forty-five (45) days of the end of each fiscal quarter of the Company, a consolidated unaudited
income statement and statement of cash flows for such quarter and a consolidated balance sheet for each Group Company as of the end of such quarter, all prepared in English and in accordance with the Accounting Standards consistently applied
throughout the period (except for customary year-end adjustments and except for the absence of notes); 

(c) within fifteen (15) days prior to the beginning of the following fiscal year of the Company, annual consolidated management
projections and an operating budget for the immediate following fiscal year (the “Budget”); 
 (d) as soon as practically
possible after the end of each fiscal quarter of the Company, a detailed capitalization table of the Company, including but not limited to a statement showing the number of shares of each class and series of shares and securities convertible into or
exercisable for shares of the Company outstanding at the end of the period, the Ordinary Shares issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Ordinary Shares and the exchange ratio or exercise
price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Shareholder to calculate their respective percentage equity
ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and correct; and 

(e) copies of all documents or other information sent to all other Shareholders (the above rights, the “Information Rights”).

 8.2 Inspection Rights. Each Shareholder (together with its Affiliates) holding at least five percent (5%) of the issued and
outstanding Series Seed Preferred Shares of the Company and each Shareholder holding at least five percent (5%) of the issued and outstanding Series A Preferred Shares of the Company (or Ordinary Shares issued upon conversion of Preferred Shares)
(other than any Investor that the Company reasonably believes to be a competitor of the Company provided, that none of the Perceptive Fund Entities, Venrock, RA Capital, FIIF, Viking, Tybourne, Pfizer, Wellington or Vida shall be deemed to be
a competitor of the Company for any reason) shall have the 

  
 20 

 
right to access to the Company’s properties to the extent customary and reasonable and to receive copies of all shareholder decisions, resolutions and communications and customary tax
reporting information of the Company, provided, however, that (a) in no event shall such access (i) disrupt or otherwise impair the normal business operation of any Group Companies or (ii) be effectuated more than once
per every two (2) calendar quarters, and (b) the Company shall have no obligation to provide information or material if the disclosure of which would adversely affect the attorney-client privilege between the a Group Company and its
counsel or result in disclosure of trade secrets, highly sensitive confidential and proprietary information or any other information reasonably deemed by the Company to present a conflict of interest (the “Inspection Rights”). 

8.3 Termination. The Information Rights and Inspection Rights shall terminate upon the consummation of a Qualified IPO. 

9. Restrictions on Transfer 
 9.1
Generally. No Ordinary Shareholder (a “Transferor” for purposes of this Section 9) shall be permitted to directly or indirectly sell, assign, transfer, pledge, hypothecate, or otherwise
encumber or dispose of in any way or otherwise grant any interest or right with respect to (a “Transfer,” and “Transferee” shall have correlative meaning) any Ordinary Shares of the Company now or hereafter
owned or held by the Transferor without the prior written approval of the Requisite Preferred Holders, provided, that any Ordinary Shareholder may Transfer all or a portion its interest in any Ordinary Shares to its Affiliate for no
consideration upon prior written notice to the Company of such proposed Transfer so long as (a) in the Company’s reasonable determination, the transferee Affiliate does not and will not, directly or indirectly, compete against the Company
and (b) the transferee Affiliate agrees to become a party to, and be bound by, the terms and conditions of this Agreement to the same extent as the transferor by executing and delivering a Deed of Adherence, attached hereto as Exhibit A.
Any Transfer of Shares of the Company not made in compliance with this Agreement shall be null and void as against the Company, and shall not be recorded on the books of the Company. 

9.2 Transfer Notice. Subject to Section 9.1, if any Transferor proposes to Transfer any
Ordinary Shares of the Company now or hereafter owned or held by the Transferor to one or more third parties (other than a permitted transfer to an Affiliate as contemplated by Section 9.1), then the Transferor shall give
the Company and each Investor written notice of the Transferor’s intention to make the Transfer (the “Transfer Notice”), which shall include (a) a description of the Ordinary Shares to be transferred (the “Offered
Shares”), (b) the identity and address of the proposed transferee (the “Proposed Transferee”), and (c) the consideration (including price and form of consideration) and the material terms and conditions upon which the
proposed Transfer is to be made. The Transfer Notice shall certify that the Transferor has received a definitive offer from the Proposed Transferee and in good faith believes a binding agreement for the Transfer is obtainable on the terms set forth
in the Transfer Notice. The Transfer Notice shall also include a copy of any written proposal, term sheet or letter of intent or other agreement relating to the proposed Transfer. 

9.3 Right of First Refusal. 

(a) Investors’ Right of First Refusal. Each Investor shall have an option for a period of thirty (30) Business Days following the
receipt of the Transfer Notice (the “Option Period”) to elect to purchase its respective pro rata share of the Offered Shares at the same price and subject to substantially the same terms and conditions as described in the Transfer
Notice. Each Investor may exercise such purchase option and request to purchase all or any portion of its pro rata share of the Offered Shares (a “Participating Investor” for the purposes of this
Section 9.3(a) and Section 9.3(b)), by notifying the Transferor and the Company in writing, before expiration of the Option Period as to the number of such shares that it wishes to purchase (the
“Participating Investor Notice”). Each Investor’s pro rata share of the Offered Shares shall be a fraction of the Offered Shares, the numerator of which shall be the total number of Ordinary Shares (including Preferred Shares
on an as-converted basis) owned by such Investor on the date of the Transfer Notice and denominator of which shall be the total number of Ordinary Shares (including Preferred Shares on an as-converted basis) held by all Investors on the date of the Transfer Notice. 

  
 21 

 (b) Payment. 

(i) The Participating Investors shall effect the purchase by check (if agreeable to the Transferor), or by wire transfer in immediately
available funds of the appropriate currency, against delivery of such Offered Shares to be purchased, at a place agreed to by the Transferor and at the time of the scheduled closing therefor, but if they cannot agree, then at the principal executive
office of the Company on the 60th Business Day following the Investors’ receipt of the Transfer Notice, unless such notice contemplated a later closing date with the Proposed Transferee or
unless the value of the purchase price has not yet been established, in which case the closing shall be on such later date or as provided in subsection (ii) below. The Company will update its register of members upon the consummation of
any such Transfer. 
 (ii) Valuation of Property 

(1) Should the purchase price specified in the Transfer Notice be payable in property other than cash or evidences of indebtedness, the
Participating Investors shall have the right to pay the purchase price in the form of cash equal in amount to the fair market value of such property. 

(2) If the Transferor and Participating Investors cannot agree on such cash value within ten (10) days after the expiration of the Option
Period, the valuation shall be made by an appraiser of internationally recognized standing jointly selected by agreement of the Transferor and the Participating Investors or, if they cannot agree on an appraiser within the Option Period, the
Transferor and the Participating Investors shall select an appraiser of internationally recognized standing and such appraisers shall designate another appraiser of internationally recognized standing, whose appraisal shall be determinative of such
value and shall be final and binding on the Transferor and the Participating Investors. 
 (3) The cost of such appraisal shall be shared
equally by the Transferor and the Participating Investors. 
 (4) If the value of the purchase price offered by the proposed transferee is
not determined within thirty (30) days following the Company’s receipt of the Transfer Notice from the Transferor, the closing of the purchase of Offered Shares by the Participating Investors shall be held on or prior to the fifth (5th)
Business Day after such valuation shall have been made pursuant to this subsection (ii). 
 9.4 Right of Co-Sale. 
 (a) To the extent any Investor does not exercise its respective rights of first refusal as
to any of its pro-rata share of the Offered Shares proposed to be sold by the Transferor to the Proposed Transferee identified in the Transfer Notice pursuant to Section 9.3, the
Transferor shall give notice thereof to such Investors (the “Co-Sale Notice”) (specifying in such Co-Sale Notice the number of remaining Offered Shares
as well as the number of Shares that the Investors may participate with), and such Investors shall have the right to participate in such sale, to the Proposed Transferee identified in the Transfer Notice, of the remaining Offered Shares not
purchased pursuant to Section 9.3, on the same terms and conditions as specified in the Transfer Notice (but in no event less favorable to the Transferor) by notifying the Transferor in writing within ten (10) Business
Days following the date of the Co-Sale Notice (the “Co-Sale Right”); provided that such Investors shall not be required to give any
representations and warranties with respect to the Company other than title to the Shares to be sold by it. Such Investors’ notice to the Transferor shall indicate the number of Shares it wishes to sell under its
Co-Sale Right. 

  
 22 

 (b) The maximum number of Shares that an Investor may elect to sell shall be equal to the
product of (i) the aggregate number of the Offered Shares identified in the Transfer Notice multiplied by (ii) a fraction, the numerator of which is the number of Ordinary Shares (including Preferred Shares on an as-converted basis) owned by such Investor on the date of the Transfer Notice and the denominator of which is the total number of Ordinary Shares (including Preferred Shares on an
as-converted basis) owned by the Transferor and such Investor exercising its Co-Sale Right hereunder. 

(c) An Investor shall effect its participation in the sale by promptly executing and delivering an instrument of transfer to the Company in
respect of the type and number of Shares which such Investor elects to sell and notifying the Transferor of the same, before the applicable closing; provided, however that if the Proposed Transferee objects to the transfer of
Ordinary Share Equivalents in lieu of Ordinary Shares, upon such Investor’s request, the Company shall (and the Transferor shall cause the Company to) effect the conversion of such Ordinary Share Equivalents into Ordinary Shares concurrent with
the actual transfer of such shares to the purchaser and contingent on such transfer. 
 (d) The share certificate or certificates that the
applicable Investor delivers to the Company pursuant to this Section 9.4 shall be submitted to the Company for cancellation and the Company shall, upon the consummation of the sale of the Shares pursuant to the terms and
conditions specified in the Transfer Notice, issue a new certificate to such Investor for any remaining balance. The Transferor shall concurrently therewith remit to such Investor that portion of the sale proceeds to which the Investor is entitled
due to its participation in such sale. The Company will update its register of shareholders upon the consummation of any such Transfer. 

(e) To the extent that any Proposed Transferee prohibits the participation by an Investor exercising its
Co-Sale Rights hereunder in a proposed Transfer or otherwise refuses to purchase Shares or other securities from the Investors exercising its Co-Sale Rights hereunder,
the Transferor shall not sell to such Proposed Transferee any Shares unless and until, simultaneously with such sale, the Transferor shall purchase from the Investor(s) such shares or other securities that such Investor(s) would otherwise be
entitled to sell to the Proposed Transferee pursuant to its Co-Sale Rights for the same consideration and on the non-price terms and conditions no less favorable to the
Transferor as the Proposed Transferee described in the Transfer Notice. 
 9.5 Non-Exercise of
Rights. 
 (a) If the Investors do not elect to exercise its right of first refusal to purchase all of the Offered Shares in accordance
with Section 9.3, then, subject to the right of the Investors to exercise its Co-Sale Right in the sale of Offered Shares within the time periods specified in
Section 9.4 (if applicable), the Transferor shall have a period of ninety (90) days from the expiration of the Option Period in which to sell the remaining Offered Shares to the Proposed Transferee upon terms and
conditions (including the purchase price) no more favorable to the purchaser than those specified in the Transfer Notice, so long as any such sale is effected in accordance with all applicable Laws. The Parties agree that each such Proposed
Transferee, prior to and as a condition to the consummation of any sale, shall execute and deliver to the Parties documents and other instruments assuming the obligations of such Transferor under this Agreement, and the transfer shall not be
effective and shall not be recognized by any Party until such documents and instruments are so executed and delivered. 
 (b) In the event
the Transferor does not consummate the sale of such Offered Shares to the Proposed Transferee within such ninety (90) day period as provided in Section 9.5(a), the rights of the Investors under
Section 9.3 and Section 9.4 shall be re-invoked and shall be applicable to each subsequent disposition of such Offered Shares by the Transferor until such
rights lapse in accordance with the terms of this Agreement. 

  
 23 

 (c) The exercise or non-exercise of the rights of
the Investors under Section 9.3 to purchase Ordinary Shares from a Transferor or participate in the sale of Ordinary Shares by a Transferor shall not adversely affect their rights to make subsequent purchases from the
Transferor of Ordinary Shares or subsequently participate in sales of Ordinary Shares by the Transferor hereunder. 
 9.6 Allocation of
Consideration. 
 (a) Subject to Section 9.6(b), the aggregate consideration payable to the Investors
exercising their Co-Sale Rights pursuant to Section 9.4 (the “Participating Investors”) and the Transferor shall be allocated based on the number of shares of Offered
Shares sold to the Transferee by each Participating Investor and the Transferor as provided in Section 9.4, provided that if a Participating Investor wishes to sell Preferred Shares, the price set forth in the
Proposed Transfer Notice shall be appropriately adjusted based on the conversion ratio of the Preferred Shares into Ordinary Shares. 
 (b)
In the event that the proposed Transfer by the Transferor constitutes a transaction or series of related transactions in which a person, or a group of related persons, acquires from shareholders of the Company shares representing more than fifty
percent (50%) of the outstanding voting power of the Company, the terms of the written purchase and sale agreement covering the Transfer shall provide that the aggregate consideration from such transfer shall be allocated to the Participating
Investors and the Transferor in accordance with Section 8.2 of the Memorandum and Articles as if (A) such Transfer were a Deemed Liquidation Event (as defined in the Memorandum and Articles), and (B) the Offered
Shares sold in the Transfer were the only Equity Securities of the Company outstanding. 
 9.7 Termination. The provisions of this
Section 9 shall terminate upon the consummation of a Qualified IPO. 
 10. Drag-along Right. 

10.1 Drag-Along Transaction. At any time after the second (2nd)
anniversary of the Initial Closing (as defined in the Subscription Agreement) and prior to the consummation of a Qualified IPO, if a Deemed Liquidation Event or a transaction or a series of related transactions in which fifty percent (50%) or more
of the Company’s voting power is transferred (the “Drag-Along Transaction”) is approved by (a) a majority of the members of the Board (including at least one Series Seed Director) and (b) the Requisite Preferred
Holders, then each Shareholder hereby agrees with respect to all the Shares that he, she or it holds or otherwise exercises dispositive power over: 

(a) in the event such Drag-Along Transaction requires the approval of Shareholders, (i) if the matter is to be brought to a vote at a
shareholders’ meeting of the Company, after receiving proper notice of any such shareholders’ meeting, to vote on the approval of a Drag-Along Transaction, to be present, in person or by proxy, as a holder of the Shares, at all such
meetings and be counted for the purposes of determining the presence of a quorum at such meeting; and (ii) to vote (in person, by proxy or by action by written consent, as applicable) all Shares in favor of such Drag-Along Transaction and in
opposition of any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to consummate such Drag-Along Transaction; 

(b) in the event that the Drag-Along Transaction is to be effected by the sale of Shares held by another Shareholder (such transaction a
“Stock Sale” and such Shareholder, the “Drag-along Selling Shareholder”) without the need for shareholder approval (including without limitation by way of a change in control of such Shareholder), to sell all Shares
beneficially held by such Shareholder (or in the event that the Drag-along Selling Shareholder is selling fewer than all of its 

  
 24 

 
Shares held in the Company, Shares in the same proportion as the Drag-along Selling Shareholder is selling) to the person to whom the Drag-along Selling Shareholder proposes to sell its Shares,
for the same per-share consideration (on an as-converted basis) and on the same terms and conditions as the Drag-along Selling Shareholder, except that the Shareholder
will not be required to sell its Shares unless (i) the liability for indemnification, if any, of the Shareholder in such Drag-Along Transaction is several, not joint, and is pro rata in accordance with the Shareholder’s relative share
ownership of the Company, and (ii) the consideration to be paid to the Shareholders in such Drag-Along Transaction will be allocated as if the consideration were the proceeds to be distributed to the Shareholders in a Deemed Liquidation Event
under Section 8.2 of the Company’s Memorandum and Articles; 
 (c) to refrain from exercising any dissenters’ rights or rights
of appraisal under applicable Law at any time with respect to such Drag-Along Transaction; 
 (d) to execute and deliver all related
documentation and take such other action in support of the Drag-Along Transaction as shall reasonably be requested by the Company; and 
 (e)
not to deposit, and to cause their Affiliates not to deposit, except as provided in this Agreement, any voting securities owned by such party or Affiliate in a voting trust or subject any such voting securities to any arrangement or agreement with
respect to the voting of such securities, unless specifically requested to do so in writing by the acquirer in connection with a Drag-Along Transaction, provided that such deposit is permissible under applicable Laws; 

provided that each Shareholder will not be required to comply with the above in connection with any proposed Drag-Along Transaction
unless: 
 (i) any representations and warranties to be made by such Shareholder in connection with the proposed Drag-Along Transaction are
limited to representations and warranties related to authority, ownership and the ability to convey title to such Shares, including, but not limited to, representations and warranties that (i) the Shareholder holds all right, title and interest
in and to the Shares such Shareholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Shareholder in connection with the transaction have been duly authorized, if applicable, (iii) the documents
to be entered into by the Shareholder have been duly executed by the Shareholder and delivered to the acquirer and are enforceable (subject to customary limitations) against the Shareholder in accordance with their respective terms; and
(iv) neither the execution and delivery of documents to be entered into by the Shareholder in connection with the transaction, nor the performance of the Shareholder’s obligations thereunder, will cause a breach or violation of the terms
of any agreement to which the Shareholder is a party, or any law or judgment, order or decree of any court or governmental agency that applies to the Shareholder; 

(ii) such Shareholder is not required to agree (unless such Shareholder is a Company officer or employee) to any restrictive covenant in
connection with the proposed Drag-Along Transaction (including, without limitation, any covenant not to compete or covenant not to solicit customers, employees or suppliers of any party to the proposed Drag-Along Transaction) or any release of
claims other than a release in customary form of claims arising solely in such Shareholder’s capacity as a Shareholder of the Company; 

(iii) the Shareholder is not liable for the breach of any representation, warranty or covenant made by any other Person in connection with the
proposed Drag-Along Transaction, other than the Company; 
 (iv) liability shall be limited to such Shareholder’s applicable share
(determined based on the respective proceeds payable to each Shareholder in connection with such proposed Drag-Along Transaction in accordance with the provisions of the Memorandum and Articles) of a negotiated aggregate indemnification amount that
applies equally to all Shareholders but that in no event exceeds the amount of consideration otherwise payable to such Shareholder in connection with such proposed Drag-Along Transaction, except with respect to claims related to fraud by such
Shareholder, the liability for which need not be limited as to such Shareholder; and 

  
 25 

 (v) upon the consummation of the proposed Drag-Along Transaction (i) each holder of
each class or series of shares of the Company will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of shares, (ii) each
holder of a series of Preferred Shares will receive the same amount of consideration per share of such series of Preferred Shares as is received by other holders in respect of their shares of such same series, (iii) each holder of Ordinary
Shares will receive the same amount of consideration per share Ordinary Share as is received by other holders in respect of their Ordinary Shares, and (iv) unless waived pursuant to the terms of the Memorandum and Articles and as may be
required by law, the aggregate consideration receivable by all holders of the Preferred Shares and Ordinary Shares shall be allocated among the holders of Preferred Shares and Ordinary Shares on the basis of the relative liquidation preferences to
which the holders of each respective series of Preferred Shares and the holders of Ordinary Shares are entitled in a Deemed Liquidation Event (assuming for this purpose that the proposed Drag-Along Transaction is a Deemed Liquidation Event) in
accordance with the Memorandum and Articles in effect immediately prior to the proposed Drag-Along Transaction. 
 10.2 Restrictions on
Sales of Control of the Company. No Shareholder shall be a party to any Stock Sale unless (a) all holders of Preferred Shares are allowed to participate in such transaction(s) and (b) the consideration received pursuant to such
transaction is allocated among the parties thereto in the manner specified in the Memorandum and Articles in effect immediately prior to the Stock Sale (as if such transaction(s) were a Deemed Liquidation Event), unless the holders of at least the
requisite percentage required to waive treatment of the transaction(s) as a Deemed Liquidation Event pursuant to the terms of the Memorandum and Articles, elect to allocate the consideration differently by written notice given to the Company at
least ten (10) business days prior to the effective date of any such transaction or series of related transactions. 
 11. Election of Directors.

 11.1 Board of Directors. 

(a) The Company shall have, and the Parties hereto agree to cause the Company to have, a Board consisting of no more than six
(6) directors, with the composition of the Board determined as follows: 
 (i) The Series Seed Majority Holders shall have the right to
collectively designate, appoint, remove, replace and reappoint two (2) directors to the Board (each a “Series Seed Director”, and collectively, the “Series Seed Directors”), initially to be Konstantin Poukalov
and Adam Stone; 
 (ii) So long as BridgeBio Pharma LLC (“Bridge”) continues to hold at least five percent (5%) or more of
the fully-diluted share capital of the Company on a fully-diluted and as-converted basis, Bridge shall have the right to designate, appoint, remove, replace and reappoint one (1) director to the Board (the “Bridge Director”),
initially to be Neil Kumar, and any subsequent appointee or replacement shall be subject to the prior approval of Series Seed Majority Holders; 

(iii) The Majority Ordinary Shareholders shall have the right to collectively designate, appoint, remove, replace and reappoint two
(2) directors to the Board (each an “Ordinary Director”, and collectively, the “Ordinary Directors”), one of whom shall initially be Bing Li; and 

  
 26 

 (iv) The Requisite Holders shall have the right to collectively designate, appoint, remove,
replace and reappoint one (1) director to the Board (the “Independent Director”), initially to be Tassos Giankakos. 

(b) Notwithstanding the foregoing, if, in accordance with this Section 11.1, Bridge loses its right to designate,
appoint, remove, replace and reappoint a Director, the number of Directors on the Board shall remain no more than six (6), and the Series Seed Majority Holders shall have the right to designate and appoint one (1) additional Director to the
Board. 
 11.2 Voting Agreements. 

(a) With respect to each election of Directors of the Board, each holder of voting securities of the Company shall vote at each meeting of
shareholders of the Company, or in lieu of any such meeting shall give such holder’s written consent with respect to, as the case may be, all of such holder’s voting securities of the Company as may be necessary (i) to keep the
authorized size of the Board at no more than six (6) Directors, (ii) to cause the election or re-election as members of the Board, and during such period to continue in office, each of the individuals
designated pursuant to Section 11.1, and (iii) against any nominees not designated pursuant to Section 11.1. 

(b) Any Director designated pursuant to Section 11.1 may be removed from the Board, either for or without cause, only
upon the vote or written consent of the Person or group of Persons then entitled to designate such Director pursuant to Section 11.1, and the Parties agree not to seek, vote for or otherwise effect the removal of any such
Director without such vote or written consent. Any Person or group of Persons then entitled to designate any individual to be elected as a Director on the Board shall have the exclusive right at any time or from time to time to remove any such
Director occupying such position and to fill any vacancy caused by the death, disability, incapacity (such as being convicted of, or pleading guilty or nolo contendere to, any felony or crime of moral turpitude), retirement, resignation or removal
of any Director occupying such position or any other vacancy therein, and each other Party agrees to cooperate with such Person or group of Persons in connection with the exercise of such right. Each holder of voting securities of the Company agrees
to always vote such holder’s respective voting securities of the Company at a meeting of the Shareholders of the Company (and given written consents in lieu thereof) in support of the foregoing. 

11.3 Quorum. Subject to the Memorandum and Articles and applicable Laws, the Board shall hold no less than one (1) board
meeting during each fiscal quarter or more frequently as approved by the Board. A meeting of the Board shall only proceed where there are present (whether in person or by means of a conference telephone or any other equipment which allows all
participants in the meeting to speak to and hear each other simultaneously) a majority of the Directors of the Board then in office, including at least one Series Seed Director. If a quorum shall not be present at any meeting of the
Board, the Directors present thereat may adjourn the meeting, until a quorum shall be present. The Company shall ensure that a notice of each meeting of the Board, agenda of the business to be transacted at the meeting and all documents and
materials to be circulated at or presented to the meeting are sent to all Directors entitled to receiving notice of the meeting at least five (5) days before the meeting and a copy of the minutes of the meeting is sent to such persons within
fourteen (14) days following the meeting. 
 11.4 Observer. 

(a) For so long as RA Capital holds at least 529,474 Series A Preferred Shares (or Ordinary Shares issued upon conversion of the Series A
Preferred Shares) as appropriately adjusted for share splits, share dividends, combinations, recapitalizations and similar events, RA Capital shall be entitled to nominate a representative board observer (the “RA Capital Observer”).

  
 27 

 (b) For so long as Venrock holds at least 352,983 Series A Preferred Shares (or Ordinary
Shares issued upon conversion of the Series A Preferred Shares) as appropriately adjusted for share splits, share dividends, combinations, recapitalizations and similar events, Venrock shall be entitled to nominate a representative board observer
(the “Venrock Observer”). 
 (c) For so long as FIIF holds at least 352,983 Series A Preferred Shares (or the Ordinary
Shares issued upon conversion of the Series A Preferred Shares) as appropriately adjusted for share splits, share dividends, combinations, recapitalizations and similar events, FIIF shall be entitled to nominate a representative board observer
(together with the RA Capital Observer and Venrock Observer, the “Observers”). 
 (d) Each Observer shall be entitled to
(i) attend and participate in all Board or committee meetings in a non-voting capacity and (ii) receive copies of all notices and materials provided to other members of the Board and the committees
at the same time and in the same manner as provided to such other members of the Board; provided, however, that the Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided;
provided further, that the Company reserves the right to withhold any information and to exclude such Observer from any meeting or portion thereof based on the advice of counsel or if the Company reasonably believes that (x) access to such
information or attendance at such meeting could reasonably result in an adverse effect to the attorney-client privilege between the Company and its counsel or (y) the Observer has a conflict of interest with respect to the subject matter. 

11.5 Termination. The provisions of this Section 11 shall terminate on the consummation of a Qualified
IPO. 
 12. Protective Provisions. 

12.1 Acts of the Group Companies Requiring Requisite Preferred Holder Approval. Notwithstanding anything else contained herein,
no Group Company shall take, permit to occur, approve, authorize, or agree or commit to do any of the following, and each Party shall procure such Group Company not to, and the Shareholders of the Company shall procure the Company not to, take,
permit to occur, approve, authorize, or agree or commit to do any of the following, whether in a single transaction or a series of related transactions, whether directly or indirectly, and whether or not by amendment, merger, consolidation, scheme
of arrangement, amalgamation, or otherwise, unless approved in accordance with applicable Law and in writing by the (i) the Requisite Holders and (ii) the Requisite Preferred Holders, which in the case of (k)-(n) must include at least
three (3) affirmative votes from the following four (4) entities: the Perceptive Fund Entities (solely for the purposes of this Section 12.1(ii), voting together as one entity), Venrock, RA Capital and FIIF: 

(a) consummate any liquidation, dissolution or winding up of the Company or a Deemed Liquidation Event (as defined in the Memorandum and
Articles, which, for the avoidance of doubt, includes a Deemed Liquidation Event involving the acquisition by a special purpose vehicle), or consent to any of the foregoing; 

(b) declare or pay any dividends or distributions on any Equity Securities of the Company; 

(c) re-domicile the Company or any Group Company to any jurisdiction other than such entity’s
original jurisdiction of incorporation or any tax-motivated re-organization or restructuring of the ownership structure of the Group Companies, unless such re-domiciliation, re-organization or restructuring does not have any material adverse effect on the holders of Preferred Shares; 

(d) amend, alter or repeal any provision of the Charter Documents; 

  
 28 

 (e) increase or decrease the authorized number of Ordinary Shares or Preferred Shares or any
series thereof (save and except for the increase or decrease caused by the issuance of (i) Ordinary Shares issued upon conversion of the Preferred Shares; and (ii) options representing up to 150,000 Ordinary Shares granted pursuant to an Equity
Plan approved by the Board), or authorize or create any Equity Security having rights preferences, privileges or powers senior to the Preferred Shares,, or take or permit any action reclassifying any outstanding shares into shares having rights,
preferences, privileges or powers senior to the Preferred Shares or reclassify any outstanding securities into shares having rights or preferences, senior to or on a parity with those preferences of the Preferred Shares; 

(f) repurchase, redeem or retire any of the Company’s Equity Securities other than pursuant to contractual rights to repurchase equity
interests held by employees, directors or consultants of the Company or any Group Company upon termination of their employment or services at no greater than the original purchase price thereof and pursuant to relevant agreements which permit such
repurchase; 
 (g) dispose of, all or substantially all of, any Group Company’s interest in any of its Subsidiaries or the assets of the
Subsidiaries; 
 (h) reduce or cancel the authorized or issued share capital (as the case may be) of any Group Company, purchase or redeem
any shares or securities of any Group Company convertible into or carrying a right of subscription in respect of shares or any share warrants, grant, issue or reserve for issuance any options, warrants or rights which may require the issue of shares
in the future (save and except for any change in authorized or issued share capital or purchase or redemption made pursuant to an arms’ length transaction); 

(i) any public offering of any Equity Securities of any Group Company (other than a Qualified IPO); 

(j) any exclusive out-licensing of any trademarks, patents or other intellectual property owned by any
Group Company (other than (i) transactions approved by the Board (which shall include the affirmative vote from at least one disinterested Director), (ii) transactions conducted at arms’ length or (iii) otherwise in the ordinary
course of business or customary for the trade licensing arrangements); 
 (k) issue, or agree to issue, share capital such that the total
outstanding share capital of the Company, calculated on an as-exercised, as converted to Ordinary Share basis, exceeds 48,184,458 (as such number may be adjusted to reflect stock splits, dividends or other
changes in the number of outstanding shares of Ordinary Shares); 
 (l) increase, from the date of the Initial Closing (as defined in the
Subscription Agreement) until April 29, 2022 (the “Restriction Period”), the total number of Ordinary Shares authorized and reserved for issuance under the Company’s Equity Plan above 1,738,538 (as such number may be
adjusted to reflect stock splits, dividends or other changes in the number of outstanding shares of Ordinary Shares); 
 (m) increase, after
the expiration of the Restriction Period, the total number of Ordinary Shares authorized and reserved for issuance (including any options granted) under the Equity Plan above 3,177,076 (as such number may be adjusted to reflect stock splits,
dividends or other changes in the number of outstanding shares of Ordinary Shares); 
 (n) other than through the Equity Plan, issue or agree
to issue any Equity Securities of the Company to any employees, directors, officers or consultants of the Company or any Group Company; or 

(o) any action by any Group Company to authorize, approve, or enter into any agreement or obligation with respect to any of the actions listed
above. 

  
 29 

 The holders of Series A Preferred Shares and Series Seed Preferred Shares shall be entitled
to vote together with the holders of the Ordinary Shares on all other matters with each Preferred Share having the number of votes equal to the number of shares of Ordinary Shares issuable upon conversion of such Preferred Share; except as otherwise
set forth herein, including but not limited to the extent that the matters to be voted as set forth in this Section 12.1 above, in which case the holders of the Series A Preferred Shares or Series Seed Preferred Shares, as
applicable, shall vote separately as a class. 
 12.2 Acts of the Group Companies Requiring Requisite Board Approval.
Notwithstanding anything else contained herein, no Group Company shall take, permit to occur, approve, authorize, or agree or commit to do any of the following, and no Person shall permit any such Group Company to, and the Shareholders of the
Company shall not permit the Company to, take, permit to occur, approve, authorize, or agree or commit to do the following, whether in a single transaction or a series of related transactions, whether directly or indirectly, and whether or not by
amendment, merger, consolidation, scheme of arrangement, amalgamation, or otherwise, unless approved by at least a majority of the members of the Board (including at least one Series Seed Director): 

(a) incurrence by any such Group Company of Indebtedness for borrowed money or guarantees of such Indebtedness except for trade facilities
obtained from banks or other financial institutions in the ordinary course of business; 
 (b) incurrence of any Lien on all or any of the
undertaking, assets or rights of any such Group Company except for the purpose of securing borrowings from banks or other financial institutions in the ordinary course of business; 

(c) incurrence of any capital expenditure or other commitment that are not contemplated in the annual budget in excess of US$5,000,000 (or its
equivalent in other currency or currencies) individually or US$10,000,000 (or its equivalent in other currency or currencies) in the aggregate during any financial year; 

(d) entering into, amending, terminating, or otherwise modifying any agreement or transaction with any Related Party; provided, that
such action shall be approved by a majority of the disinterested Directors; 
 (e) entering into, amending, terminating, or otherwise
modifying any material transaction with a transaction amount in excess of US$5,000,000 (or its equivalent in other currency or currencies); 

(f) the appointment or removal of, the modification of responsibilities of, or approval of the remuneration package for, any executive officer
or key personnel of any such Group Company; 
 (g) the adoption, amendment or termination of any Equity Plan or any other equity incentive,
purchase or participation plan for the benefit of any employees, officers, directors, contractors, advisors or consultants of any of such Group Companies; 

(h) approval of or any material amendment to the business scope and/or operating plans of any such Group Company; 

(i) the appointment or removal of the Auditors for any such Group Company; 

(j) any material change in the business activities and/or strategy of any such Group Company; 

  
 30 

 (k) initiating, defending or settling any legal proceedings (with the understanding that
legal proceedings pertaining to a dispute with any then existing Shareholder will only require the approval of a majority of the disinterested members of the Board); 

(l) delegating to any committee of the Board the authority to approve any of the foregoing or establishing any committee for such purpose. 

12.3 Termination. The provisions of this Section 12 shall terminate on the consummation of a Qualified
IPO. 
 13. Additional Covenants. 

13.1 Anti-corruption Undertakings; Compliance with Law. 

(a) Within a reasonable period of time following the Initial Closing (but in no event greater than six months after the date of the Initial
Closing), the Parties shall cause each Group Company to: 
 (i) adopt and implement rules and policies regarding anti-bribery or
anti-corruption issues and a code of conduct of the Group Companies (including a written travel and entertainment policy) consistent with global best practices (the “Anti-Corruption Policies”), with the understanding that such
Anti-Corruption Policies will forbid the Company and each other Group Company and their respective Affiliates and agents or representatives from promising, authorizing or making any payment to, or otherwise contributing any item of value, directly
or indirectly, to any third party, including any Government Official, in each case, in violation of the Anti-Corruption Laws or the Anti-Corruption Policies; 

(ii) permit the Investors to inspect (and, upon written request, the Company shall furnish copies of) the Company’s books and records for
the purposes of evaluating and verifying the Company’s implementation of and compliance with the Anti-Corruption Policies; 
 (iii)
maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the Anti-Corruption Policies and the Anti-Corruption Laws. The Group Companies will monitor
their operations with the purpose of ensuring the systems and controls are effective at the reasonable assurance level and make necessary changes from time to time, in particular as their business activities expand; and 

(iv) maintain books, records, and accounts which, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
Company’s assets. 
 (b) The Company agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates,
agents, representatives, consultants and subcontractors hired in connection with the subject matter of this Agreement (together with the Company, the “Company Representatives”) that for the performance of its obligations hereunder:

 (i) The Company Representatives shall not directly or indirectly pay, offer or promise to pay, or authorize the payment of any money, or
give, offer or promise to give, or authorize the giving of anything else of value, to: 
 (1) any Government Official in order to influence
official action; 

  
 31 

 (2) any Person (whether or not a Government Official) (x) to influence such Person to
act in breach of a duty of good faith, impartiality or trust (“Acting Improperly”), (y) to reward such Person for Acting Improperly, or (z) where such Person would be Acting Improperly by receiving the money or other
thing of value; or 
 (3) any other Person while knowing or having reason to know that all or any portion of the money or other thing of
value will be paid, offered, promised or given to, or will otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement. 

(ii) The Company Representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else
of value in violation of the Anti-Corruption Laws. 
 (iii) The Company Representatives shall comply with the Anti-Corruption Laws, shall
adopt and comply with the Anti-Corruption Rules and Policies and the code of conduct, and shall not take any action that will, or would reasonably be expected to, cause the Company (or its Affiliates) to be in violation of any such laws, policies or
code. 
 (c) The Company shall promptly provide the Investors with written notice of the following events: 

(i) Upon becoming aware of any breach or violation by any Group Company or any of their respective Affiliates of any representation, warranty
or undertaking set forth in Section 12.1(b); 
 (ii) Upon receiving a formal notification that it is the target of
a formal investigation by a Governmental Authority for any violation of any Anti-Corruption Law or upon receipt of information. 
 (d) The
Shareholders shall cause the Company to, and shall cause the Company to cause each Subsidiary to comply with all Laws and with the directions of Governmental Authorities having jurisdiction over them or their business or property. 

13.2 United States Tax Matters. 

(a) The Company shall use its best efforts to avoid the status of the Company or any Group Company as a PFIC, provided, however,
the foregoing shall be deemed to have been met to the extent that the PFIC status of the Company arises from any cash that it holds including by reason of the current or any future equity or debt financing. 

(b) The Company shall use its best efforts to avoid future status of the Company or any Group Company as a CFC. The Company and each Group
Company shall use their reasonable best efforts to avoid generating for any taxable year in which the Company or any Group Company is a CFC, income that would be includible in the income of each Investor that is a United States Person pursuant to
Section 951 of the Code. 
 (c) The Company shall: 

(i) engage a Big Four Accounting Firm to, as soon as practicable, but in any event within sixty days after the end of each fiscal year of the
Company, examine whether the Company or any Group Company is a PFIC or a CFC, in each case for U.S. federal income tax purposes, for any applicable year; 

(ii) immediately notify the Shareholders if, as a result of the analysis of the Big Four Accounting Firm, the Company or any Group Company
becomes aware of any change in the PFIC or CFC status of the Company for any taxable year; and 

  
 32 

 (iii) if it is determined that the Company or Group Company is a PFIC or CFC for any
applicable year, engage a Big Four Accounting Firm to obtain and provide to each Shareholder such information as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company, as
such Shareholder may reasonably require in writing in order to comply with such Shareholder’s applicable U.S. federal income tax reporting and any related requirements, including timely filing and maintaining any tax elections necessary to
reduce taxes due and maintaining financial information prepared in accordance with U.S. generally accepted accounting principles. 
 (d) The
Company shall be classified as an association taxable as a corporation for U.S. federal income tax purposes and shall not make (and shall not cause to be made) any election inconsistent with such classification; provided, that the Company may change
such classification if the Company (i) gives written notice to the Shareholders no later than seventy-five (75) days prior to the effective date of such change and (ii) permits any Shareholder to complete a transfer of such
Shareholder’s equity interest in the Company to an Affiliate of such Shareholder prior to the effective date of such change. 
 13.3
Other Tax Matters. The Shareholders shall cause the Company to, and the Company shall (and shall cause each Subsidiary to), (a) comply with all applicable Tax Laws and regulations in all material respects, and (b) timely and accurately file
all Tax returns required to be filed and timely pay all Taxes required to be paid. Further, each Shareholder shall (a) comply with all applicable Tax Laws and regulations in all material respects, and (b) timely and accurately file all Tax
returns required to be filed and timely pay all Taxes required to be paid, in each case in connection with their rights and responsibilities relating to the Company or any Subsidiary. The Shareholders shall use their reasonable best efforts to cause
the Company to, and the Company shall (and shall cause each Subsidiary to) use its reasonable best efforts to, conduct its activities in a manner such that (a) it is not treated for Tax purposes as resident in a country other than its country
of incorporation, and (b) no Shareholder or Group Company is required to pay Tax or file Tax returns in a country other than its country of incorporation. 

13.4 Compliance with PRC Laws. The Company covenants it shall fully comply with all the applicable Laws of the PRC as well as all
requirements of the competent Governmental Authorities with respect to their conducting of business in all material respects, on a continuing basis. 

13.5 Directors and Officers Insurance. The Company will purchase and, at all times, maintain for the benefit of each director, an
adequate directors and officers insurance policy against liability for negligence, breach of duty and breach of trust with a reputable insurance company with a coverage of no less than US$3,000,000 and on commercially reasonable and customary terms
approved by the Board. The Company shall indemnify and hold harmless each director, to the fullest extent permissible by Law, from and against all liabilities, damages, actions, suits, proceedings, claims, costs, charges and expenses suffered or
incurred by or brought or made against such director or his alternate as a result of any act, matter or thing done or omitted to be done by him or her in the course of acting as a Director, as applicable, of the Company (save and except for fraud,
gross negligence or willful default). 
 13.6 Intellectual Property. The Company shall take all steps promptly to obtain and
maintain all necessary patent, trademark, and copyright registrations, in the reasonable judgment of the Shareholders with advice of counsel, in all relevant jurisdictions, for the protection of Intellectual Property of the Company and the other
Group Companies. 
 13.7 Non-solicitation. Unless the Requisite Holders otherwise
consent in writing, each Shareholder, so long as it holds any Shares of the Company and for a period of one (1) year following the date that it ceases to hold any Shares of the Company, shall not and shall cause its Affiliates not to, solicit,
recruit or entice away or endeavor to solicit, recruit or entice away (a) any current director, officer, consultant or employee of any Group Company or any other Shareholders (each a
“Non-

  
 33 

 
soliciting Party”) or (b) any former director, officer, consultant or employee of the Non-soliciting Party following his or her voluntary
departure from such Non-soliciting Party; provided, however, that this Section 13.7 shall not prohibit any Shareholder or its Affiliates from soliciting or hiring any
Person who responds to a general advertisement or solicitation, including but not limited to advertisements or solicitations through newspapers, trade publications, periodicals, radio or internet database, or efforts by any recruiting or employment
agencies, not specifically directed at employees of the Non-soliciting Party. Such restrictions in this Section 13.7 shall not apply to Pfizer or any Affiliates (including but not
limited in such exclusion to “portfolio companies” (as such term is customarily used among institutional investors)) of RA Capital, Venrock, the Perceptive Funds Entities, FIIF, Viking, T. Rowe, Tybourne, Pfizer, Wellington, Casdin and
Farallon; and provided, further that in the event the Company and any other shareholder of the Company enter into any agreement or understanding regarding the provisions set forth in this Section 13.7 which
provides for less restrictive non-solicitation obligations of such shareholder, each of RA Capital, Venrock, the Perceptive Funds Entities and FIIF shall only be subject to such less restrictive provisions
relating to this Section 13.7. 
 13.8 Confidentiality. 

(a) Each Party covenants and agrees that without the prior written consent from the other Parties, such Party shall (i) not divulge or
communicate to any Person the existence or contents of this Agreement and other Transaction Documents, except to an Affiliate, (ii) not divulge or communicate to any Person any Confidential Information which may be within, or which may come to,
its knowledge, provided, however, that such Party may disclose the Confidential Information to its current directors, officers, employees, accountants, attorneys or other professional advisors, in each case only on an as-needed basis and where such Persons are under appropriate non-disclosure obligations. In the event that any Party is requested or becomes legally compelled (including
without limitation, pursuant to securities Laws and regulations) to disclose the existence or contents of any Transaction Document or any of the Confidential Information in contravention of the provisions of this
Section 13.8, such Party (the “Disclosing Party”) shall, unless prohibited by Law, provide the other Parties with prompt written notice of that fact and shall consult with the other Parties regarding such
disclosure. The Disclosing Party shall, to the extent possible and with the cooperation and reasonable efforts of the other Parties, seek a protective order, confidential treatment or other appropriate remedy. In such event, the Disclosing
Party shall furnish only that portion of the information which is legally required and shall exercise reasonable efforts to obtain reliable assurance that confidential treatment will be accorded such information. Each Party shall use its best
endeavours not to utilize any Confidential Information for any purpose that harms or is reasonably likely to harm the goodwill of the Group Companies. 

(b) The provisions of this Section 13.8 shall be in addition to, and not in substitution for, the provisions of any
separate nondisclosure agreement executed by any of the parties with respect to the transactions contemplated hereby, including without limitation, any term sheet, letter of intent, memorandum of understanding or other similar agreement (but not the
Charter Documents) entered into by the Company and the Investors in respect of the transactions contemplated hereby, except for the confidentiality provision in the Subscription Agreement, which shall remain in full force and effect. 

13.9 Management Personnel. 

(a) The Company shall have a chief executive officer, chief financial officer, chief technology officer, chief medical officer, chief
compliance officer, corporate secretary and such other corporate officers as is desired by the Board (collectively, the “C-Suite Executives”). 

(b) Any nomination, appointment and/or removal of any C-Suite Executive (other than the nomination,
appointment and/or removal of the chief executive officer, which shall be subject to the provisions of Section 11.1) shall be subject to the individual approvals of the Series Seed Majority Holders, with the understanding
that each such Party shall only retain such individual approval right for so long as such Party continues to hold the right to appoint one or more Directors to serve on the Board in accordance with Section 11.1. 

  
 34 

 13.10 Employee Agreements. Unless otherwise approved by a majority of the members of
the Board (including at least one Series Seed Director) the Company will cause (i) each Person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access
to confidential information and/or trade secrets to be bound by nondisclosure, proprietary rights assignment and non-solicitation obligations; and (ii) each Key Employee to enter into a noncompetition
designed with the advice of counsel. 
 13.11 Chop Management Policies. The Company covenants it shall procure the PRC Company to
adopt written chop management policies and procedures that are reasonably designed to ensure the safe-keeping and proper use of the chops of the PRC Company. 

13.12 Right to Conduct Activities. The Company hereby agrees and acknowledges that each of the Perceptive Fund Entities, Venrock, RA
Capital, FIIF, Viking, Tybourne, Pfizer, Wellington, Sphera, Casdin, Vida and Farallon (together with their Affiliates) are professional investment organizations, and as such review the business plans and related proprietary information of many
enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). Nothing in this Agreement shall preclude or in any way restrict the Investors from
evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the
Company; and the Company hereby agrees that, to the extent permitted under applicable law, each of Perceptive Fund Entities, Venrock, RA Capital, FIIF, Viking, Tybourne, Pfizer, Wellington, Sphera, Casdin, Vida, Pfizer and Farallon (together with
their Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by the Perceptive Fund Entities, Venrock, RA Capital, FIIF, Viking, Tybourne, Pfizer, Wellington, Sphera, Casdin, Vida, Pfizer
and Farallon (together with their Affiliates) in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of the Perceptive Fund Entities, Venrock, RA Capital, FIIF, Viking,
Tybourne, Pfizer, Wellington, Sphera, Casdin, Vida and Farallon (together with their Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or
otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s
confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

Further, each of the Parties hereto acknowledges and agrees that Pfizer may presently have, or may engage in the future in, internal
development programs, or may receive information from third parties that relates to, and may develop and commercialize products independently or in cooperation with such third parties, that are similar to or that are directly or indirectly
competitive with, the Company’s development programs, products or services. The exercise by such Pfizer of any rights under any Transaction Document shall not in any way preclude or restrict Pfizer from conducting any development program,
commercializing any product or service or otherwise engaging in any enterprise, whether or not such development program, product, service or enterprise, competes with those of the Company, so long as such activities do not result in a violation of
the confidentiality provisions of this Agreement. Nothing in any Transaction Document shall be construed to impose on Pfizer any restriction, duty or obligation other than as expressly set forth therein. 

13.13 Termination. The provisions of Section 13, except for Section 13.12,
shall terminate on the consummation of a Qualified IPO. 

  
 35 

 14. Miscellaneous. 

14.1 Termination. This Agreement shall terminate upon written consent of the Parties hereto; provided, that this Agreement
shall terminate with respect to each Investor and Ordinary Shareholder once each ceases to be a Shareholder of the Company. Upon termination of this Agreement, the Parties shall be released from their obligations under this Agreement, except in
respect of any obligation stated, explicitly or otherwise, to continue to exist after the termination of this Agreement (including without limitation those under this Section 14). If any Party breaches this Agreement before
the termination of this Agreement, it shall not be released from its obligations arising from such breach on termination. 
 14.2 Further
Assurances. Upon the terms and subject to the conditions herein, each of the Parties hereto agrees to use its reasonable best efforts to take or cause to be taken all actions, to do or cause to be done, to execute such further
instruments, and to assist and cooperate with the other Parties hereto in doing, all things necessary, proper or advisable under applicable Laws or otherwise to consummate and make effective, in the most expeditious manner practicable, the
transactions contemplated by this Agreement. 
 14.3 Assignments and Transfers; No Third Party Beneficiaries. Except as
otherwise provided herein, this Agreement and the rights and obligations of the Parties hereunder shall inure to the benefit of, and be binding upon, their respective successors, permitted assigns and legal representatives, but shall not otherwise
be for the benefit of any third party. The rights of any Investor hereunder are assignable (together with the related obligations) in connection with the transfer of all or part of the Equity Securities of the Company held by such Investor, so long
as (a) the transferee does not and will not, directly or indirectly, compete against the Company and (b) the transferee agrees to become a party to, and be bound by, the terms and conditions of this Agreement to the same extent as the
transferor by executing and delivering a Deed of Adherence, attached hereto as Exhibit A. Except as provided in the preceding sentence and Section 9.1, this Agreement and the rights and obligations of each Party
hereunder shall not otherwise be assigned without the written consent of the other Parties except as expressly provided herein. 
 14.4
Governing Law. This Agreement shall be governed by and construed under the Laws of the State of New York, without regard to conflict of law principles that would result in the application of any law other than the Laws of the State of New York.

 14.5 Dispute Resolution. 

(a) The Parties agree to negotiate in good faith to resolve any dispute, controversy or claim (each, a “Dispute”) arising out
of or relating to this Agreement, or the interpretation, breach, termination, validity or invalidity thereof. If the negotiations do not resolve the Dispute to the satisfaction of both Parties within thirty (30) days after one Party delivers
written notice of a Dispute to the other Parties, Section 14.5(b) shall apply. 
 (b) In the event the Parties are
unable to settle a Dispute in accordance with Section 14.5(a) above, such Dispute shall be referred to and conclusively determined by arbitration upon the demand of any Party to the Dispute with notice (the
“Arbitration Notice”) to the other. 
 (c) The Dispute shall be settled by arbitration in Hong Kong by the Hong Kong
International Arbitration Centre (the “HKIAC”) in accordance with the HKIAC Administered Arbitration Rules then in force when the Arbitration Notice is submitted. 

  
 36 

 (d) The disputing Parties may jointly select one (1) arbitrator, or agree that the
Chairman of HKIAC shall select the arbitrator. In the absence of such agreement, there shall be three (3) arbitrators, the claimant to the Dispute, or in the case of multiple claimants, all such claimants acting collectively (the
“Claimant”) shall select one (1) arbitrator and the respondent to the Dispute, or in the case of more than one respondent, the respondents acting collectively (the “Respondent”) shall select one
(1) arbitrator. All selections shall be made within thirty (30) days after the selecting Party gives or receives the demand for arbitration. Such arbitrators shall be freely selected, and neither the Claimant nor the Respondent shall be
limited in their selection to any prescribed list. The Chairman of HKIAC shall select the third arbitrator who will act as chairman of the arbitration board. If any arbitrator to be appointed by a Party has not been appointed and consented to
participate within thirty (30) days after the selection of the first arbitrator, the relevant appointment shall be made by the Chairman of HKIAC. 

(e) The arbitral proceedings shall be conducted in English. To the extent that the HKIAC Administered Arbitration Rules are in conflict with
the provisions of this Section 14.5, including the provisions concerning the appointment of the arbitrators, the provisions of this Section 14.5 shall prevail. 

(f) Each Party to the arbitration shall cooperate with the other Parties to the arbitration in making full disclosure of and providing complete
access to all information and documents requested by such other Party in connection with such arbitral proceedings, subject only to any confidentiality obligations binding on such Party. 

(g) The award of the arbitral tribunal shall be final and binding upon the Parties thereto, and the prevailing Party may apply to a court of
competent jurisdiction for enforcement of such award. 
 (h) The arbitral tribunal shall decide any Dispute submitted by the Parties to the
arbitration strictly in accordance with the Laws of Hong Kong (without regard to principles of conflict of Laws thereunder) and shall not apply any other substantive Law. 

(i) Any Party to the Dispute shall be entitled to seek preliminary injunctive relief, if possible, from any court of competent jurisdiction
pending the constitution of the arbitral tribunal. 
 (j) During the course of the arbitral tribunal’s adjudication of the Dispute, this
Agreement shall continue to be performed except with respect to the part in dispute and under adjudication. 
 (k) Notwithstanding the
foregoing in this Section 14.5, the Parties agree that each Party shall have the right, without posting any bond, to seek preliminary injunction, temporary restraining order or other temporary relief from any court of
competent jurisdiction. 
 14.6 Notices. Any notice required or permitted pursuant to this Agreement shall be given in writing
and shall be given either personally or by sending it by next-day or second-day courier service, fax, electronic mail or similar means to the address of the relevant
Party set forth in the signature pages hereto (or at such other address as such Party may designate by fifteen (15) days’ advance written notice to the other Parties to this Agreement given in accordance with this
Section 14.6). Where a notice is sent by next-day or second-day courier service, service of the notice shall be deemed to be effected by
properly addressing, pre-paying and sending by next-day or second-day service through an internationally-recognized courier a
letter containing the notice, with a written confirmation of delivery, and to have been effected at the earlier of (i) delivery (or when delivery is refused) and (ii) expiration of two (2) Business Days after the letter containing the
same is sent as aforesaid. Where a notice is sent by fax or electronic mail, service of the notice shall be deemed to be effected by properly addressing, and sending such notice through a transmitting organization, with a written confirmation of
delivery, and to have been effected on the day the same is sent as aforesaid, if such day is a Business Day and if sent during normal business hours of the recipient, otherwise the next Business Day. Notwithstanding the foregoing, to the extent a
“with a copy to” address is designated, notice must also be given to such address in the manner above for such notice, request, consent or other communication hereunder to be effective. 

  
 37 

 14.7 Rights Cumulative; Specific Performance. Each and all of the various rights,
powers and remedies of a Party hereto will be considered to be cumulative with and in addition to any other rights, powers and remedies which such Party may have at Law or in equity in the event of the breach of any of the terms of this Agreement.
The exercise or partial exercise of any right, power or remedy will constitute neither the exclusive election thereof nor the waiver of any other right, power or remedy available to such Party. Without limiting the foregoing, the Parties hereto
acknowledge and agree irreparable harm may occur for which money damages would not be an adequate remedy in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that the Parties shall be entitled to injunction to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement. 

14.8 Severability. In case any provision of the Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby. If, however, any provision of this Agreement shall be invalid, illegal, or unenforceable under any such applicable Law in any jurisdiction, it shall, as
to such jurisdiction, be deemed modified to conform to the minimum requirements of such Law, or, if for any reason it is not deemed so modified, it shall be invalid, illegal, or unenforceable only to the extent of such invalidity, illegality, or
limitation on enforceability without affecting the remaining provisions of this Agreement, or the validity, legality, or enforceability of such provision in any other jurisdiction. 

14.9 Amendments and Waivers. 

(a) General. Any provision in this Agreement may be amended or waived, only by the written consent of the Company and the Requisite
Preferred Holders, provided that (i) Section 12.1(k)-(n) may not be amended without obtaining the written consent from at least three (3) out of the four (4) following entities: the Perceptive
Fund Entities (solely for purpose of this Section 14.9(a)(i), voting together as one entity), RA Capital, Venrock and FIIF;(ii) Section 13.7 may not be amended without the written consent of RA
Capital, Venrock and the Perceptive Funds Entities; and (iii) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such
Investor, unless such amendment, modification, termination, or waiver applies to all Investors. Notwithstanding the foregoing, any Party hereunder may waive any of its/his rights hereunder without obtaining the consent of the other Parties. Any
amendment or waiver effected in accordance with this Section shall be binding upon all the Parties hereto. The Company shall give prompt written notice of any amendment or waiver hereunder to any Party that did not consent in writing thereto. 

(b) Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Series A
Preferred Shares after the date hereof in an Additional Closing (as defined in the Subscription Agreement), the purchaser of such Series A Preferred Shares may become a party to this Agreement by executing and delivering an additional counterpart
signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as
such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. Upon such Investor’s execution and delivery of an additional counterpart signature page to this Agreement, the Company
shall update Schedule III hereto to add such additional Investor to Schedule III and shall distribute a copy of the updated Shareholders Agreement, with the updated Schedule III, to all Parties. 

  
 38 

 14.10 Delays or Omissions. No delay or omission to exercise any right, power or
remedy accruing to any Party under this Agreement, upon any breach or default of any other Party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting Party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any
single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any Party of any breach or default under this Agreement,
or any waiver on the part of any Party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. 

14.11 No Presumption. The Parties acknowledge that any applicable Law that would require interpretation of any claimed ambiguities in
this Agreement against the Party that drafted it has no application and is expressly waived. If any claim is made by a Party relating to any conflict, omission or ambiguity in the provisions of this Agreement, no presumption or burden of proof or
persuasion will be implied because this Agreement was prepared by or at the request of any Party or its counsel. 
 14.12 Adjustments for
Share Splits, Etc. Wherever in this Agreement there is a reference to a specific number of shares of the Company, then, upon the occurrence of any subdivision, combination or share dividend of the relevant class or series of the shares, the
specific number of shares so referenced in this Agreement shall automatically be proportionally adjusted, as appropriate, to reflect the effect on the outstanding shares of such class or series of shares by such subdivision, combination or share
dividend. 
 14.13 Entire Agreement. This Agreement (including the Schedule hereto) together with the other agreements and instruments
referenced herein constitutes the full and entire understanding and agreement among the Parties with regard to the subject matters hereof, and supersedes all prior agreements and understandings between or among any of the Parties with respect to the
subject matters hereof. 
 14.14 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Facsimile and e-mailed copies of signatures shall be deemed to be originals for purposes of the effectiveness of this
Agreement. 
 14.15 Control. In the event of any conflict or inconsistency between any of the terms of this Agreement and any of
the terms of any of the Charter Documents of the Company, or in the event of any dispute related to any such Charter Document, the terms of this Agreement shall prevail in all respects as between the shareholders of the Company
only, the Parties shall give full effect to and act in accordance with the provisions of this Agreement over the provisions of such Charter Documents, and the Parties hereto shall exercise all rights and powers (including to procure any
required alteration to such Charter Documents to resolve such conflict or inconsistency) to make the provisions of this Agreement effective, and not to take any actions that impair any provisions in this Agreement. 

14.16 Termination of Prior Shareholders Agreement. In consideration of the mutual covenants and promises contained herein, each of the
parties to the Prior Shareholders Agreement hereby confirms and covenants with each of the other parties thereto that immediately as of the execution of this Agreement, the Prior Shareholders Agreement shall be irrevocably terminated and replaced in
its entirety by this Agreement. 
 [The remainder of this page has been intentionally left blank.] 

  
 39 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	LIANBIO
		
	By:	 	 /s/ Bing Li

	Name:	 	Bing Li
	Title:	 	Authorized Representative
	Address:	 	LianBio
		 	 c/o Ogier Global (Cayman) Limited
 89 Nexus Way,
Camana Bay
 Grand Cayman, KY1-9009, Cayman Islands

	Attention:	 	Bing Li

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	LIANBIO DEVELOPMENT (CAYMAN) LIMITED
		
	By:	 	 /s/ Konstantin Poukalov

	Name:	 	Konstantin Poukalov
	Title:	 	Director
	Address:	 	LianBio Development (Cayman) Limited
		 	 c/o Ogier Global (Cayman) Limited
 89 Nexus Way,
Camana Bay
 Grand Cayman, KY1-9009, Cayman Islands

	Attention	 	Konstantin Poukalov
	
	LIAN ONCOLOGY
		
	By:	 	 /s/ Konstantin Poukalov

	Name:	 	Konstantin Poukalov
	Title:	 	Director
	Address:	 	Lian Oncology
		 	 c/o Ogier Global (Cayman) Limited
 89 Nexus Way,
Camana Bay
 Grand Cayman, KY1-9009, Cayman Islands

	Attention	 	Konstantin Poukalov
	
	LIAN CARDIOVASCULAR
		
	By:	 	 /s/ Konstantin Poukalov

	Name:	 	Konstantin Poukalov
	Title:	 	Director
	Address:	 	Lian Cardiovascular
		 	 c/o Ogier Global (Cayman) Limited
 89 Nexus Way,
Camana Bay
 Grand Cayman, KY1-9009, Cayman Islands

	Attention	 	Konstantin Poukalov

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	 LIANBIO DEVELOPMENT (HK) LIMITED

(聯拓生物科技有限公司)

		
	By:	 	 /s/ Konstantin Poukalov

	Name:	 	Konstantin Poukalov
	Title:	 	Director
	Address:	 	LianBio Development (HK) Limited
		 	 RM 1901, 19/F Lee Garden One
 33 Hysan Avenue
Causeway Bay
 Hong Kong

	Attention	 	Konstantin Poukalov
	
	 LIAN ONCOLOGY LIMITED

(聯諾腫瘤生物科技有限公司)

		
	By:	 	 /s/ Konstantin Poukalov

	Name:	 	Konstantin Poukalov
	Title:	 	Director
	Address:	 	Lian Oncology Limited
		 	 RM 1901, 19/F Lee Garden One
 33 Hysan Avenue
Causeway Bay
 Hong Kong

	Attention	 	Konstantin Poukalov
	
	 LIAN CARDIOVASCULAR LIMITED

(聯諾心血管生物科技有限公司)

		
	By:	 	 /s/ Konstantin Poukalov

	Name:	 	Konstantin Poukalov
	Title:	 	Director
	Address:	 	Lian Cardiovascular Limited
		 	 RM 1901, 19/F Lee Garden One
 833 Hysan Avenue
Causeway Bay
 Hong Kong

	Attention	 	Konstantin Poukalov

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	LIANBIO, LLC
		
	By:	 	 /s/ Bing Li

	Name:	 	Bing Li
	Title:	 	Authorized Officer
	Address:	 	LianBio, LLC
		 	 1209 Orange Street
 City of Wilmington

State of Delaware 19801

	Attention:	 	Bing Li
	
	LIANBIO LICENSING, LLC
		
	By:	 	 /s/ Bing Li

	Name:	 	Bing Li
	Title:	 	Authorized Signatory
	Address:	 	LianBio Licensing, LLC
		 	 1209 Orange Street
 City of Wilmington

State of Delaware 19801

	Attention:	 	Bing Li
	
	SHANGHAI LIANBIO DEVELOPMENT CO., LTD. (上海联拓生物科技有限公司)
	
	(Corporate Chop)
		
	By:	 	 /s/ Bing Li

	Name:	 	Bing Li
	Title:	 	Legal Representative
	Address:	 	Shanghai LianBio Development Co., Ltd.
		 	 3/F, Building No. 1
 400 Fangchun Road

China (Shanghai) Pilot Free Trade Zone

	Attention:	 	Bing Li

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
		
	By:	 	 /s/ Joseph Edelman

	Name:	 	Joseph Edelman
	Title:	 	Authorized Representative
	Address:	 	 c/o Perceptive Advisors, LLC
 51 Astor Place,
10th Floor
 New York, NY 10003

	Attention:	 	James Mannix
	Email:	 	accounting@perceptivelife.com
	
	LEV LB HOLDINGS, LP
		
	By:	 	LEV LB Holdings GP, LLC its General Partner
		
	By:	 	 /s/ Joseph Edelman

	Name:	 	Joseph Edelman
	Title:	 	Manager
	Address:	 	 c/o Perceptive Advisors, LLC
 51 Astor Place,
10th Floor
 New York, NY 10003

	Attention:	 	Sam Cohn
	Email:	 	accounting@perceptivelife.com
	
	PERCEPTIVE XONTOGENY VENTURE FUND, LP
		
	By:	 	Perceptive Xontogeny Venture GP, LLC its General Partner
		
	By:	 	 /s/ Joseph Edelman

	Name:	 	Joseph Edelman
	Title:	 	Authorized Representative
	Address:	 	 c/o Perceptive Advisors, LLC
 51 Astor Place,
10th Floor
 New York, NY 10003

	Attention:	 	Sam Cohn
	Email:	 	accounting@perceptivelife.com

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	BRIDGEBIO PHARMA LLC
		
	By:	 	 /s/ Neil Kumar

	Name:	 	Neil Kumar
	Title:	 	Chief Executive Officer
	Address:	 	 BridgeBio Pharma LLC
 421 Kipling St.

Palo Alto, CA 94301

	Attention:	 	Neil Kumar, Chief Executive Officer
	Email:	 	nk@bridgebio.com
	Tel:	 	650-391-9740

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	C2 LIFE SCIENCES LLC
		
	By:	 	 /s/ Joseph Edelman

	Name:	 	Joseph Edelman
	Title:	 	Managing Member
	Address:	 	 c/o Perceptive Advisors, LLC
 51 Astor Place, 10th Floor
 New York, NY 10003

	Attention:	 	Peter Fierro
	Email:	 	accounting@perceptivelife.com

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	RA CAPITAL HEALTHCARE FUND, L.P.
		
	By:	 	RA Capital Healthcare Fund GP, LLC, its General Partner
		
	By:	 	 /s/ Raj Shah

	Name:	 	Raj Shah
	Title:	 	Managing Partner
	Address:	 	 RA Capital Management, L.P.
 200 Berkeley
Street, 18th Floor
 Boston, MA 02116

	Attention:	 	General Counsel
	
	RA CAPITAL NEXUS FUND II, LP
		
	By:	 	RA Capital Nexus Fund II GP, LLC, its General Partner
		
	By:	 	 /s/ Raj Shah

	Name:	 	Raj Shah
	Title:	 	Managing Partner
	Address:	 	 RA Capital Management, L.P.
 200 Berkeley
Street, 18th Floor
 Boston, MA 02116

	Attention:	 	General Counsel

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

					
	BLACKWELL PARTNERS LLC - SERIES A
			
	By:	  	 /s/ Abayomi Adigun
	  	 /s/ Jannine M. Lall

	Name:	  	Abayomi A. Adigun	  	Jannine M. Lall
	Title:	  	 Investment Manager
 DUMAC, Inc.

Authorized Agent
	  	 Head of Finance & Controller
 DUMAC,
Inc.
 Authorized Agent

	
	 Address: Blackwell Partners LLC – Series A

280 S. Mangum Street, Suite 210
 Durham, NC 27701

Attention: Jannine Lall

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.
		
	By:	 	VHCP Management III, LLC, its general partner
	By:	 	VR Advisor, LLC, its manager
		
	By:	 	 /s/ Nimish Shah

	Name:	 	Nimish Shah
	Title:	 	Authorized Signatory
	Address:	 	 7 Bryant Park, 23rd Floor

New York, NY 10018

	Attention:	 	Nimish Shah
	
	VHCP CO-INVESTMENT HOLDINGS III, LLC
		
	By:	 	VHCP Management III, LLC, its manager
	By:	 	VR Advisor, LLC, its manager
		
	By:	 	 /s/ Nimish Shah

	Name:	 	Nimish Shah
	Title:	 	Authorized Signatory
	Address:	 	 7 Bryant Park, 23rd Floor

New York, NY 10018

	Attention:	 	Nimish Shah
	
	VENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P
		
	By:	 	VHCP Management EG, LLC, its General Partner
		
	By:	 	 /s/ Nimish Shah

	Name:	 	Nimish Shah
	Title:	 	Authorized Signatory
	Address:	 	 7 Bryant Park, 23rd Floor

New York, NY 10018

	Attention:	 	Nimish Shah

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	AQUILA INVESTMENTS XII
		
	By:	 	 /s/ Tanvir Ghani

	Name:	 	Tanvir Ghani
	Title:	 	Director
	Address:	 	 c/o Tybourne Capital Management (HK) Limited

30/F, AIA Central
 1 Connaught Road Central

Hong Kong
 Attention: Bosun Hau

 
 With a copy (which shall not constitute notice) to:

 
 Tybourne Capital Management (HK) Limited

30/F, AIA Central
 1 Connaught Road Central

Hong Kong
 Attention: Head of Legal

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP
		
	By:	 	Viking Global Opportunities Portfolio GP LLC, its General Partner
		
	By:	 	 /s/ Matthew Bloom

	Name:	 	Matthew Bloom
	Title:	 	Authorized Signatory
	Address:	 	 c/o Viking Global Investors LP
 55 Railroad
Avenue
 Greenwich, CT 06830

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	 T. ROWE PRICE HEALTH SCIENCES FUND, INC.
  

T. ROWE PRICE HEALTH SCIENCES PORTFOLIO
  

Each account severally, and not jointly

		
	By:	 	T. Rowe Price Associates, Inc., Investment Advisor
		
	By:	 	 /s/ Andrew Baek

	Name:	 	Andrew Baek
	Title:	 	Vice President
	Address:	 	 T. Rowe Price Associates, Inc.
 100 East Pratt
Street
 Baltimore, MD 21202

	Attention:	 	Andrew Baek, Vice President and Senior Legal Counsel
	Phone:	 	410-345-2090
	Email:	 	andrew.baek@troweprice.com

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	PFIZER INC.
		
	By:	 	 /s/ Monika Vnuk

	Name:	 	Monika Vnuk
	Title:	 	Vice President, Worldwide Business Development
	Address:	 	 235 East 42nd Street

New York, NY 10017

	Attention:	 	 Bill Burkoth
  

With a copy to:
  

Pfizer Inc.
 235 East 42nd Street
 New York, NY 10017

Attention: Andrew J. Muratore

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	BLACKROCK GLOBAL FUNDS – WORLD HEALTHSCIENCE FUND
		
	By:	 	BlackRock Investment Management LLC, its Investment Advisor
		
	By:	 	 /s/ Hongying Erin Xie

	Name:	 	Hongying Erin Xie
	Title:	 	Managing Director
	Address:	 	 c/o BlackRock Advisors, LLC
 BlackRock Capital
Management, Inc.
 60 State Street, 19th/20th
Floor
 Boston, MA 02109

	Attention:	 	Erin Xie
	Email:	 	 erin.xie@blackrock.com and FEPMAssistantsUS@blackrock.com
  

With a copy (which shall not constitute notice) to:
  

c/o BlackRock, Inc.
 Office of the General Counsel

40 East 52nd Street

New York, NY 10022
 Attn: David Maryles and Michael Roth

Email: legaltransactions@blackrock.com

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	BLACKROCK HEALTH SCIENCES TRUST II
		
	By:	 	BlackRock Advisors, LLC, its Investment Advisor
		
	By:	 	 /s/ Hongying Erin Xie

	Name:	 	Hongying Erin Xie
	Title:	 	Managing Director
	Address:	 	 c/o BlackRock Advisors, LLC
 BlackRock Capital
Management, Inc.
 60 State Street, 19th/20th
Floor
 Boston, MA 02109

	Attention:	 	Erin Xie
	Email:	 	 erin.xie@blackrock.com and FEPMAssistantsUS@blackrock.com
  

With a copy (which shall not constitute notice) to:
  

c/o BlackRock, Inc.
 Office of the General Counsel

40 East 52nd Street

New York, NY 10022
 Attn: David Maryles and Michael Roth

Email: legaltransactions@blackrock.com

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	BLACKROCK HEALTH SCIENCES MASTER UNIT TRUST
		
	By:	 	BlackRock Capital Management, Inc., its Investment Advisor
		
	By:	 	 /s/ Hongying Erin Xie

	Name:	 	Hongying Erin Xie
	Title:	 	Managing Director
	Address:	 	 c/o BlackRock Advisors, LLC
 BlackRock Capital
Management, Inc.
 60 State Street, 19th/20th
Floor
 Boston, MA 02109

	Attention:	 	Erin Xie
	Email:	 	 erin.xie@blackrock.com and FEPMAssistantsUS@blackrock.com
  

With a copy (which shall not constitute notice) to:
  

c/o BlackRock, Inc.
 Office of the General Counsel

40 East 52nd Street

New York, NY 10022
 Attn: David Maryles and Michael Roth

Email: legaltransactions@blackrock.com

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	VIDA VENTURES II, LLC
		
	By:	 	VV Manager II LLC, its Managing Member
		
	By:	 	 /s/ Helen S. Kim

	Name:	 	Helen S. Kim
	Title:	 	Managing Director
	Address:	 	 40 Broad Street, Suite 201
 Boston, MA
02109

	Attention:	 	Helen S. Kim

  

			
	VIDA VENTURES II-A, LLC
		
	By:	 	VV Manager II LLC, its Managing Member
		
	By:	 	 /s/ Helen S. Kim

	Name:	 	Helen S. Kim
	Title:	 	Managing Director
	Address:	 	 40 Broad Street, Suite 201
 Boston, MA
02109

	Attention:	 	Helen S. Kim

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.
		
	By:	 	Wellington Management Company LLP, as investment advisor
		
	By:	 	 /s/ Peter McIsaac

	Name:	 	Peter McIsaac
	Title:	 	Managing Director and Counsel
	Address:	 	 c/o Wellington Management Company LLP
 Legal and
Compliance
 280 Congress Street
 Boston, MA 02210

	Telephone number:	 	(617) 790-7770
	Attention:	 	Peter McIsaac, Managing Director and Counsel
	Email:	 	 #legal-ecm@wellington.com
  

with a copy (which shall not constitute notice) to:
  

Wilmer Cutler Pickering Hale and Dorr LLP
 60 State Street

Boston, MA 02109
 Attn: Jason Kropp

Email: Jason.Kropp@wilmerhale.com

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	ZONE II HEALTHCARE HOLDINGS, LLC
		
	By:	 	Farallon Capital Management, L.L.C., its Manager
		
	By:	 	 /s/ Philip Dreyfuss

	Name:	 	Philip Dreyfuss
	Title:	 	Authorized Signatory
	Address:	 	 c/o Farallon Management Company, L.L.C.
 One
Maritime Plaza, Suite 2100
 San Francisco, CA 94111

	Attention:	 	Philip Dreyfuss
	Email:	 	pdreyfuss@faralloncapital.com and generalcounsel@faralloncapital.com

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	LOGOS OPPORTUNITIES FUND II, L.P.
		
	By:	 	Logos Opportunities GP, LLC, its General Partner
		
	By:	 	 /s/ Graham Walmsley

	Name:	 	Graham Walmsley
	Title:	 	Manager
	Address:	 	 1 Letterman Drive
 Building D, Suite D3-700
 San Francisco, CA 94129

	Attention:	 	Graham Walmsley
	Email:	 	graham@logoscapital.com

 [Signature Page to Second Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	CASDIN PRIVATE GROWTH EQUITY FUND, L.P.
		
	By:	 	Casdin Private Growth Equity Fund GP, LLC, its General Partner
		
	By:	 	 /s/ Kevin O’Brien

	Name:	 	Kevin O’Brien
	Title:	 	General Counsel
	Address:	 	 1350 Avenue of the Americas, Suite 2600
 New
York, NY 10019

	Attention:	 	Fund Accounting
	Email:	 	FundAcct@casdincapital.com

  

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 IN WITNESS WHEREOF, the Parties hereto have caused their respective duly authorized
representatives to execute this Agreement on the date first above written. 
  

			
	SPHERA GLOBAL HEALTHCARE MASTER FUND
		
	By:	 	 /s/ Doron Breen

	Name:	 	Doron Breen
	Title:	 	Director
	Address:	 	 C/O/ Sphera Global Healthcare Management, LP
 21
Ha’arbaa Street
 Tel Aviv, Israel 6473921

  
 [Signature Page to Second
Amended and Restated Shareholders Agreement] 

 Schedule I 

LIST OF SUBSIDIARIES 
  

	 	•	 	 LianBio, LLC, a limited liability company organized and existing under the laws of the State of Delaware;

  

	 	•	 	 LianBio Licensing, LLC, a limited liability company organized and existing under the laws of the State of
Delaware; 

  

	 	•	 	 LianBio Development (Cayman) Limited, an exempted company organized under the Laws of the Cayman Islands;

  

	 	•	 	 LianBio Development (HK) Limited
(聯拓生物科技有限公司), a company limited by shares incorporated under the Laws of Hong Kong; 

  

	 	•	 	 The PRC Company; 

  

	 	•	 	 Lian Oncology, an exempted company organized under the Laws of the Cayman Islands; 

 

	 	•	 	 Lian Oncology Limited
(聯諾腫瘤生物科技有限公司), a company limited by shares incorporated under the Laws of Hong Kong; 

 

	 	•	 	 Lian Cardiovascular, an exempted company organized under the Laws of the Cayman Islands; and

  

	 	•	 	 Lian Cardiovascular Limited
(聯諾心血管生物科技有限公司), a company limited by shares incorporated under the Laws of Hong Kong. 

 Schedule II 

LIST OF ORDINARY SHAREHOLDERS 
 List of
“Ordinary Shareholders”: 
  

	 	•	 	 Perceptive Life Sciences Master Fund, Ltd. 

 

	 	•	 	 LEV LB Holdings, LP 

  

	 	•	 	 Perceptive Xontogeny Venture Fund, LP 

 

	 	•	 	 BridgeBio Pharma LLC 

 Schedule III 

LIST OF INVESTORS 
 Part A: List of
“Series Seed Investors”: 
  

	 	•	 	 Perceptive Life Sciences Master Fund, Ltd. 

 

	 	•	 	 LEV LB Holdings, LP 

  

	 	•	 	 Perceptive Xontogeny Venture Fund, LP 

Part B: List of “Series A Investors”: 
  

	 	•	 	 Perceptive Life Sciences Master Fund, Ltd. 

 

	 	•	 	 C2 Life Sciences LLC 

  

	 	•	 	 RA Capital Healthcare Fund, LP 

 

	 	•	 	 RA Capital Nexus Fund II, LP 

 

	 	•	 	 Blackwell Partners LLC—Series A 

 

	 	•	 	 Venrock Healthcare Capital Partners III, L.P. 

 

	 	•	 	 VHCP Co-Investment Holdings III, LLC 

 

	 	•	 	 Venrock Healthcare Capital Partners EG, L.P. 

 

	 	•	 	 Aquila Investments XII 

 

	 	•	 	 Viking Global Opportunities Illiquid Investments Sub-Master LP

  

	 	•	 	 Pfizer Inc. 

  

	 	•	 	 T. Rowe Price Health Sciences Fund, Inc. 

 

	 	•	 	 T. Rowe Price Health Sciences Portfolio 

 

	 	•	 	 BlackRock Global Funds – World Healthscience Fund 

 

	 	•	 	 BLACKROCK HEALTH SCIENCES TRUST II 

 

	 	•	 	 BLACKROCK HEALTH SCIENCES MASTER UNIT TRUST 

 

	 	•	 	 Vida Ventures II, LLC 

  

	 	•	 	 Vida Ventures II-A, LLC 

 

	 	•	 	 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 

 

	 	•	 	 Zone II Healthcare Holdings, LLC 

 

	 	•	 	 Logos Opportunities Fund II, L.P. 

 

	 	•	 	 Casdin Private Growth Equity Fund, L.P. 

 

	 	•	 	 Sphera Global Healthcare Master FundEX-10.1

 Exhibit 10.1 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, 

MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND 

WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

EXCLUSIVE LICENSE AGREEMENT 

THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), entered into as of August 10th, 2020 (the “Effective Date”), is entered into by and among LianBio, an exempted company organized under the laws of the Cayman Islands (“LianBio”), LianBio
Licensing, LLC, a limited liability company organized and existing under the laws of the State of Delaware and a wholly-owned subsidiary of LianBio (“Licensee”), and MyoKardia, Inc., a corporation organized and existing under the
laws of the State of Delaware, United States (“Company”). 
 INTRODUCTION 

WHEREAS, Licensee wishes to obtain from Company and Company wishes to grant to Licensee certain rights and licenses under intellectual
property owned or controlled by Company to Develop, have Manufactured and Commercialize the Compound and Licensed Products in the Field in the Territory (each as defined below), subject to the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE I 
 DEFINITIONS

 Section 1.1. Definitions. 

Unless the context clearly indicates otherwise, the following terms used in this Agreement will have the meanings set forth in this Section:

 “Accounting Standards” means, with respect to a Person, as applicable (a) generally accepted accounting principles
as practiced in the United States, (b) the PRC generally accepted accounting principles, (c) the International Financial Reporting Standards issued by the International Financial Reporting Standards Foundation and the International
Accounting Standards Board, or (d) applicable accounting standards followed by such Person, in each case, consistently applied. 

“Action” means any claim, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at
law or in equity, whether civil or criminal), assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to, from, by or before any Governmental Authority. 

“Adverse Event” or “AE” has the meaning set forth in the PRC Measures for the Administration of Reporting
and Surveillance of Drug Adverse Events (effective as of July 1, 2011) or the equivalent applicable Laws in any relevant Region, and generally means any untoward medical occurrence associated with the use of a product in human subjects, whether
or not considered related to such product. An AE does not necessarily have a causal relationship with a product, that is, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally
associated with the use of such product. 

 “Affiliate” means, with respect to any Person, any Person controlling,
controlled by or under common control with such first Person, for as long as such control exists. For purposes of this definition, “control” means (a) direct or indirect ownership of fifty percent (50%) or more of the stock or
shares having the right to vote for the election of directors of such Person (or if the jurisdiction where such Person is domiciled prohibits foreign ownership of such entity, the maximum foreign ownership interest permitted under such Laws;
provided, however, that such ownership interest provides actual control over such Person), (b) status as a general partner in any partnership, or (c) the possession, directly or indirectly, of the power to direct, or cause the
direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise. Affiliates of a Party will exclude Persons who are financial investors of such Party or under common control of
such financial investors other than such Party and its subsidiary entities. Notwithstanding the foregoing, [***] Entities will not be deemed an Affiliate of Licensee for purposes of this Agreement. For purposes of
Section 2.2(a), an Affiliate of Lian Cardiovascular shall include only such Persons as are Affiliates within the meaning of this definition by virtue of their being controlled by Lian Cardiovascular, and not controlling or
under common control with Lian Cardiovascular. 
 “Agreement” has the meaning set forth in the preamble. 

“Alliance Manager” has the meaning set forth in Section 5.7(a). 

“Anti-Corruption Laws” means laws, regulations, or orders prohibiting the provision of a financial or other advantage for a
corrupt purpose or otherwise in connection with the improper performance of a relevant function, including without limitation, the US Foreign Corrupt Practices Act (FCPA), the Anti-Unfair Competition Law of the PRC and the Criminal Law of the PRC,
and similar laws governing corruption and bribery, whether public, commercial or both, to the extent applicable in the applicable territory. 

“Auditor” has the meaning set forth in Section 6.6(a). 

“Blocking Third Party Intellectual Property Costs” means any [***] paid by or on behalf of Licensee, its Affiliates or its or
their Sublicensees to a Third Party who Controls Blocking Third Party Intellectual Property Rights for the right to Develop, Manufacture or Commercialize Licensed Products under such Blocking Third Party Intellectual Property Rights. 

“Blocking Third Party Intellectual Property Rights” means, with respect to the Licensed Product in any Region, any [***]
Controlled by a Third Party that, absent a license thereunder, would be infringed by the Development, Manufacture or Commercialization of such Licensed Product in such Region. 

“Breaching Party” has the meaning set forth in Section 12.3(a). 

“Business Day” means any day, other than a Saturday or a Sunday, on which the banks in New York, San Francisco, Beijing, Hong
Kong or the Cayman Islands are open for business. 
 “Calendar Quarter” means each of the three month periods ending on
March 31, June 30, September 30, and December 31 of any Calendar Year; provided, however: (a) the first Calendar Quarter of the Term will extend from the Effective Date to the end of the Calendar Quarter in
which the Effective Date occurs; and (b) the last Calendar Quarter will extend from the beginning of the Calendar Quarter in which this Agreement expires or terminates until the effective date of such expiration or termination. 

“Calendar Year” means, for the first Calendar Year, the period beginning on the Effective Date and ending on
December 31, 2020, and for each Calendar Year thereafter each twelve (12)-month period commencing on January 1, and ending on December 31, except that the last Calendar Year will commence on January 1 of the year in which this
Agreement expires or terminates and end on the effective date of such expiration or termination. 
 “CDE” means the Center
for Drug Evaluation of the NMPA. 

  
 2 

 “cGMP” or “Current Good Manufacturing Practice” means all
applicable then-current standards for Manufacturing, including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. §§ 201, 211, 600 and 610 and all applicable FDA guidelines and
requirements, (b) European Directive 2003/94/EC for medicines and investigational medicines for human use and the applicable guidelines stated in the Eudralex guidelines, (c) PRC Good Manufacturing Practices for Pharmaceuticals effective
as of March 1, 2011 and its appendices, (d) the principles detailed in the applicable ICH guidelines, (e) the conduct of an inspection by a Qualified Person (as defined therein) and the execution by such Qualified Person of an
appropriate certification of inspection; and (f) the equivalent applicable Laws in any relevant Region, each as may be amended and applicable from time to time. 

“Change of Control” means, with respect to an entity, (a) a merger or consolidation of such entity with a third
party that is not an Affiliate of such entity, which results in the voting securities of such entity outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent
more than fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a third party
that is not an Affiliate of such entity, together with Affiliates of such third party, becomes the direct or indirect beneficial owner of more than fifty percent (50%) of the combined voting power of the outstanding securities of such entity, or
(c) the sale or other transfer to a third party that is not an Affiliate of such entity of all or substantially all of such entity’s and its controlled Affiliates’ assets. Notwithstanding the foregoing, any transaction or series of
transactions effected for the primary purpose of financing the operations of the applicable entity (including the issuance or sale of securities for financing purposes), or changing the form or jurisdiction of organization of such entity will not be
deemed a “Change of Control” for purposes of this Agreement. 
 “China Bridging Study” has the meaning set forth
in the definition of Development Key Milestone in this Section 1.1. 
 “Clinical Study” means a
study in which human subjects or patients are dosed with a drug, whether approved or investigational. 
 “CMC” means
Chemistry, Manufacturing and Controls. 
 “CMC Data” means any data included in the CMC portion of a Regulatory Filing or
in any supporting development reports thereto, in each case, with respect to any Licensed Product in any country in the world. 

“CMO Qualifications” has the meaning set forth in Section 4.2. 

“Code” means Title 11 of the U.S. Code. 

“Combination Product” means a Licensed Product that contains or comprises both (a) the Compound and (b) at least
one other active ingredient(s) (each, an “Other Active”), whether packaged together or in a single finished dosage form. 

“Commercial Plan” has the meaning set forth in Section 4.6(c). 

“Commercial Key Milestone” means one or either of the milestones listed below:
 
 (a) [***]; and 
 (b)
[***]. 
 “Commercial Supply Agreement” has the meaning set forth in Section 4.1. 

  
 3 

 “Commercialization”, “Commercializing” or
“Commercialize” means any and all activities related to the pre-marketing, launching, marketing, promotion (including advertising and detailing), medical affairs and education, labeling,
bidding and listing, pricing and reimbursement, distribution, storage, handling, offering for sale, selling, having sold, importing and exporting for sale, having imported and exported for sale, distribution, having distributed, customer service and
support, post-marketing safety surveillance and reporting of a product (including the Licensed Product), and other activities normally undertaken by a pharmaceutical company to commercialize a pharmaceutical product, but not including Manufacturing.

 “Commercialization Partner” means a Third Party engaged by Licensee or its Affiliates or its or their Sublicensees to
Commercialize (inclusive of the right to distribute) Licensed Products in a Region in the Territory. 
 “Commercially Reasonable
Efforts” means, in respect of a Party, [***]. 
 “Company” has the meaning set forth in the preamble. 

“Company Controlled Third Party Intellectual Property Costs” means any [***] paid by or on behalf of Licensee, its Affiliates
or its or their Sublicensees to Company or its Affiliates or, if agreed by Company and Licensee, to the Third Party from which Company or its Affiliates acquires or in-licenses the applicable Company
Controlled Third Party Intellectual Property Rights, for the license or sublicense by Company to Licensee of rights to Develop, Manufacture or Commercialize Licensed Products in the Field in the Territory under Company Controlled Third Party
Intellectual Property Rights. 
 “Company Controlled Third Party Intellectual Property Rights” means any [***] which
Company or its Affiliates acquires or in-licenses from a Third Party that is (a) Controlled by Company or its Affiliate as a result of Licensee electing, as provided in the exception to clause (b) of
the definition of “Control” set forth in this Section 1.1, to take a license or sublicense thereto and agreeing to make the associated Third Party payments to the extent resulting from Licensee’s activities or exercise of its
license or sublicense to such [***], and (b) reasonably necessary for the Development, Manufacture or Commercialization of the Compound or Licensed Products in the Field in the Territory. Notwithstanding the foregoing, Company Controlled Third
Party Intellectual Property Rights shall not include any (i) any [***] Controlled by any Third Party that becomes an Affiliate of Company after the Effective Date as a result of an acquisition, unless such [***] were licensed to Licensee
hereunder prior to such acquisition and are subsequently transferred or assigned to such Affiliate or (ii) any [***] Controlled by Company or any of its Affiliates that claim or Cover an Other Active. 

“Company Indemnified Party” has the meaning set forth in Section 10.2. 

“Company Patent” has the meaning set forth in Section 7.2(d). 

“Competing Product” means any compound or product, other than a Compound or Licensed Product, that is being Developed or
Commercialized [***] as the Compound or Licensed Product that is being Developed or Commercialized in the Territory. 

“Compound” means mavacamten, and [***]. The chemical structure of mavacamten is attached hereto as Exhibit A. 

“Confidential Information” means (a) all trade secrets or confidential or proprietary information (including any
tangible materials embodying any of the foregoing) of the disclosing Party or its Affiliates provided or disclosed to the other Party or any of its Affiliates in connection with this Agreement, (b) “Confidential Information” (as defined in
the Prior CDA) that was disclosed by a Party or any of its Affiliates to the other Party or any of its Affiliates under the Prior CDA, and (c) the terms and conditions of this Agreement (which shall be deemed Confidential Information of both
Parties and, subject to the exceptions provided herein, may not be disclosed by a Party without the other Party’s prior consent); provided, however, that Confidential Information will not include information that: 

  
 4 

 (i) has been published by a Third Party or otherwise is or hereafter becomes
part of the public domain by public use, publication, general knowledge or the like through no breach of confidentiality obligations, wrongful act, fault or negligence on the part of the receiving Party or its Affiliates; 

(ii) has been in the receiving Party’s or its Affiliate’s possession prior to disclosure by the disclosing Party
without any obligation of confidentiality with respect to such information (as evidenced by the receiving Party’s or such Affiliate’s written records or other competent evidence); 

(iii) is subsequently received by the receiving Party or its Affiliate from a Third Party without restriction and without
breach of any agreement between such Third Party and the disclosing Party; or 
 (iv) has been independently developed by or
for the receiving Party or any of its Affiliates without reference to, or use or disclosure of, the disclosing Party’s Confidential Information (as evidenced by the receiving Party’s or such Affiliate’s written records or other
competent evidence); 
 provided, further, that clauses (ii) through (iv) above will not apply to the
terms and conditions of this Agreement. 
 “Continued Patent Right” has the meaning set forth in
Section 7.2(d). 
 “Contract Manufacturing Organization” or “CMO” means a Third
Party contract manufacturing organization. 
 “Control” or “Controlled” means, with respect to any Know-How, Patent Right, Regulatory Filing, Regulatory Approval or other property right, the legal authority or right (whether by ownership, license (other than a license granted pursuant to this Agreement) or
otherwise) of a Person or its Affiliate, to grant access, a license or a sublicense of or under such Know-How, Patent Right, Regulatory Filing, Regulatory Approval or other property right, without [***]
breaching the terms of any agreement with a third party or [***]. Notwithstanding the foregoing, for purposes of the definitions of “Blocking Third Party Intellectual Property Costs” and “Blocking Third Party Intellectual Property
Rights” in this Section 1.1, this defined term “Control” or “Controlled” means, with respect to any [***], the legal authority or right (whether by ownership, license (other than a license
granted pursuant to this Agreement) or otherwise) of a Person or its Affiliate, to grant access, a license or a sublicense of or under such [***], without breaching the terms of any agreement with a third party. 

“Cover,” “Covering” or “Covered” means, when referring to the Licensed Product:
(a) with respect to a Patent Right, that, in the absence of a license granted to a Person under an issued claim included in such Patent Right, the practice by such Person of a specified activity with respect to such Licensed Product would
infringe such claim, or (b) with respect to an application for Patent Rights, that, in the absence of a license granted to a Person under a claim included in such application, the practice by such Person of a specified activity with respect to
such Licensed Product would infringe such claim if such patent application were to issue as a patent. 
 “[***] Agreement”

 “[***]” means [***], a Delaware corporation. 

“Cure Plan” has the meaning set forth in Section 5.2(f). 

  
 5 

 “Cure Plan Notice” has the meaning set forth in
Section 5.2(f). 
 “Data” means non-clinical, clinical,
chemical, manufacturing and analytical data and any other data and information generated, obtained or resulted from the Development or Commercialization of the Licensed Product, including, but not limited to, any and all patient information,
clinical trial data, results, analyses and conclusions. 
 “Development” or “Develop” means non-clinical, pre-clinical, and clinical drug research and development activities, in each of the foregoing, in furtherance of obtaining or maintaining Regulatory Approval of
any Licensed Product, whether before or after Regulatory Approval, including drug metabolism and pharmacokinetics, translational research, toxicology, pharmacology, test method development and stability testing, process and packaging development and
improvement, process validation, process scale-up, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, conduct of Clinical Studies,
regulatory affairs, the preparation and submission of Regulatory Filings, Clinical Study regulatory activities, and any other activities directed towards obtaining or maintaining such Regulatory Approval of any Licensed Product. Development includes
use and importation of the relevant compound or Licensed Product to conduct such Development activities. Development will not include Commercialization activities. 

“Development Key Milestone” means [***], (a) [***], and (b) [***]. 

“Development Key Milestone Deadlock” has the meaning set forth in Section 3.3(a). 

“Development Milestone Event” has the meaning set forth in Section 6.1(d). 

“Development Milestone Payment” has the meaning set forth in Section 6.1(d). 

“Development Plan” has the meaning set forth in Section 3.2. 

“Development Supply Agreement” has the meaning set forth in Section 4.1. 

“Diligence Dispute” has the meaning set forth in Section 5.2(f). 

“Discontinued Patent Right” has the meaning set forth in Section 7.2(d). 

“Dollars” or “US$” means United States dollars. 

“Effective Date” has the meaning set forth in the preamble. 

“Expanded Indication” means an indication that is not [***]. 

“Expert” has the meaning set forth in Section 3.5(b)(ii). 

“Expert Panel” has the meaning set forth in Section 3.5(b)(ii). 

“Export Control Laws” means all applicable U.S. laws and regulations relating to (a) sanctions and embargoes imposed by
the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the Export Administration Act of 1979, 24 U.S.C.
§§ 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706, the Trading with the Enemy Act, 50 U.S.C. §§ 1 et. seq., the Arms Export Control Act, 22 U.S.C. §§ 2778 and 2779, and the
International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended). 
 “Family 1 Licensed
Patent” has the meaning set forth in Section 7.2(d). 
 “FDA” means the United States
Food and Drug Administration or any successor agency thereto. 

  
 6 

 “Failure to Supply” means either of Company or its Affiliates failing to
supply Licensee, its Affiliates or Sublicensees with [***]. 
 “Field” means any indication in humans, which includes any
prophylactic or therapeutic use in humans. 
 “First Commercial Sale” means with respect to the Licensed Product in any
Region, the first sale for monetary value for use or consumption [***]. 
 “Force Majeure Event” has the meaning set
forth in Section 14.10. 
 “FTE” means the equivalent of the work of a full-time individual for a
twelve-month period.  
 “Fully Burdened Manufacturing Cost” means,
with respect to any Licensed Product supplied by or on behalf of Company to Licensee: 
 (a) if such Licensed Product is Manufactured by a
CMO (or by multiple CMOs), the actual, invoiced cost of acquiring such Licensed Product from such CMO (or the sum of such actual, invoiced costs, if Manufactured by multiple CMOs) (i.e., the actual, as invoiced, supply price charged by such CMO(s)),
[***]; or 
 (b) if such Licensed Product (or the Compound contained therein) (or any precursor or intermediate thereof) is Manufactured by
Company or its Affiliates, the actual, fully-burdened cost of such Manufacturing, including [***]. 
 Such costs will be calculated in
accordance with the Accounting Standards and Company’s standard cost accounting policies that are consistently applied to other products that Company or Company’s Affiliates Manufactures or supplies and shall not include inter-company
profits among Company and Company’s Affiliates. Notwithstanding the foregoing, transportation, freight, insurance, import duties, and other shipping costs for any Licensed Products that Licensee is responsible for paying under the shipping
terms under the Supply Agreement will be excluded from the Fully Burdened Manufacturing Costs of such Licensed Products. 

“GCP” or “Good Clinical Practice” means all applicable then-current standards for the design, conduct,
performance, monitoring, auditing, recording, analyses and reporting of Clinical Studies, including, as applicable, (a) as set forth in the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other
guidelines for good clinical practice for trials on medicinal products, (b) the Declaration of Helsinki (2013) as last amended at the 64th World Medical Association in October 2013 and any further amendments or clarifications thereto,
(c) as set forth in the PRC Good Clinical Practice for Pharmaceuticals, as released by the NMPA in 2020, and its subsequent amendments, (d) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56
(Institutional Review Boards) and 312 (Investigational New Drug Application), and (e) the equivalent applicable Laws in any relevant Region, each as may be amended and applicable from time to time and in each case, that provide for, among other
things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. 

“Generic Product” means, with respect to a Licensed Product in a Region, any product that (a) (i) contains the same
active pharmaceutical ingredient(s) as such Licensed Product and (ii) qualifies as a generic or is bioequivalent to and exchangeable with the Licensed Product, as determined by the applicable Regulatory Authority (e.g., for the PRC, currently,
a medication created to be the same as the Licensed Product in dosage form, safety, strength, route of administration, quality, and performance characteristics, and for the same indication) under the applicable Laws in such Region, (b) has
received Regulatory Approval from the relevant Regulatory Authority in such Region in reliance on the Regulatory Approval for such Licensed Product in such Region or any data contained in such Regulatory Approval, (c) during the Royalty Term,
is not owned or licensed by Licensee under this Agreement, and (d) is sold in the same Region as the relevant Licensed Product by a Third Party that is not a Sublicensee or Affiliate of Licensee, and that did not purchase such product in a
chain of distribution that included Licensee, or its Affiliates or its or their Sublicensees. 

  
 7 

 “GLP” or “Good Laboratory Practice” means all applicable
then-current standards for laboratory activities for pharmaceuticals, as set forth in the FDA’s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58, the PRC Good Laboratory Practice effective as of September 1, 2003, or
the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development (OECD), and such standards of good laboratory practice as are required by the equivalent applicable Laws in
the relevant Region and other organizations and governmental agencies in countries in which the Licensed Product is intended to be sold by the Party that is subject to such standards. 

“Governmental Authority” means any multinational, federal, national, state, provincial, local or other entity, office,
commission, bureau, agency, political subdivision, instrumentality, branch, department, authority, board, court, arbitral or other tribunal, official or officer, exercising executive, judicial, legislative, police, regulatory, administrative or
taxing authority or functions of any nature pertaining to government. 
 “HFpEF” means heart failure with preserved
ejection fraction. 
 “Hong Kong” means the Hong Kong Special Administration Region of the PRC. 

“ICH” means the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for
Human Use. 
 “Indemnified Party” means a Person entitled to indemnification under ARTICLE X. 

“Indemnifying Party” means a Party from whom indemnification is sought under ARTICLE X. 

“Infringement” has the meaning set forth in Section 7.3(a). 

“Infringement Action” has the meaning set forth in Section 7.3(b). 

“Infringement Claim” has the meaning set forth in Section 7.4. 

“Initial Commercial Plan” has the meaning set forth in Section 4.6(c). 

“Initial Development Plan” has the meaning set forth in Section 3.2(a). 

“Invention” means inventions, Know-How, developments or discoveries, whether
patentable or non-patentable. 
 “JMC” has the meaning set forth in
Section 5.6(b). 
 “JSC” has the meaning set forth in Section 5.1. 

“Key Milestone” means a Development Key Milestone or a Commercial Key Milestone. 

“Know-How” means all chemical and biological materials and other tangible materials,
inventions, practices, methods, protocols, formulae, knowledge, know-how, trade secrets, processes, procedures, assays, skills, experience, techniques, information, data and results of experimentation and
testing, including pharmacological, toxicological and pre-clinical and clinical test data and analytical and quality control data, patentable or otherwise.
“Know-How” excludes Patent Rights. 

  
 8 

 “Law” or “Laws” means all laws, statutes, rules, codes,
regulations, orders, decrees, judgments or ordinances of any Governmental Authority, or any license, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. 

“LianBio” has the meaning set forth in the preamble. 

“Lian Cardiovascular” means Lian Cardiovascular, an exempted company organized under the laws of the Cayman Islands and, as
of the Effective Date, a wholly-owned subsidiary of LianBio and an Affiliate of Licensee. 
 “Licensed Know-How” means any and all Know-How that is (a) Controlled by Company or any of its Affiliates as of the Effective Date or at any time during the Term
(including any and all Regulatory Filings, Regulatory Approvals, CMC Data, and any and all information contained therein) and (b) [***] for the Development, Manufacture or Commercialization of the Compound or Licensed Products in the Field in the
Territory. Exhibit B contains a list of Licensed Know-How as of the Effective Date that are contained in the data room for transfer to Licensee. For the avoidance of doubt, Licensed Know-How will include any Know-How contained in the Product Inventions Controlled by Company or any of its Affiliates to the extent it meets the definition of Licensed Know-How above. Notwithstanding the foregoing, Licensed Know-How shall not include [***]. 

“Licensed Patents” means any and all Patent Rights (a) Controlled by Company or any of its Affiliates as of the
Effective Date or at any time during the Term and (b) that are [***] for the Development, Manufacture or Commercialization of the Compound or Licensed Products in the Field in the Territory. Exhibit C contains a list of Licensed Patents
as of the Effective Date. For the avoidance of doubt, Licensed Patents will include any Patent Rights contained in the Product Inventions Controlled by Company or any of its Affiliates to the extent it meets the definition of Licensed Patents above.
Notwithstanding the foregoing, Licensed Patents shall not include [***]. 
 “Licensed Product” means any pharmaceutical
product containing the Compound (whether alone as the sole active ingredient or as a combination with other active ingredient(s)) in any form, presentation, formulation or dosage form. 

“Licensed Technology” means, collectively, Licensed Patents and Licensed Know-How.

 “Licensed Trademark” means the mark that has been or will be registered with a trademark office in a Region with respect
to a Licensed Product as may be provided by Company to Licensee in writing from time to time during the Term. 
 “Licensee”
has the meaning set forth in the preamble. 
 “Licensee Indemnified Party” has the meaning set forth in
Section 10.1. 
 “Local Trademarks” has the meaning set forth in
Section 4.6(f). 
 “Long-Form Document” means a draft agreement containing all material terms
applicable to the Transaction to which it relates (including grant of rights or licenses, field of use, territory, sublicensing rights, scope of licensed intellectual property, material scope of Development or Commercialization rights, Development
and Commercialization diligence obligations and milestones, material manufacturing and supply terms, material governance and final decision-making terms, scope of exclusivity, intellectual property ownership,
non-compete covenants, and material financial and tax terms). For the avoidance of doubt, a Long-Form Document may or may not be intended to be an definitive, executable agreement and may or may not contain
all terms customary for agreements for transactions similar to such Transaction. 

  
 9 

 “Losses” means damages, losses, liabilities, costs (including costs of
investigation and defense), fines, penalties, taxes, expenses, or amounts paid in settlement (in each case, including reasonable attorneys’ and experts’ fees and expenses), in each case resulting from an Action. 

“Macau” means the Macao Special Administration Region of the PRC. 

“Manufacture” or “Manufacturing” of the Compound or Licensed Product, as the case may be, means all
activities related to the production of the Compound or Licensed Product, as the case may be, including the production of any of the following to the extent used in the Compound or Licensed Product: any drug substance produced in bulk form for use
as an active pharmaceutical ingredient, drug product, compounded or finished final packaged and labeled form, and in intermediate states, including the following activities: reference standard preparation, purification, formulation, scale-up, packaging, quality assurance oversight, quality control testing (including in-process release and stability testing), validation activities directly related to all
of the foregoing, and data management and recordkeeping related to all of the foregoing. References to Manufacturing activities performed by a Party will include having any or all of the foregoing activities performed by a Third Party. 

“Manufacturing Technology Transfer” has the meaning set forth in Section 4.2(a). 

“Marketing Authorization” means the grant of all necessary final or conditional permits, registrations, authorizations,
licenses and approvals (or waivers) required for the importation and Commercialization of the Licensed Product for use in the Field in the Territory, including any Regulatory Approval for sale or marketing, and, where required, Pricing and
Reimbursement Approvals. 
 “[***]” means Company’s product candidate externally known as [***]. 

“NDA” means a new drug application or similar application or submission filed with or submitted to any Regulatory Authority
to obtain permission to commence marketing and sales of a pharmaceutical product in any particular jurisdiction. 
 “Net
Sales” means, with respect to a Licensed Product in a Region for any period, the total amounts invoiced for sales of such Licensed Product in such Region for such period by Licensee, its Affiliates or its or their Sublicensees or
Commercialization Partners (the “Selling Party”) to Third Parties that are not Selling Parties in the Territory, in bona fide arm’s length transactions and as calculated in accordance with the applicable Accounting Standards,
less the following deductions, in each case, related specifically to such Licensed Product and actually incurred, paid or accrued by the Selling Party in accordance with the Selling Party’s Accounting Standards and not otherwise recovered by or
reimbursed to the Selling Party: 
 (a) discounts (including trade, cash and quantity discounts), cash and non-cash coupons, charge back payments and rebates granted to managed health care organizations, hospitals, pharmacies, or group purchasing organizations, or to federal, state and local governments, their agencies,
and purchasers and reimbursers or to customers or required by applicable Law (including governmental medical assistance programs); 

(b) [***] credits, allowances, repayments, discounts to and chargebacks for claims, spoiled, damaged, or outdated goods,
rejections or returns of the Licensed Products, including Licensed Products returned in connection with recalls or withdrawals; 

(c) any sales, value added or similar taxes, insurance, custom duties, excise (including annual fees due under
Section 9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48)) or other similar governmental charges levied directly on the production, sale,
transportation, delivery or use of a Licensed Product [***]; 

  
 10 

 (d) [***] freight and insurance costs and other expenses incurred in
distributing, warehousing, importing, handling and transporting the Licensed Product to distributors or customers, [***]; 

(e) wholesalers’ stocking, inventory management or distribution fees [***]; 

(f) delayed ship order credits, discounts, or payments related to the impact of price increases [***]; 

(g) retroactive price reductions or billing corrections; 

(h) amounts that are written off as uncollectible; [***]; and 

(i) other specifically identifiable amounts deducted for reasons similar to those listed above in accordance with the Selling
Party’s Accounting Standards. 
 Each of the amounts set forth above will be determined from the books and records of
the Selling Party, maintained in accordance with their respective Accounting Standards, consistently applied. No amount for which deduction is permitted pursuant to the above shall be deducted more than once. In addition, to the extent any amounts
deducted pursuant to the above are subsequently recovered by or reimbursed to the Selling Party, such recovered amounts shall be deemed “Net Sales” for the subsequent Calendar Quarter; provided that, if no royalties are owed
by Licensee for such subsequent Calendar Quarter pursuant to this Agreement, Licensee shall promptly refund such recovered amounts to Company. 

Net Sales will be calculated only once for the first bona fide arm’s length sale of the Licensed Product to a Third Party
that is not a Selling Party. Net Sales does not include (a) any sale of such Licensed Product to or between Licensee, its Affiliates or its or their Sublicensees or Commercialization Partners for further sale by such entity (but includes the
subsequent sale by such entity to a Third Party that is not a Selling Party), (b) samples of Licensed Product used to promote additional Net Sales, in amounts consistent with normal business practices of a Selling Party, (c) any use of such
Licensed Product in Clinical Studies, pre-clinical studies or other Development activities, or (d) the disposal, use or transfer of such Licensed Product at or below cost for a bona fide charitable
purpose, including expanded access, compassionate use, patient assistance or named patient use. 
 [***] 

Subject to the above, Net Sales will be calculated in accordance with the standard internal policies and procedures of the
Selling Party, if any, copies of which policies and procedures will be furnished to Company upon request, and which must in any case be in accordance with its Accounting Standards. 

“nHCM” means non-obstructive hypertrophic cardiomyopathy. 

“NMPA” means the National Medical Product Administrations of the PRC, or its successor. 

“Non-Breaching Party” has the meaning set forth in
Section 12.3(a). 
 “oHCM” means obstructive hypertrophic cardiomyopathy. 

“Other Actives” has the meaning set forth in the definition of “Combination Product” in this
Section 1.1. 
 “Party” means Company or Licensee; “Parties” means Company and
Licensee, collectively. 

  
 11 

 “Party Vote” has the meaning set forth in
Section 5.5. 
 “Patent Rights” means the rights and interests in and to (a) all patents and
patent applications (including provisional applications), including all divisionals, continuations, substitutions, continuations-in-part,
re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any other pre- or post-grant forms of
any of the foregoing, (b) any confirmation patent or registration patent or patent of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations, foreign counterparts, and
the like of any of the foregoing, (c) any and all patents that have issued or in the future issue from the foregoing patent applications, including author certificates, utility models, petty patents, innovation patents and design patents and
certificates of invention. 
 “[***] Entities” means [***]. 

“Permissible Third Party” means a Third Party with [***] capabilities in the business of pharmaceutical sales or development
or that a Party can demonstrate has or can acquire the capabilities to perform the Development and/or Commercialization of the Licensed Product in the Field in the Territory as contemplated by this Agreement. 

“Person” means any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship or
other business organization or a Governmental Authority. 
 “Pharmacovigilance Agreement” has the meaning set forth in
Section 3.7. 
 “PRC” means the People’s Republic of China, which for the purposes of this
Agreement, excludes Hong Kong, Macau and Taiwan. 
 “PRC Manufacturer” has the meaning set forth in
Section 4.2(a). 
 “Pricing and Reimbursement Approval” means, with respect to the Licensed
Product, the governmental approval, agreement, determination or decision establishing the price or level of reimbursement for such Licensed Product, in a given Region prior to the sale of such Licensed Product in such Region. 

“Prior CDA” means the Mutual Confidential Disclosure Agreement, executed June 29, 2020, by and between LianBio and
Company. 
 “Product Data and Materials” has the meaning set forth in Section 7.1(b). 

“Product Inventions” has the meaning set forth in Section 7.1(a). 

“Product Marks” has the meaning set forth in Section 4.6(f). 

“Product Trademarks” has the meaning set forth in Section 4.6(f). 

[***] 

“Province” means each of the provinces, autonomous regions, and municipalities of the PRC. 

“Qualified Financing” means the [***] round of equity financing of LianBio or Lian Cardiovascular after the Effective Date
(which shall include any convertible debt, convertible preferred share or other equity-linked derivative security financing), in a single or series of related transactions, which raises gross proceeds to LianBio or Lian Cardiovascular of at least
[***]. 
 “Referee” has the meaning set forth in Section 3.3(b). 

  
 12 

 “Region” means each country or region in the Territory, comprising of each
of the PRC, Macau, Hong Kong, Taiwan, Thailand, and Singapore. 
 “Regulatory Approval” means the final or conditional
approval of the applicable Regulatory Authority necessary for the marketing and sale of the Licensed Product in the Field in a country(ies) or Region(s), excluding separate Pricing and Reimbursement Approval that may be required. 

“Regulatory Approval Application” means an application to seek regular or expedited Regulatory Approval of the Licensed
Product for sale or marketing in any country(ies) or Region(s) in the Territory, as defined in the applicable Laws and filed with the Regulatory Authority of such country(ies) or Region(s), such as NDAs. 

“Regulatory Authority” means any multinational, federal, national, state, provincial or local regulatory agency, department,
bureau or other Governmental Authority with authority over the clinical development, Manufacture, marketing or sale of the Licensed Product in a Region, including the NMPA in the PRC. 

“Regulatory Deadlock” has the meaning set forth in Section 3.5(b)(ii). 

“Regulatory Exclusivity” means, with respect to a Licensed Product in a Region, the period of time during which: (a) a
Party or its Affiliates or its or their sublicensees has been granted the exclusive legal right by a Regulatory Authority in such Region to market and sell such Licensed Product; or (b) the data and information submitted by a Party or its
Affiliates or its or their sublicensees to the relevant Regulatory Authority in such Region for purposes of obtaining Regulatory Approval of such Licensed Product in such Region may not be disclosed, referenced, or relied upon in any way by a Third
Party or such Regulatory Authority (including by relying upon the Regulatory Authority’s previous findings regarding the safety or effectiveness of the Licensed Product) to support the Regulatory Approval of any product of a Third Party in such
Region. 
 “Regulatory Filing” means any documentation comprising any filing or application with any Regulatory Authority
with respect to the Licensed Product, and any documents submitted to any Regulatory Authority, including INDs, Regulatory Approval Applications, Regulatory Approvals, Marketing Authorizations, and all correspondence with any Regulatory Authority
with respect to any Licensed Product (including minutes of any meetings, telephone conferences or discussions with any Regulatory Authority). 

[***] 

“Royalty Term” has the meaning set forth in Section 6.2(b). 

“Rules” has the meaning set forth in Section 13.2. 

“Safety Data” means any Adverse Event information from human trials and all results from
non-clinical safety studies, including toxicology and carcinogenicity data (if any), with respect to the Licensed Product required by one or more Regulatory Authorities to be collected or to be reported to
such Regulatory Authorities under applicable Laws, but excluding any information related to the efficacy of the Licensed Product. 

“Safety Issue” has the meaning set forth in Section 3.5(b)(ii). 

“Sale Transaction” has the meaning set forth in Section 14.1(b). 

“[***]” has the meaning set forth in Section 14.1(b). 

  
 13 

 “Sales Milestone Event” has the meaning set forth in
Section 6.1(e). 
 “Sales Milestone Payment” has the meaning set forth in
Section 6.1(e). 
 “Selling Party” has the meaning set forth in the definition of “Net
Sales” in this Section 1.1. 
 “Senior Officers” means (a) with respect to
Company, the Chief Executive Officer of Company, and (b) with respect to Licensee, the Chief Executive Officer of LianBio. If the position of any of the Senior Officers identified in this definition no longer exists due to a corporate
reorganization, corporate restructuring or the like that results in the elimination of the identified position, the applicable title of the Senior Officer set forth herein will be replaced with the title of another executive officer with
responsibilities and seniority comparable to the eliminated Senior Officer, and the relevant Party will promptly provide notice of such replacement title to the other Party. 

“Subcommittee” has the meaning set forth in Section 5.6. 

“Sublicense” means a grant of rights from Licensee to a Sublicensee under any of the rights licensed to Licensee by Company
under Section 2.1 with respect to the Development, Manufacture or Commercialization of any Licensed Product in the Field in the Territory. 

“Sublicensee” means any Third Party to whom Licensee has directly or indirectly granted a Sublicense under all or any portion
of the license granted by Company hereunder. 
 “Supply Agreement” means any of the Development Supply Agreement and
Commercial Supply Agreement. 
 “Tax Withholdings” has the meaning set forth in Section 6.7(a).

 “Tech Transfer Agreement” has the meaning set forth in Section 4.3. 

“Tech Transfer Notice” has the meaning set forth in Section 4.2(a). 

“Tech Transfer Plan” has the meaning set forth in Section 4.3. 

“Term” has the meaning set forth in Section 12.1. 

“Territory” means the PRC, Macau, Hong Kong, Taiwan, Thailand and Singapore.
 
 “Third Party” means any Person other than a Party or any of its Affiliates. 

“Third Party Claim” has the meaning set forth in Section 10.3(a). 

“Third Party Losses” means Losses resulting from an Action by a Third Party. 

“Trademark” means all registered and unregistered trademarks, service marks, trade dress, trade names, logos, insignias,
domain names, symbols, designs, and combinations thereof. 
 “Transaction” means any direct or indirect license,
assignment, sale, joint venture or any other form of transaction that would grant any Third Party any right to Develop or Commercialize [***] in the Field in all or any portion of the Territory. 

“Two-Invoice Policy” means the policy described in the “Opinion on the
Implementation of the ‘Two-Invoices’ System in the Procurement of Pharmaceutical Products by Public Medical Institutions (trial)” (Guoyigaibanfa [2016] No. 4), officially released on
January 9, 2017 and in any other applicable Laws, which policy mandates public hospitals or any other purchaser of drugs in the PRC to purchase drugs from the distributor that purchases the drugs directly from the drug manufacturer, limiting
the total number of invoices to two. 

  
 14 

 “United States” or “U.S.” or “US” means
the United States and its territories, possessions and commonwealths. 
 “Upstream Licenses” means any and all agreements
between Company or any of its Affiliates, on the one hand, and any Third Party, on the other hand, existing as of the Effective Date pursuant to which Company (a) in-licenses any Patent Rights or Know-how owned or Controlled by such Third Party that are included as part of the Licensed Patents or Licensed Know-How or (b) agrees to provisions that would require
Licensee to make any payments (including royalties) to any Third Party or to undertake or observe any restrictions or obligations with respect to the Development, Manufacture or Commercialization of Licensed Products in the Field in the Territory.

 “Valid Claim” means either: (a) a claim of an issued and unexpired patent included within the Licensed Patents that
(i) has not been irrevocably or unappealably disclaimed or abandoned, or been held unenforceable, unpatentable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction; and (ii) has not been admitted to
be invalid or unenforceable through reissue, disclaimer, or otherwise; or (b) a claim included in a patent application included within the Licensed Patents that has neither been irretrievably cancelled, withdrawn or abandoned, nor been pending
for more than [***] from the earliest filing date to which such patent application or claim is entitled. 
 “Warrant
Shares” means has the meaning set forth in Section 6.1(b). 
 “Warrants” means has the
meaning set forth in Section 6.1(b). 
 ARTICLE II 

LICENSE GRANTS 

Section 2.1. License Grant; Right of Reference.  

(a) Exclusive License Grant. Subject to the terms and conditions of this Agreement, Company hereby grants to Licensee an exclusive (even
with respect to Company and its Affiliates), sublicensable (subject to Section 2.2), royalty-bearing right and license under the Licensed Technology to Develop, have Manufactured (subject to
Section 4.1 and Section 4.2 and solely for the purpose of Developing and Commercializing the Licensed Products in the Field in the Territory), Commercialize, use, offer for sale, sell, have sold,
and import the Licensed Products in the Field in the Territory. 
 (b) Licensee Right of Access and Reference. Company hereby grants
Licensee access to, and a right of reference with respect to, (i) all Regulatory Filings, and (ii) all Data generated relating to the Licensed Products, including clinical and pre-clinical data,
Safety Data and CMC Data contained or referenced in such Regulatory Filings, in each case (i) and (ii), Controlled by Company or its Affiliates as of the Effective Date or at any time during the Term that are reasonably necessary for
Developing, seeking and securing INDs, Regulatory Approvals, and Marketing Authorizations for the Development, Manufacture and Commercialization of the Compound and Licensed Products in the Field in the Territory. Notwithstanding the foregoing, the
foregoing rights do not extend to the materials, data and information set forth in clauses (i) and (ii) that relate to, and to the extent they relate to, any Other Active. The foregoing rights include the right for Licensee and, to the extent
permitted under this Agreement, its Affiliates and its and their Sublicensees, to make copies of and reproduce such documentation and information for the purposes set forth in this Section 2.1(b). 

  
 15 

 (c) Delivery of Documentation. From time-to-time during the Term, upon a Party’s reasonable request, the other Party will promptly provide the requesting Party with copies of all data and information relating to the Licensed Products that
are (i) Controlled by and in the possession of the other Party or its Affiliates and (ii) reasonably necessary for the requesting Party’s Development or obtaining Regulatory Approval or Marketing Authorization for, the Compound and
Licensed Products, in the case that Licensee is the requesting Party, in the Field in the Territory, and in the case that Company is the requesting Party, outside the Field in the Territory or outside or in the Field outside the Territory. 

Section 2.2. Sublicensing.  

(a) Licensee Right to Sublicense. Licensee will have the right to grant sublicenses under the rights granted to Licensee by Company
pursuant to Section 2.1: (i) to its Affiliate that is Lian Cardiovascular or an Affiliate of Lian Cardiovascular [***]; provided that any such sublicense to Lian Cardiovascular will terminate if such
sublicensee ceases to be an Affiliate of Licensee and any such sublicense to an Affiliate of Lian Cardiovascular will terminate if such sublicensee ceases to be an Affiliate of Licensee or of Lian Cardiovascular; or (ii) to an Affiliate of
Licensee that is not Lian Cardiovascular nor an Affiliate of Lian Cardiovascular or to a Third Party [***]; provided that any such sublicense to an Affiliate that is not Lian Cardiovascular nor an Affiliate of Lian Cardiovascular will
terminate if such sublicensee ceases to be an Affiliate of Licensee. Notwithstanding the foregoing, Licensee’s exercise of the sublicense right and its Affiliates’ exercise of the further sublicense right shall not have a material adverse
impact on the value of the Warrant. 
 (b) Sublicense Requirements. Each Sublicense granted by Licensee to a Third Party pursuant to
Section 2.2(a) will (i) be in writing and be subject to and consistent with the applicable terms and conditions of this Agreement, (ii) be provided to Company at least [***] prior to the effective date thereof,
and (iii) [***]. Without limiting the foregoing, all sublicenses must include provisions for (x) assignment of intellectual property rights consistent with Licensee’s obligations under Section 2.6(b),
Section 4.6(f) and ARTICLE VII; and (y) protection of Confidential Information at least as stringent as those contained in ARTICLE VIII. [***]. Licensee shall keep Company informed through the JSC of each
sublicense granted to an Affiliate or Third Party, specifying the name of the sublicensee and the material terms (including duration) of the sublicense. 

Section 2.3. Performance by Independent Contractors. Licensee may contract or delegate any portion of its obligations hereunder to
an Affiliate, Sublicensee or contractor, subject to the terms and conditions of Section 14.9 and, with respect to the Manufacture of the Licensed Product, Section 4.1 and
Section 4.2; provided that Licensee shall keep Company informed through the JSC of each subcontract entered into therewith, specifying the name of the contract service provider and the material terms
(including duration) of the subcontract. Licensee is responsible for the compliance of its Affiliates, Sublicensees and contractors with the terms and conditions of this Agreement, and any act or omission of an Affiliate, a sublicensee or
subcontractor that would be a material breach of this Agreement if performed by Licensee will be deemed to be a material breach by Licensee under this Agreement. For clarity, Licensee shall have no right to contract or delegate its obligations
hereunder to any Affiliate of Licensee or any contractor, CMO or other Third Party, in each case, under terms permitting the performance of any activities related to the Compound or Licensed Product outside the Territory, including any Manufacture
(for any purpose) of any Licensed Product or any Compound contained therein outside the Territory. 
 Section 2.4. Exclusivity
Covenant.  
 (a) During the Term, Licensee will not, and will cause its Affiliates and Sublicensees not to, (i) directly or
indirectly, whether by itself or with or through any of its Affiliates or (ii) with, through or in collaboration with any Third Party, whether through license, assignment, joint venture, investment or otherwise (including via any arrangement or
series of arrangements with a Third Party), Develop or Commercialize any Competing Product in the Field in the Territory. 
 (b) [***] 

  
 16 

 Section 2.5. [***] 

Section 2.6. Licensor Right of Access and Reference.  

(a) Regulatory Filings and Documentation. Licensee hereby grants Company, its Affiliates and its and their licensees access to, and a
right of reference with respect to, all Regulatory Filings Controlled by Licensee, its Affiliates, or Sublicensees as of the Effective Date or at any time during the Term after the Regulatory Approvals have been transferred to Licensee. 

(b) Data and Materials. Licensee hereby grants Company an exclusive (even with respect to Licensee and its Affiliates), sublicensable,
royalty-free, fully-paid license to use the Product Data and Materials for any purpose outside the Territory and for research purposes in the Territory. Licensee shall (i) transfer or otherwise provide to Company access to Product Data and
Materials at the request of Company, and (ii) take all such other steps as Company may deem necessary or appropriate in order to achieve Company’s right to the Product Data and Materials (including Company’s right to the Product Data
and Materials upon termination of this Agreement set forth in Section 12.4(h)) as provided under this Agreement. Without limiting the foregoing, Licensee shall obtain, and shall cause its Affiliates, and/or Sublicensees to
obtain, a written consent from all trial subjects in form and substance approved by Company (which consent form shall contain such provisions that would give Company consent to access and use all data and samples obtained from trial subjects) and in
the circumstances agreed by Company and Licensee when performing its or their obligations under this Agreement in accordance with such study protocol for Developing the Product in the Territory as set forth in the Development Plan approved by the
JSC. In addition, Licensee shall cooperate with Company to ensure that all relevant agreements reflect Company’s right hereunder (including Company’s right to the Product Data and Materials upon termination of this Agreement set forth in
Section 12.4(h)), including inclusion in the agreements with trial sites and clinical research organizations an obligation for such service providers to give Company (or its designee) full access to all data and samples
collected as well as results and reports of the clinical trials on the Compound and Licensed Products conducted in the Territory to the extent not expressly prohibited by applicable Laws. In the event that, and to the extent that, applicable Laws
prevent the disclosure or transfer of any Product Data and Materials (including data associated with clinical trials or individual patients) to, or the processing of data by, Company, then Licensee shall, and shall procure its Affiliates, and
Sublicensee to, to the extent not expressly prohibited by applicable Laws, disclose or transfer the same to an entity designated by Company. In the event that applicable Laws prevent disclosure or transfer of Product Data and Materials by Licensee
(or, if applicable, its Affiliates or Sublicensee) to, or the processing of Product Data and Materials by, Company’s designee, then Company and Licensee shall negotiate in good faith to put in place arrangements that will allow Company to as
far as permitted under applicable Laws to obtain the same rights and economic benefits as it would have been entitled to had a transfer to Company or Company’s designee been permitted. 

Section 2.7. Reservation of Rights. No rights, other than those expressly set forth in this Agreement, are granted to any Party
under this Agreement, and no additional rights will be deemed granted to any Party by implication, estoppel or otherwise, with respect to any intellectual property rights. All rights not expressly granted by any Party or its Affiliates to the other
Party under this Agreement are reserved. Neither Party nor any of its Affiliates will use or practice any Know-How or Patent Rights licensed or provided to such Party or any of its Affiliates outside the scope
of or otherwise not in compliance with the rights and licenses granted to such Party or its Affiliates under this Agreement. For clarity, Company reserves the exclusive right to conduct or have conducted any research under the Licensed Technology
anywhere in the world (including the Territory) and the right to conduct or have conducted the Development and Manufacturing activities of the Product anywhere in the world (including the Territory) for the purposes of Developing and Commercializing
the Compound and any Licensed Product outside the Territory. 

  
 17 

 ARTICLE III 

DEVELOPMENT 

Section 3.1. Development Diligence; Development Responsibilities. 

(a) Development Diligence. Licensee shall, and shall cause its Sublicensees (including any Affiliate which is granted a sublicense by
Licensee pursuant to Section 2.2(a)) to, use Commercially Reasonable Efforts to perform the activities assigned to it in the Development Plan, at its sole expense. Licensee will not be deemed to be in breach of its
obligations under this Section 3.1(a) to the extent it is prevented from or delayed in using Commercially Reasonable Efforts to perform an activity assigned to it in the Development Plan as a result of the acts or omissions
of Company, including Company’s breach of any of its obligations under this Agreement or failure to timely perform its obligations under the Development Plan. If Licensee is delayed in performing (or fails to perform) an obligation assigned to
Licensee in the Development Plan or fails to timely achieve a Development Key Milestone as a result of Company’s failure to timely perform any of its obligations under this Agreement or the Development Plan, then the deadlines for the
performance of Licensee’s obligations under the Development Plan or to achieve the applicable Development Key Milestone will be extended commensurate with the delay caused by Company. 

(b) Development Responsibilities; Certain Limitations. Subject to the terms and conditions of this Agreement, including this ARTICLE
III and ARTICLE V, Licensee will have sole responsibility for, authority over, and discretion with respect to, at its own expense, the Development of the Compound and Licensed Products for the purpose of obtaining Regulatory Approval in
the Field in the Territory. Licensee will be responsible for the day-to-day implementation of any Development activities for which it (or any of its Affiliates) is
assigned responsibility under this Agreement (including the Development Plan). Licensee shall not Develop any Licensed Product in the Territory for an indication other than indications approved by the JSC and included in the then-current Development
Plan. 
 Section 3.2. Development Plan. 

(a) Development in the PRC. As of the Effective Date, a high-level plan with respect to the Development of the Licensed Products in the
PRC for [***] is attached hereto as Exhibit F (the “Initial Development Plan”). Within [***] of the Effective Date, the JSC will develop and approve a detailed development plan for the Development and Regulatory Approval for
a Licensed Product in the Field in the PRC for [***], and within [***] after the Effective Date, the JSC will develop and approve a detailed development plan for the Development and Regulatory Approval for a Licensed Product in the Field in the PRC
for each of [***] and certain segments of [***], including details with respect to [***], and such plan, once approved by the JSC, will be attached hereto as Exhibit F and replace the Initial Development Plan (such development plan, together
with the Initial Development Plan until it is replaced in accordance with the foregoing, the “Development Plan”). For the avoidance of doubt, such Development Plan shall specify milestones as agreed by the JSC. Any material changes
to the Development Plan, including proposed changes to the Development Plan as a result of any interaction with any Regulatory Authority, will be agreed upon by the JSC pursuant to Section 5.2, subject to the
decision-making and escalation procedures set forth in Section 5.5. 
 (b) Development in Other Regions.
With respect to any Region, other than the PRC, in which the approval of a Regulatory Approval Application of a Licensed Product can be based on [***], Licensee shall provide the JSC with an updated Development Plan for approval no later than [***]
and, following the approval of such updated Development Plan by the JSC, shall use Commercially Reasonable Efforts to Develop such Licensed Product in such Region in accordance with such updated Development Plan. With respect to any Region, other
than the PRC, in which the approval of a Regulatory Approval Application of a Licensed Product can be based on [***], Licensee shall provide the JSC with an updated Development Plan for approval no later than [***] and, following the approval of
such updated Development Plan by the JSC, shall use Commercially Reasonable Efforts to 

  
 18 

 
Develop such Licensed Product in such Region in accordance with such updated Development Plan. For the avoidance of doubt, Licensee’s failure to provide the JSC with the applicable updated
Development Plan for approval in accordance with this Section 3.2(b) shall be deemed to be a material breach for the purposes of Section 12.3(a) solely with respect to the applicable Region, and
Company will only have the right to terminate this Agreement with respect to such Region under Section 12.3(a). With respect to any Region, other than the PRC, in which the approval of a Regulatory Approval Application of a
Licensed Product can be based on [***], Licensee’s obligation under this Section 3.2(b) shall be triggered by the one that occurs first. 

Section 3.3. Development Key Milestones. 

(a) In the event a Regulatory Authority (including CDE and NMPA) requires or permits a different Development pathway than that contemplated in
the then-current Development Plan, and that materially changes (in either an expedited or in a delayed fashion) the timing for achieving any of the Development Key Milestones, then (i) the existing Development Key Milestones will no longer
apply to Licensee, its Affiliates and its and their Sublicensees, (ii) the JSC will determine new Development Key Milestones taking into consideration [***]; provided that if, following the decision-making procedures under
Section 5.5, the JSC and the Senior Officers are not able to agree on new Development Key Milestones (a “Development Key Milestone Deadlock”), then the new Development Key Milestones will be determined in
accordance with Section 3.3(b), and (iii) the Parties will memorialize such new Development Key Milestones in writing, whether through an amendment to this Agreement or separate side letter. Following such amendment or
side letter, the JSC will update the Development Plan as necessary. Licensee will use Commercially Reasonable Efforts to perform the activities assigned to it in the updated Development Plan in accordance with Section 3.1.

 (b) Either Company or Licensee may refer any Development Key Milestone Deadlock to [***] with expertise in the pharmaceutical industry in
the PRC who is neutral, independent, disinterested, and impartial (the “Referee”) pursuant to the following procedures. Company and Licensee will in good faith jointly choose the Referee. Each of Company and Licensee agrees to use
Commercially Reasonable Efforts to jointly choose a Referee within [***] after the date of the last discussion of the matter by the Senior Officers. Each of Company and Licensee will submit to the Referee the last new Development Key Milestone
proposed by its Senior Officer to the Referee with a copy to the other Party. The Referee will promptly review such proposals and resolve the matter by determining the new Development Key Milestone taking into consideration [***], which may differ
from the new Development Key Milestones last proposed by each Party’s Senior Officer. The Referee will resolve the matter pursuant to such procedures that it establishes and in a manner he or she deems fair and equitable; provided,
however, that each of Company and Licensee will be afforded an opportunity to provide a written submission in support of its position and to advocate for its position personally before the Referee. Each of Company and Licensee agrees to use
Commercially Reasonable Efforts to cooperate with the Referee and to cause the Referee to resolve the matter as promptly as practicable and in any event no later than [***] after selection of the Referee. All submissions to, and communications and
proceedings of, the Referee shall be in the English language. The new Development Key Milestone determined by the Referee will be final, conclusive and binding on the Parties. The fees and expenses of the Referee will be borne by the Party whose
last new Development Key Milestone proposed by its Senior Officer varies the greatest from the new Development Key Milestone determined by the Referee. 

Section 3.4. Development Records and Reporting. 

(a) Records. Licensee will maintain complete and accurate records of all work conducted by Licensee in furtherance of seeking Regulatory
Approval for the Licensed Products in the Field in the Territory. Such records will be maintained in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and in accordance with applicable Laws. 

  
 19 

 (b) Reporting. Licensee will provide the JSC with a written report, at least [***],
in English, describing in reasonable detail Licensee’s activities and progress related to the pursuit of Regulatory Approval for the Licensed Products in the Field in the Territory. Licensee will respond to the JSC’s reasonable questions
or requests for additional information relating to such activities in a timely manner. Unless otherwise agreed by Company, any documentation that Licensee provides or presents to the JSC shall be in the English language, and Licensee shall prepare
and provide, at [***] expense, accurate English translations or English summaries of any documentation that Licensee provides or presents to the JSC originally in a language other than English; provided that, [***]. 

Section 3.5. Regulatory Submissions and Approvals; Communications; Meetings. 

(a) Regulatory Filings and Approvals. Licensee, or its relevant Affiliates or Sublicensees, will have the sole and exclusive right to
file and hold all Regulatory Filings, and to apply for and maintain all Regulatory Approvals and Pricing and Reimbursement Approvals, in each case, for all Licensed Products in the Field in the Territory at Licensee’s cost and expense in the
name of Licensee or any of its Affiliates or its or their Sublicensees; provided that [***]. Subject to the terms and conditions of this Agreement, Licensee will be responsible, at its sole cost and expense, for all regulatory
activities leading up to and including the obtaining of Regulatory Approvals and any Pricing and Reimbursement Approvals, as applicable, for Licensed Products in the Field from Regulatory Authorities or Governmental Authorities in the Territory;
provided that [***]. 
 (b) Regulatory Communications. Subject to applicable Laws and this
Section 3.5 (including the rest of this Section 3.5(b)), Licensee will oversee, monitor and manage all interactions and communications with Regulatory Authorities with respect to the Licensed
Products in the Field in the Territory. 
 (i) If any regulatory activities are conducted in Licensee’s name, Licensee will have final
decision-making authority regarding all regulatory activities, including the content of Regulatory Filings for Licensed Products in the Field in the Territory; provided that Licensee will (A) promptly notify Company of all
communications or correspondence with Regulatory Authorities with respect to the Licensed Products in the Field in the Territory that are received by Licensee from any Regulatory Authority or submitted by Licensee to any Regulatory Authority and
will provide copies of such communications or correspondence and Regulatory Filings in their original format and language, English summaries of material communications or correspondence, and English translations of material Regulatory Filings to
Company for review and comment (which will be provided with sufficient advanced notice so that Company may meaningfully review and comment); and (B) reasonably consider in good faith all comments provided by Company with respect to such
communications or correspondence. Notwithstanding Section 3.5(b)(i)(B) above, Licensee shall [***] any reasonable comment provided by Company to the extent such comment is related to a Safety Issue or any data, results or
other information provided by or obtained from Company.  
 (ii) If any regulatory activities are conducted in Company’s name,
subject to the rest of this Section 3.5(b)(ii), (A) Company will [***]; and (B) Licensee shall, and shall ensure that its relevant Affiliates and Sublicensees will, [***]. If Licensee reasonably believes [***], will
materially delay or adversely impact the Development or Commercialization of the Licensed Product in Field in the Territory, Company and Licensee shall discuss and attempt to resolve such matters through the JSC and the Senior Officers pursuant to
the procedures set forth in Section 5.5. If, following the decision-making procedures under Section 5.5, the JSC and the Senior Officers are not able to reach an unanimous decision with respect to
such matter (“Regulatory Deadlock”), either Company or Licensee may refer any Regulatory Deadlock to an expert panel comprising [***], with expertise in the pharmaceutical industry and the Development and Regulatory Approval of
pharmaceutical products in the relevant Region(s) in the Territory and who are neutral, independent, disinterested, and impartial (each, an “Expert” and collectively, the “Expert Panel”), pursuant to the following
procedures. Each of Company and Licensee shall appoint one (1) Expert who shall together choose a third Expert. Each of Company and Licensee shall appoint its Expert by written notice to the 

  
 20 

 
other Party no later than [***] after the Senior Officers fail to resolve such matter. Company and Licensee shall direct their appointed Experts to choose the third Expert no later than [***]
after the date of appointment of the second Expert. The Expert Panel will resolve the Regulatory Deadlock by making the final decision in good faith by majority vote; provided, however, that each of Company and Licensee will be
afforded an opportunity to provide a written submission in support of its position and to advocate for its position personally before the Expert Panel. Each of Company and Licensee agrees to use Commercially Reasonable Efforts to cooperate with the
Expert Panel and shall instruct the Expert Panel to resolve the matter as promptly as practicable and in any event no later than [***] after selection of the Expert Panel. The Expert Panel’s decision will be final, conclusive and binding on the
Parties. All submissions to, and communications and proceedings of, the Expert Panel shall be in the English language. The fees and expenses of the Expert Panel will be borne by the Party whose decision proposed by its Senior Officer varies the
greatest from the final decision made by the Expert Panel. For purposes of Section 3.5(b)(i) and Section 3.5(b)(ii), [***]. The deadline to achieve the applicable Development Key Milestone will be
extended commensurate with the time required to resolve any matter under this Section 3.5(b)(ii) in accordance with the dispute resolution procedures of this Section 3.5(b)(ii) (including
discussion of the matter at the JSC and by the Senior Officers and resolution of a Regulatory Deadlock). 
 (c) Regulatory Meetings.
Licensee will provide Company with reasonable prior written notice (within [***] after its receipt of the meeting notice from a Regulatory Authority) of all meetings with Regulatory Authorities in the Field in the Territory (including advisory
committee meetings and any other meeting of experts convened by a Regulatory Authority) regarding the Licensed Product unless expressly prohibited by applicable Laws or the Regulatory Authority. Company will have the right to request to be present
at (but not participate in, unless requested by Licensee or the Regulatory Authority) all such meetings with Regulatory Authorities to the extent permitted under applicable Laws and by the applicable Regulatory Authorities and to the extent
Company’s attendance would not delay such meetings, at Company’s sole cost; provided that if Company’s attendance or participation in any of such meetings is required by applicable Laws or requested by Licensee or any
Regulatory Authority, Licensee shall reimburse Company for all costs incurred by Company. 
 (d) Termination or Suspension of Clinical
Studies. Notwithstanding anything to the contrary in this Agreement or the Pharmacovigilance Agreement, the Parties hereby agree that (i) Licensee may terminate or suspend any Clinical Study relating to the Licensed Product in the Field in
the Territory, without the approval or consent of the JSC or Company, if (A) a Regulatory Authority, institutional review board or safety data review board for such Clinical Study has required or recommended such termination or suspension or
(B) Licensee believes, in good faith, that such termination or suspension is warranted because of observed safety risks to the study subjects or patients, and (ii) Licensee shall terminate or suspend any Clinical Study relating to the
Licensed Product in the Field in the Territory if Company notifies Licensee of Company’s good faith belief that such termination or suspension is warranted because of observed safety risks to the study subjects or patients; provided
that, prior to terminating or suspending such Clinical Study as provided in Section 3.5(d)(i)(B) or Section 3.5(d)(ii), the JSC shall first convene a safety committee as a Subcommittee
comprised of [***] representatives of Licensee and [***] representatives of Company, each with expertise in the area of pharmaceutical product safety, that shall meet and discuss such terminating Party’s concerns and, following such meeting,
prepare a written summary of their conclusions, or if the safety committee cannot reach a unanimous conclusion, a written summary of each Party’s representative’s conclusions, and the terminating Party shall consider such conclusions in
good faith before terminating or suspending, or directing the termination or suspension of, such Clinical Study. In either case, Licensee will promptly notify Company in writing of such termination or suspension. In the event that Licensee
terminates any Clinical Study pursuant to Section 3.5(d)(i)(B) (after considering in good faith the conclusions of the safety committee or each Party’s representative), Company shall have the right (but not the
obligation) to take over the conduct of such Clinical Study and, if Company elects to do so, Licensee shall cooperate with Company to transfer the conduct of such Clinical Study to Company, to the extent permitted by applicable
Laws.      

  
 21 

 (e) Regulatory Investigation or Inquiry. If any Regulatory Authority
(i) contacts Licensee or its Affiliate with respect to the alleged improper Development, Manufacture or Commercialization of any Licensed Product, (ii) conducts, or gives notice of its intent to conduct, an inspection at Licensee’s,
its Affiliates’ or its or their Sublicensees’ or its subcontractors’ facilities used in the Development of the Licensed Product, or (iii) takes, or gives notice of its intent to take, any other regulatory action with respect to
any activity of Licensee, its Affiliates or its or their Sublicensees or subcontractors, with respect to (i) through (iii), then Licensee will promptly notify Company in writing of such contact, inspection or notice. Unless expressly prohibited
by applicable Laws or the Regulatory Authority, Company shall be entitled to be present during any such inspection; provided that, Licensee shall not be required to reschedule any such inspection in order for Company to be present.

 Section 3.6. Development of the Licensed Products outside the Territory or outside the Field. For clarity, Company retains
the exclusive right and will be solely responsible and have sole discretion and control over the Development activities (including regulatory activities) of the Licensed Products outside the Field, whether in or outside the Territory, and in the
Field outside the Territory. Company will oversee, monitor and manage all interactions and communications with Regulatory Authorities with respect to such Licensed Products in such fields and territories. Company will have final decision-making
authority regarding all regulatory activities, including the labeling strategy and the content of Regulatory Filings with respect to such Licensed Products in such fields and territories. In the event Company’s or its Affiliates’ or its or
their other licensees’ Development activities (including regulatory activities) of such Licensed Product in the Field outside the Territory would reasonably be expected to materially adversely impact Licensee’s Development, or
Commercialization of the Licensed Products in the Field in the Territory, Company will give the JSC reasonable advance notice of any such activities prior to undertaking such activities. Without limiting Section 3.1,
Company and Licensee, through their representatives on the JSC, will discuss in good faith such activities and Company will consider in good faith the views and suggestions of the JSC to minimize the impact of such activities on Licensee’s
Development or Commercialization of the Licensed Products in the Field in the Territory. 
 Section 3.7. Pharmacovigilance.
Within [***] after the Effective Date, Company and Licensee will negotiate in good faith and finalize the actions that Company and Licensee will employ with respect to the Licensed Products to protect patients and promote their well-being in a
written pharmacovigilance agreement (the “Pharmacovigilance Agreement”). These responsibilities will include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication, and exchange (as
between Company and Licensee) of Adverse Event reports and any other information concerning the safety of any Licensed Product, including recall and withdrawal responsibilities, processes and procedures. Such guidelines and procedures will be in
accordance with, and enable Company and Licensee to fulfill, local and national regulatory reporting obligations under applicable Laws. Furthermore, such agreed procedure will be consistent with relevant ICH guidelines, except where said guidelines
may conflict with existing local regulatory reporting safety reporting requirements, in which case local reporting requirement will prevail. Licensee will be responsible for reporting quality complaints, Adverse Events and safety data related to the
Licensed Product in the Field to applicable Regulatory Authorities in the Territory, as well as responding to safety issues and to all requests of Regulatory Authorities relating to Licensed Products in the Field in the Territory; provided
that Licensee will conduct such activities (1) in its own name, if Licensee is the legal and beneficial owner of the Regulatory Approvals for the Licensed Products in the Field in the Territory or (2) as the express and authorized
regulatory agent of record for Company in the Field in the Territory, if Company is the legal and beneficial owner of the Regulatory Approvals for the Licensed Products in the Territory, under which situation such actions will be taken on behalf of
Company and for the benefit of Licensee in the Field in the Territory. Company will be responsible for reporting quality complaints, Adverse Events and safety data related to Licensed Product to applicable Regulatory Authorities outside the Field in
the Territory and outside the Territory, as well as responding to safety issues and to all requests of Regulatory Authorities relating to Licensed Product outside the Field in the Territory and outside the Territory. The Pharmacovigilance Agreement
will also provide for a worldwide safety database to be maintained by Company at its sole cost and expense, to which Licensee shall contribute 

  
 22 

 
data in such form and format, and on such other terms, as provided in the Pharmacovigilance Agreement and which worldwide safety database will be accessible by Licensee, its Affiliates,
Sublicensees and contractors to the full extent necessary for Licensee to exercise its rights under this Agreement, comply with its obligations under this Agreement, and comply with all applicable Laws. Each of Company and Licensee hereby agrees to
comply with its respective obligations under such Pharmacovigilance Agreement and to cause its Affiliates and its and their sublicensees and contractors to comply with such obligations. 

ARTICLE IV 
 MANUFACTURE,
SUPPLY AND COMMERCIALIZATION 
 Section 4.1. General. Subject to Section 4.2, (a) within [***]
following the Effective Date, Company and Licensee will negotiate in good faith and enter into a supply agreement for the Manufacture and supply of the Licensed Products by Company to Licensee for Development in the Field in the Territory (such
agreement, “Development Supply Agreement”), under which Development Supply Agreement Licensee, its Affiliates and its and their Sublicensees will exclusively purchase from Company all of its and their needs for the Licensed Products
for Development in such form as Company and Licensee will mutually agree in the Development Supply Agreement and at a price equal to [***] of Company’s Fully Burdened Manufacturing Cost; provided that such price shall not be
greater than [***] per unit (subject to an appropriate inflation factor); and (b) within [***] following the first submission of a NDA for a Licensed Product in the Field in the Territory, Company and Licensee will negotiate in good faith and
enter into a supply agreement for the Manufacture and supply of such Licensed Product by Company to Licensee for Commercialization in the Field in the Territory (such agreement, “Commercial Supply Agreement”), under which Commercial
Supply Agreement Licensee, its Affiliates and its and their Sublicensees will exclusively purchase from Company all of its and their needs for the Licensed Product for Commercialization in such form as Company and Licensee will mutually agree in the
Commercial Supply Agreement and at a price not to exceed [***] of Company’s Fully Burdened Manufacturing Cost. Each Supply Agreement will specify customary terms, including a quality agreement. In addition, the Commercial Supply Agreement will
specify (i) such additional details with regard to a Failure to Supply as may be agreed by the Parties, (ii) an arrangement for Commercialization whereby Company and Licensee agree on a rolling forecast of anticipated demand by Licensee,
its Affiliates and its and their Sublicensees for Licensed Product for not less than a [***] period, which forecast for the nearest [***] period is a binding forecast, and (iii) lead time for placing orders. In the event Company and Licensee
agree to another definition of fully burdened manufacturing costs for Commercial supply or failure to supply for Commercialization in the Commercial Supply Agreement, such definition of fully burdened manufacturing cost for Commercial supply or
failure to supply for Commercialization in such Commercial Supply Agreement will supersede and replace the definition of Fully Burdened Manufacturing Cost or Failure to Supply in this Agreement for the purpose of such Commercial Supply Agreement.

 Section 4.2. Exceptions to Company’s General Supply Obligation. Notwithstanding
Section 4.1: 
 (a) if the JSC approves Licensee’s request to have the Licensed Product Manufactured in the
PRC, then Licensee may, upon written notice to Company (such notice, the “Tech Transfer Notice”), have Manufactured such Licensed Product in the PRC via a Third Party CMO in the PRC approved by Company (which approval (i) shall
not be unreasonably withheld so long as such Third Party CMO satisfies all the qualification requirements set forth in Exhibit H (the “CMO Qualifications”) and (ii) may be withheld at Company’s sole discretion if
such Third Party CMO fails to satisfy any of the CMO Qualifications) (such approved Third Party CMO, the “PRC Manufacturer”); and thereafter, Company will transfer or cause to be transferred to such PRC Manufacturer all Know-How Controlled by Company or its Affiliates that is reasonably necessary to Manufacture such Licensed Product in the PRC, including, with respect to the Compound, in substantially the same manner as Company
Manufactures such Licensed Product, for Licensee, its Affiliates or its or their Sublicensees for the PRC as of the date of the Tech Transfer Notice, including as further provided in Section 4.3 (the “Manufacturing
Technology Transfer”); 

  
 23 

 (b) notwithstanding Section 4.2(a), if (i) a Failure to
Supply occurs with respect to a Licensed Product in the Territory or (ii) Licensee is entitled to terminate this Agreement pursuant to Section 12.3(d) but elects not to terminate this Agreement, then, in each case,
Licensee may issue a Tech Transfer Notice to Company and cause Company to transfer or cause to be transferred to Licensee’s designated Third Party CMO, [***], and Company will, upon the receipt of the Tech Transfer Notice, initiate the
Manufacturing Technology Transfer to such Third Party CMO; and 
 (c) periodically during the Term, Company and Licensee, acting through
their representatives on the JSC, will discuss whether to establish additional Manufacturing sources for Licensed Products in the Territory and, if the JSC decides to establish such additional sources, then Company and Licensee will meet and agree
on any appropriate amendments to this Agreement, including with respect to the exclusivity obligations set forth in Section 4.1. 

Section 4.3. Manufacturing Technology Transfer. In the event Licensee provides a Tech Transfer Notice to Company with
respect to a Licensed Product, within [***] of Company’s receipt of such Tech Transfer Notice, Company and the PRC Manufacturer will enter into a technology transfer agreement (the “Tech Transfer Agreement”) in English
detailing a technology transfer plan (the “Tech Transfer Plan”) for the Manufacturing Technology Transfer. Within [***] following the execution of the Tech Transfer Agreement, Company will commence the Manufacturing Technology
Transfer to the PRC Manufacturer in accordance with the Tech Transfer Plan. All reasonable and documented out-of-pocket costs incurred by Company in connection with the
Manufacturing Technology Transfer will be borne by Licensee and its Affiliates. Company will have the right to oversee any such Manufacturing Technology Transfer, subject to applicable Laws. Among other things, the Tech Transfer Plan will provide
that Company will, or will cause its applicable CMOs to, provide all reasonable assistance it could reasonably provide to the PRC Manufacturer to effectuate the Manufacturing Technology Transfer and otherwise enable the PRC Manufacturer to
Manufacture the Licensed Product in substantially the same manner as Company Manufactures such Licensed Product, including with respect to the Compound, for Licensee, its Affiliates or its or their Sublicensees for the applicable Region as of the
date of the Tech Transfer Notice, including providing or causing Company’s CMOs to provide Licensee with knowledge transfer activities at Licensee’s costs. Upon release of the first cGMP batch of such Licensed Product from the PRC
Manufacturer, the Manufacturing Technology Transfer will be deemed completed. 
 Section 4.4. Two-Invoice
Policy. The Parties agree that in the event, under the Two-Invoice Policy and tendering policies and applicable Laws in a given province in the PRC,
neither Licensee nor any of its Affiliates can, based on their existing qualifications, distribute the Licensed Products for such province directly or indirectly to its distributors for the PRC, then Company and Licensee will use Commercially
Reasonable Efforts to discuss in good faith and agree to alternative arrangements for the distribution of the Licensed Product in such province that complies with the Two-Invoice Policy as implemented in such
province and that maintains the economic interests of Company and Licensee as agreed under this Agreement. 
 Section 4.5. Audit by
Licensee. Company will keep any and all records, materials and documents relating to the Manufacture of the Compound and Licensed Products for Licensee, its Affiliates and its and their Sublicensees during the Term and [***] thereafter. During
the Term, Licensee will have the right [***] to have an independent, certified public accountant, selected by Licensee and reasonably acceptable to Company to inspect such records, materials and documents for the purpose of determining the accuracy
of the applicable fully burdened manufacturing cost due within the prior [***] period. Such audit may not be conducted more than [***] and will take place at the location(s) where such records, materials, documents are maintained by Company upon
reasonable prior written notice, during regular business hours and under obligations of confidentiality. If it is determined that any amounts were overpaid or underpaid during such period, Company will pay Licensee such

  
 24 

 
overpaid amounts, or Licensee will pay Company the overpaid amounts within [***] of the date the independent certified public accountant’s written report is received by the paying Party. The
fees charged by such independent certified public accountant will be paid by Licensee, unless it is determined that any overpaid amounts exceed [***] of the total amount payable by Licensee to Company for the period then being audited, in which case
Company will be responsible for the fees charged by such independent certified public accountant. 
 Section 4.6.
Commercialization. 
 (a) Commercialization Diligence. Upon receipt of the first Marketing Authorization for the first Licensed
Product in the Field in a Region, Licensee shall, and shall cause its Affiliates, Sublicensees or Commercialization Partners to use Commercially Reasonable Efforts to Commercialize such Licensed Product in the Field in such Region in accordance with
the Commercial Plan, at its sole expense. If Licensee is delayed in performing (or fails to perform) an obligation assigned to Licensee in the Commercial Plan as a result of Company’s failure to timely perform any of its obligations under this
Agreement or the Commercial Plan or to timely achieve a Commercial Key Milestone, then the deadlines for the performance of Licensee’s obligations under the Commercial Plan or to achieve the applicable Commercial Key Milestone will be extended
commensurate with the delay caused by Company. 
 (b) Commercial Responsibilities. Subject to the terms and conditions of this
Agreement, including this Section 4.6 and ARTICLE V, Licensee will have sole responsibility for, authority over, and discretion with respect to, at its own expense, the Commercialization of the Licensed Products in
the Field in the Territory. Licensee will be responsible for the day-to-day implementation of any such Commercialization activities. 

(c) Commercial Plan. As of the Effective Date, a high-level plan with respect to the Commercialization of Licensed Products in the
Territory is attached hereto as Exhibit G (the “Initial Commercial Plan”). No later than [***], the JSC will develop and approve a standard commercial plan for the Commercialization of the Licensed Product in the Field in
such Region, including details with respect to [***], will be attached hereto as Exhibit G and replace the Initial Commercial Plan (such commercial plan, together with the Initial Commercial Plan until it is replaced in accordance with the
foregoing, the “Commercial Plan”). Any material changes to the Commercial Plan, including proposed changes to the Commercial Plan as a result of any interaction with any Regulatory Authority, will be agreed upon by the JSC pursuant
to Section 5.2, subject to the decision-making and escalation procedures set forth in Section 5.5. 

(d) Commercialization Report. Licensee shall update the JSC at the JSC’s regularly-scheduled meetings regarding Licensee’s
significant Commercialization activities for the Licensed Products in the Territory. Without limiting the foregoing, Licensee shall present written reports [***] to the JSC that summarize Licensee’s significant Commercialization activities with
respect to the Licensed Products in the Territory, at a level of detail reasonably sufficient to enable Company to determine Licensee’s compliance with its diligence obligations pursuant to this Section 4.6. 

(e) Commercial Key Milestones. In the event Licensee or its Affiliates or its or their Sublicensees wishes to engage a Permissible Third
Party to Commercialize Licensed Products in the PRC, then Licensee or its Affiliates or its or their Sublicensees, as applicable, must [***], then (i) the existing Commercial Key Milestones will no longer apply to Licensee, its Affiliates and
its or their Sublicensees, (ii) Company and Licensee will use good faith efforts to modify the Commercial Key Milestones with the Permissible Third Party only to such an extent that would not materially delay the overall Commercialization
timeline or adversely affect the overall Commercialization activities set forth in the Commercial Plan then in effect before such Permissible Third Party is engaged, and (iii) memorialize such agreement in writing, whether through an amendment
to this Agreement or separate side letter. Following such amendment or side letter, the JSC will update the Commercial Plan as necessary to reflect the newly agreed Commercial Key Milestones. For clarity, neither Licensee, its Affiliates nor its or
their Sublicensees will need to obtain Company’s prior written consent before engaging a Permissible Third Party to Commercialize Licensed Products in a Region in the Territory other than the PRC. 

  
 25 

 (f) Trademarks. Subject to obtaining necessary Regulatory Approvals, Licensee will
Commercialize the Licensed Products in the Field and in the Territory using (i) the Licensed Trademark (the “Product Trademarks”); or (ii) a local language product name and related trademarks for each Region selected by
Licensee and approved by the JSC (the “Local Trademarks”, and together with the Product Trademarks, the “Product Marks”). If Company has a global brand trademark for the Licensed Product and such trademark is
available for use in a Region in accordance with applicable Laws and without opposition from a Third Party, then upon the request of Licensee, Company shall designate such global brand trademark as the Licensed Trademark hereunder. Company will own
and retain all rights to all Product Marks (together with all goodwill associated therewith) in the Territory, and will prepare, file, prosecute and maintain all Product Marks in the Territory at its own expense; provided, however,
Company will provide to Licensee copies of all applications, submissions, communications, and correspondence intended to be sent to, sent to or received by Governmental Entities or Third Parties in connection with such filing, prosecution, and
maintenance of the Product Marks in the Territory so that Licensee may review and comment thereon (which will be provided with sufficient advanced notice so that Licensee may meaningfully review and comment, to the extent practicable), and will
incorporate any reasonable comments provided by Licensee with respect to such applications, submissions, communications, or correspondence. Subject to terms and conditions of this Agreement, Company will grant and hereby grants a non-exclusive, sublicensable (subject to Section 2.2), fully paid-up, royalty free, non-transferrable
(subject to Section 14.1) license under the Product Marks for Licensee to Commercialize the Licensed Products in the Field in the Territory. Licensee shall comply with Company’s guidelines on the use and display of the
Product Marks and quality control instructions. 
 (g) Marking. To the extent permitted by applicable Laws, Licensee shall include on
all packaging and promotional materials for each Licensed Product a designation, in accordance with a written guidelines by Company, (i) that the Licensed Product incorporates the Licensed Patent Rights, including the word “patent” or
the abbreviation “pat.” and either the relevant Licensed Patents or a web address that is freely accessible to the public and that lists the relevant Licensed Patents and (ii) if applicable, that the Licensed Product is Manufactured
by Company, which designations must be in accordance with the patent marking provisions of 35 U.S.C. § 287(a) and any other applicable Laws in the Territory and include Company’s mark(s) designated by Company in a form and manner
reasonably acceptable to Company. Licensee shall also ensure that all Sublicensees and applicable subcontractors mark the Licensed Product accordingly. 

(h) Diversion. Subject to applicable Laws, each of Company and Licensee hereby covenants and agrees that (i) it and its Affiliates
will not, and it will contractually obligate (and use Commercially Reasonable Efforts to enforce such contractual obligation) its licensees, sublicensees and contractors not to, directly or indirectly, actively promote, market, distribute, import,
sell or have sold any Licensed Product, including via the Internet or mail order, to any Third Party or to any address or Internet Protocol address or the like, in the other Party’s territory, and (ii) neither Company nor Licensee will
engage, nor permit its Affiliates, sublicensees or contractors to engage, in any advertising or promotional activities relating to any Licensed Product for use directed primarily to customers or other buyers or users of such product located in any
country, Region or jurisdiction in the other Party’s territory, or solicit orders from any prospective purchaser located in any country, Region or jurisdiction in the other Party’s territory. If either Company or Licensee or any of its
Affiliates or sublicensees receives any order for Licensed Product for use from a prospective purchaser located in a country or jurisdiction outside such Party’s territory, such Party, its Affiliates or sublicensees shall immediately refer that
order to the other Party and shall not accept any such orders. Neither Company nor Licensee shall, nor permit its Affiliates or sublicensees to, deliver or tender (or cause to be delivered or tendered) any Product for use in the other Party’s
territory. 

  
 26 

 (i) No Violation. Notwithstanding anything to the contrary contained herein, Licensee
(including its Affiliates, Sublicensees and contractors) will not be obligated to undertake or continue any Commercialization activities with respect to Licensed Products if Licensee (or its Affiliates, Sublicensees or contractors, as applicable)
reasonably determines that performance of such Commercialization activity would violate applicable Laws or infringe any Third Party Patent Rights. 

ARTICLE V 
 GOVERNANCE;
JOINT STEERING COMMITTEE 
 Section 5.1. Formation; Purposes and Principles. As soon as practicable following the Effective
Date, but in no event later than [***] after the Effective Date, Company and Licensee will form a joint steering committee (the “JSC”) to provide oversight and to facilitate information sharing between Company and Licensee with
respect to the activities of Company and Licensee under this Agreement. 
 Section 5.2. Specific Responsibilities. In addition
to its overall responsibility to provide strategic oversight and to facilitate information sharing between Company and Licensee with respect to the activities of Company and Licensee under this Agreement, the JSC will: 

(a) coordinate and share information with respect to the Development and Commercialization of the Licensed Product by Licensee in the Field in
the Territory; 
 (b) as set forth in Section 3.2 and Section 4.6(c), review, discuss and
approve the Development Plan and Commercial Plan and amendments or changes thereto; 
 (c) in furtherance of
Section 2.1(b), Section 2.1(c), Section 2.6, and Section 3.5, coordinate and share information and progress with respect to (i) the
Development and Commercialization of Licensed Products and (ii) any interactions with Regulatory Authorities relating to Licensed Products, with respect to each foregoing clause (i) and (ii), by or on behalf of Licensee and occurring in
the Territory; 
 (d) in furtherance of Section 2.1(b), Section 2.1(c) and
Section 3.6, coordinate and share information and progress with respect to (i) the Development and Commercialization of products or (ii) any interaction with Regulatory Authorities relating to products, with
respect to each, by or on behalf of Company and occurring outside of the Territory, but solely to the extent such Development activities, Commercialization activities or interactions with Regulatory Authorities are reasonably likely to materially
impact Licensee’s Development or Commercialization of Licensed Products in the Territory; 
 (e) (i) oversee JMC’s activities,
(ii) review JMC’s report and recommendation and decide on whether to use a Third Party Manufacturing Contractor in the PRC or Licensee Manufacture the Licensed Products in the Territory, and (iii) once JSC approves Licensee’s
request to have the Licensed Products Manufactured in the PRC pursuant to Section 4.2(a) or the conditions set forth in Section 4.2(b) are satisfied, coordinate and share information to facilitate
the Manufacturing Technology Transfer to the PRC Manufacturer as set forth in Section 4.2 and Section 4.3; 

(f) establish Cure Plan (as defined below) as follows: if Company determines Licensee has (i) breached any of its general Development or
Commercialization diligence obligations as set forth in Section 3.1(a) or Section 4.6(a) or (ii) failed to achieve a Key Milestone by the applicable date for such Key Milestone, subject to
Section 3.3 and Section 4.6(e), then (A) Company will notify Licensee of the foregoing in writing (such notice, “Cure Plan Notice”), (B) the JSC will, within [***] (which time
period will be extended to [***] if either Company or Licensee reasonably determines that it is necessary or useful to seek guidance from the applicable Regulatory Authority in 

  
 27 

 
establishing the Cure Plan) after Company serving the Cure Plan Notice to Licensee, establish a plan to remedy such breach or failure (a “Cure Plan”), and (C) Licensee shall
remedy such breach or failure in accordance with the terms of such Cure Plan; provided that, if (X) there is a dispute between Company and Licensee concerning whether Licensee has (1) breached any of its general Development
or Commercialization diligence obligations as set forth in Section 3.1(a) or Section 4.6(a), or (2) failed to achieve a Key Milestone by the applicable date for such Key Milestone;
(Y) the JSC has failed to establish a Cure Plan within [***] (or [***], as applicable) after Company serving the Cure Plan Notice to Licensee; or (Z) in the case where the JSC has timely established a Cure Plan, there is a dispute
concerning whether Licensee has remedied such breach or failure in accordance with the terms of such Cure Plan (each of (X) through (Z), a “Diligence Dispute”), then either Company or Licensee may submit the Diligence Dispute
for final resolution by binding arbitration in accordance with Section 13.2, and only if it is finally resolved that Licensee has (I) breached any of its general Development or Commercialization diligence obligations
as set forth in Section 3.1(a) or Section 4.6(a), (II) failed to achieve a Key Milestone by the applicable date for such Key Milestone, or (III) failed to remedy such breach or failure in
accordance with the terms of the Cure Plan, with respect to each, will Company be allowed to terminated this Agreement pursuant to Section 12.3(a) with respect to subclause (i) above or
Section 12.3(b) with respect to subclause (ii) above; and 
 (g) perform such other functions as are assigned
to it in this Agreement or as appropriate to further the purposes of this Agreement to the extent agreed to in writing by Company and Licensee. 

Section 5.3. Membership. The JSC will be composed of a total of [***] representatives, [***] of which will be appointed by each of
Company and Licensee. Each individual appointed by either Company or Licensee as a representative to the JSC will be an employee of such Party, or an employee of such Party’s Affiliate with sufficient seniority within the applicable Party to
provide meaningful input and make decisions arising within the scope of the JSC’s responsibilities, and have knowledge and expertise in the Development and Commercialization of compounds and products similar to the Compound and Licensed
Products under this Agreement. The JSC may change its size from time to time by consent of its members, provided that the JSC will consist at all times of an equal number of representatives of each of Company and Licensee, unless
otherwise agreed by Company and Licensee in writing. Each of Company and Licensee may replace any of its JSC representatives at any time upon written notice to the other Party, which notice may be given by
e-mail, sent to the other Party’s co-chairperson. The JSC will be co-chaired by one designated representative of each of
Company and Licensee. The co-chairperson of the JSC will cast its Party’s vote on the JSC and such designee will have the authority to make decisions on behalf of such Party. Each co-chairperson will alternate being responsible for each meeting for (a) calling meetings, (b) preparing and circulating an agenda in advance of each meeting; provided, however, that the
applicable co-chairperson will include any agenda items proposed by each of Company and Licensee on such agenda and a Party’s co-chairperson may perform such
actions if the other Party’s co-chairperson fails to timely or adequately do so, (c) preparing and issuing minutes of each meeting that reflect the material decisions made and action items identified
at such meetings promptly thereafter, and (d) sending draft meeting minutes to each member of the JSC for review and approval within [***] after each JSC meeting. Meeting minutes issued in accordance with subclause (d) of this
Section 5.3 will be deemed approved unless one or more member of the JSC objects to the accuracy of such minutes within [***] of receipt. The Alliance Managers will work with the chairpersons to prepare and circulate
agendas and to ensure the preparation and approval of minutes. Each JSC representative will be subject to confidentiality obligations no less stringent than those in ARTICLE VIII. In addition, each of Company and Licensee may from time to
time invite a reasonable number of participants, in addition to its representatives, to attend the JSC meetings in a non-voting capacity; provided that if either Company or Licensee intends to
have any Third Party (including any consultant) attend such a meeting, such Party will provide prior written notice to the other Party. Such Party will also ensure that such Third Party is bound by confidentiality and
non-use obligations no less stringent than those set forth in ARTICLE VIII of this Agreement. 

  
 28 

 Section 5.4. Meetings; Reports. The JSC will hold meetings at least [***] during
the Term for so long as the JSC exists, unless Company and Licensee mutually agree in writing to a different frequency. No later than [***] prior to any meeting of the JSC (or such shorter time period as Company and Licensee may agree), the
applicable co-chairperson will prepare and circulate an agenda for such meeting. Either Company or Licensee may also call a special meeting of the JSC by providing at least [***] prior written notice to the
other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such Party will work with the applicable co-chairperson of the JSC
and the Alliance Managers to provide the members of the JSC no later than [***] prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision on the matters to be considered. The JSC may
meet in person or by audio or video conference as its representatives may mutually agree. Other representatives of Company and Licensee, their Affiliates and Third Parties involved in the Development, Manufacture, or Commercialization of Licensed
Products may be invited by the members of the JSC to attend meetings as non-voting observers; provided, however, that such representatives are subject to confidentiality obligations no less
stringent than those set forth in ARTICLE VIII. No action taken at a meeting will be effective unless at least [***] representative of each of Company and Licensee on the JSC is present or participating. Neither Company nor Licensee will
unreasonably withhold attendance of at least [***] representative of such Party at any meeting of the JSC for which reasonable advance notice was provided. 

Section 5.5. Decision-Making; Escalation to Senior Officers. Company and Licensee will endeavor in good faith and in
compliance with this Agreement to reach unanimous agreement with respect to all matters within the JSC’s authority. Company’s representatives on the JSC will collectively have one vote and Licensee’s representatives on the JSC will
collectively have one vote, (the “Party Vote”) and no action or decision will be taken by the JSC without unanimous Party Vote (i.e., the affirmative Party Vote of each of Company and Licensee), which will be documented in
written meeting minutes, which shall be approved by the JSC through formal processes that the JSC may reasonably put in place. Should the JSC not be able to reach agreement with respect to a matter at a duly called meeting of the JSC, either Company
or Licensee may refer such matter to the Senior Officers for resolution, and the Senior Officers will attempt to resolve the matter in good faith. If the Senior Officers fail to resolve such matter within [***] after the date on which the matter is
first referred to the Senior Officers (unless a longer period is agreed to by Company and Licensee), then, the Senior Officer of Licensee will have the final decision-making authority on all matters relating to [***], unless such matter relates to:

 (a) [***]. 
 To the extent the Senior
Officer of Company reasonably requests any documentation from Licensee reasonably necessary for the Senior Officer of Company to consider and resolve any matter hereunder, Licensee shall prepare and provide, at Licensee’s expense, accurate
English translations or English summaries, as reasonably requested by such Senior Officer, of such documentation originally in a language other than English. 

Notwithstanding any provision of this ARTICLE V to the contrary, neither Company nor Licensee (nor its Senior Officer) has any right to exercise its
final decision-making authority [***]. Notwithstanding any provision of this ARTICLE V to the contrary, the JSC will not have the authority to (a) amend, modify, or waive compliance with, the terms or conditions of this Agreement, which
may only be amended, modified, or waived as provided in Section 14.7; and (b) act on behalf of either such Party in relation to any Third Party. Each of Company and Licensee will retain the rights, powers, and
discretion granted to it under this Agreement and no such rights, powers, or discretion will be delegated to or vested in the JSC unless such delegation or vesting of rights is expressly provided for in this Agreement or Company and Licensee
otherwise expressly agree in writing. 

  
 29 

 Section 5.6. Subcommittees. 

(a) From time to time during the Term, the JSC may establish and disband subcommittees to oversee particular projects or activities, as it
deems necessary or advisable, including a joint development committee and a joint commercial committee (each, a “Subcommittee”). Each Subcommittee will consist of such equal number of representatives of each of Company and Licensee
as the JSC determines is appropriate from time to time. Such members will be individuals with expertise and responsibilities that are relevant to the applicable project or activity. Each Subcommittee will meet with such frequency as the JSC will
determine. For clarity, no Subcommittee shall have the rights, powers or discretion to make any decision, and any action or decision shall be taken in accordance with ARTICLE V by the JSC or otherwise other provisions of this Agreement. 

(b) As soon as practicable, but no later than [***] after the Effective Date, Company and Licensee shall form a subcommittee for Manufacturing
(the “JMC”) to (i) coordinate and share information with respect to Company’s Manufacture and supply (pursuant to Section 4.1) of Licensed Products to Licensee for the Development and
Commercialization of the Compound and Licensed Products in the Territory in accordance with this Agreement, (ii) pursuant to Section 4.2(c), discuss the need to contract or establish a facility for Manufacturing
Licensed Products in the Territory and based on the discussion, make recommendations to the JSC, (iii) if the applicable conditions set forth in Section 4.2(a) or Section 4.2(b) are satisfied,
coordinate and share information to facilitate the Manufacturing Technology Transfer to the PRC Manufacturer as set forth in Section 4.2 and Section 4.3, and (iv) adjust the CMO Qualifications
when and to the extent necessary. JMC will consist of such equal number of representatives of each of Company and Licensee as the JSC determines is appropriate from time to time. Such members will be individuals with expertise and responsibilities
in Manufacturing and supply chain management. 
 Section 5.7. Alliance Managers. 

(a) Appointment. Each of Company and Licensee will appoint a person to oversee interactions between Company and Licensee for all matters
related to the Development, Manufacture, and Commercialization of Licensed Products between meetings of the JSC (each, an “Alliance Manager”). The Alliance Managers will have the right to attend all meetings of the committees
as non-voting participants and may bring to the attention of the JSC any matters or issues either Alliance Manager reasonably believes should be discussed and will have such other responsibilities as Company
and Licensee may mutually agree in writing. Each of Company and Licensee may replace its Alliance Manager at any time by notice in writing to the other Party. 

(b) Responsibility. The Alliance Managers, if appointed, will have the responsibility of creating and maintaining a constructive work
environment within the JSC and between Company and Licensee for all matters related to this Agreement. Without limiting the generality of the foregoing, each Alliance Manager will: 

(i) provide a single point of communication within Company’s and Licensee’s respective organizations and between Company and
Licensee with respect to this Agreement; 
 (ii) coordinate cooperative efforts, internal communications and external communications between
Company and Licensee with respect to this Agreement; and 
 (iii) take such other steps as may be required to ensure that meetings of the
JSC occur as set forth in this Agreement, that procedures are followed with respect to such meetings (including working with the co-chairpersons with respect to the giving of proper notice and the preparation
and approval of minutes) and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed. 

  
 30 

 ARTICLE VI 

FINANCIAL PROVISIONS 

Section 6.1. Upfront Payment; Warrants; Milestone Payments. 

(a) Upfront Payment. Subject to the terms and conditions of this Agreement, Licensee will pay Company a
non-refundable, non-creditable payment in the amount of [***] which payment will be due and payable to Company within [***] following the Effective Date. 

(b) Warrants. In partial consideration for the licenses and rights granted to Licensee by Company under
Section 2.1, Licensee shall ensure that Lian Cardiovascular will issue one or more Warrants to Company in substantially the form set forth hereto as Exhibit E (the “Warrants”) exercisable for such
number of ordinary shares of Lian Cardiovascular as is equal to [***] of the then-fully diluted equity of Lian Cardiovascular at the time of issuance (the “Warrant Shares”), at a price per share [***]. The Warrants will be
exercisable by Company at any time after issuance. 
 (c) Financing Milestone Payment.
Subject to the terms and conditions of this Agreement, Licensee will pay Company a non-refundable, non-creditable payment in the amount of [***], which payment
will be due and payable to Company within [***] following the earlier of (i) [***] following the Effective Date and (ii) consummation of the Qualified Financing, with respect to (i) and (ii), or such longer period of time as is required to
effectuate the transfer of such upfront payment in accordance with applicable Laws. 
 (d) Development Milestone Payment. During the
Term, (i) Licensee will notify Company in writing of the achievement by or on behalf of Licensee, its Affiliates or Sublicensees of any of the milestone events (each, a “Development Milestone Event”) #1 through #3 set forth in
this Section 6.1(d) promptly after the occurrence thereof, and (ii) Company will notify Licensee in writing of the achievement by or on behalf of Company, its Affiliates or other licensees of any of the Development
Milestone Events #4 through #6 promptly after the occurrence thereof; following which Licensee will pay Company a non-refundable, non-creditable milestone payment set
forth in the tables below (each, a “Development Milestone Payment”) within [***] of the achievement of each such Development Milestone Event. Each Development Milestone Payment is payable only upon the first achievement of such
Development Milestone Event by the first Licensed Product to achieve such Development Milestone Event, and none of the Development Milestone Payments will be payable more than once regardless of how many times such Development Milestone Event is
achieved. 
  

			
	 Development Milestone Event
	  	 Development Milestone

Payment (in Dollars)

	 1. [***]*
	  	[***]
	 2. [***]*
	  	[***]
	 3. [***]*
	  	[***]
	 4. [***]**
	  	[***]
	 5. [***]**
	  	[***]
	 6. [***]**
	  	[***]

  

	*	 The corresponding milestone payment shall be increased by [***] in the event the Marketing Authorization is for
an Expanded Indication. 

  
 31 

	**	 The corresponding milestone payment shall be increased by [***] in the event the Marketing Authorization is for
an Expanded Indication. 

 (e) Sales Milestone Payments. During the Term, following the end of each Calendar
Quarter, Licensee will notify Company through the applicable final written report mentioned in Section 6.3(b) or Section 6.3(c) if cumulative Net Sales of all Licensed Products in the Territory
during the Term first exceed the indicated Dollar value set forth in the table below for such Calendar Year (each, a “Sales Milestone Event” and the corresponding one-time milestone payment, a
“Sales Milestone Payment”). Promptly following delivery of such report, Company will invoice Licensee for the applicable Sales Milestone Payment due. Licensee will pay to Company the applicable Sales Milestone Payment due
(i) if Licensee receives an invoice therefor prior to the end of such Calendar Year, within [***] following the end of the Calendar Year in which the Sales Milestone Event is achieved, and (ii) if Licensee does not receive an invoice
therefor prior to the end of such Calendar Year, within [***] of Licensee’s receipt of such invoice. Each of the Sales Milestone Payments set forth in this Section 6.1(e) is payable only upon the first achievement of
such Sales Milestone Event and none of the Sales Milestone Payments will be payable more than once regardless of how many times such Sales Milestone Event is achieved. For clarity, the Sales Milestone Payments are additive, such that if more than
one Sales Milestone Events are achieved in the same time period, then the Sales Milestone Payments for all such Sales Milestones Events shall be payable. 
  

			
	 Sales Milestone Event
	  	 Sales Milestone Payment (in Dollars)

	 1. [***]
	  	[***]
	 2. [***]
	  	[***]
	 3. [***]
	  	[***]
	 4. [***]
	  	[***]
	 Total
	  	[***]

 Section 6.2. Royalties. 

(a) Royalty Rate. Subject to the terms and conditions of this Agreement, including the provisions of
Section 6.5, on a Licensed Product-by-Licensed Product basis during the applicable Royalty Term for a Licensed Product, Licensee will pay to
Company a royalty on the Net Sales of Licensed Products in the Territory in the amount shown as follows: 
  

			
	 Portion of the Annual Net Sales of the Licensed Products
	  	 Royalty Rate

	 1. [***]
	  	[***]
	 2. [***]
	  	[***]
	 3. [***]
	  	[***]

 For clarity, with respect to royalties payments made during a Calendar Quarter, the above tiered royalties are calculated such
that the higher tiered royalties are only paid after the Net Sales in such Calendar Year exceed the top threshold of the previous tier. 

  
 32 

 (b) Royalty Term. Royalties will be due under this
Section 6.2, on a Licensed Product-by-Licensed Product basis, with respect to a given Licensed Product in a given Region during the period
commencing upon the First Commercial Sale of such Licensed Product in such Region and ending upon the latest to occur of (i) the expiration of the last Valid Claim within the Licensed Patents in such Region Covering [***], (ii) the expiry of
the applicable Regulatory Exclusivity for such Licensed Product in such Region, and (iii) the [***] anniversary of the First Commercial Sale of such Licensed Product in such Region (such period, the “Royalty Term”). 

Section 6.3. Royalty Payments and Reports. Commencing with the Calendar Quarter during which the First Commercial Sale of a
Licensed Product is made anywhere in the Territory and during the remainder of the Term (such period, the “Reporting Period”), Licensee will provide to Company: (a) within [***] after the end of each Calendar Quarter during the
Reporting Period, a written summary setting forth estimates of the Net Sales during such Calendar Quarter and the royalties which will have accrued hereunder with respect thereto due to Company on a Licensed Product-by-Licensed Product and Region-by-Region basis during such Calendar Quarter; (b) within [***] after the end of each
Calendar Quarter during the Reporting Period, either (x) refined estimates of the Net Sales and royalties abovementioned in Section 6.3(a) in writing or (y) a final written report in writing setting forth the
items set forth in Section 6.3(c)(i)-(iv); and (c) only if License provided Company with refined estimates of the Net Sales and royalties abovementioned in Section 6.3(b)(x), within [***]
after the end of each Calendar Quarter during the Reporting Period a final written report setting forth (i) the amount of the gross and Net Sales of the Licensed Product, on a Licensed Product-by-Licensed Product and Region-by-Region basis, during such Calendar Quarter (including such amounts expressed in local
currency and as converted to Dollars); (ii) an itemized summary of the type and amount of permitted deductions from gross sales to determine Net Sales as set forth in the definition of Net Sales and the total amount of such deductions;
(iii) the applicable royalty rates for each Licensed Product in each Region after applying any permitted deductions set forth in Section 6.5; and (iv) a calculation of the royalties which will have accrued
hereunder with respect to Net Sales due to Company with respect to such Licensed Product for such Calendar Quarter. For clarity, if two or more Licensed Products have achieved First Commercial Sale, the report provided by Company pursuant to this
Section 6.3 will be provided on a Licensed Product-by-Licensed Product basis. Promptly following the delivery of the applicable final quarterly
report abovementioned in Section 6.3(c), Company will invoice Licensee for the royalties due to Company with respect to all Net Sales for such Calendar Quarter. Licensee will pay the reported amounts to Company within [***]
following Licensee’s receipt of such invoice. 
 Section 6.4. [***] Agreement. 

Section 6.5. Royalty Payment Reductions. The following will only apply if royalties are being paid pursuant to
Section 6.2: 
 (a) Blocking Third Party Intellectual Property and Company Controlled Third Party Intellectual
Property. With respect to a particular Region, Licensee will be entitled to deduct from royalty payments under Section 6.2 otherwise payable to Company for such Region [***] of any Blocking Third Party Intellectual
Property Costs or Company Controlled Third Party Intellectual Property Costs applicable to such Region. Notwithstanding anything to the contrary, with respect to any Combination Product, in the event that the license under the applicable Blocking
Third Party Intellectual Property Rights or Company Controlled Third Party Intellectual Property Costs is required due to the Other Active(s), Licensee shall not be entitled to the foregoing deduction with respect to such license. 

(b) Generic Entry. If, at any time during the Royalty Term with respect to a Licensed Product, [***] a first commercial sale of a
Generic Product with respect to such Licensed Product in a Region occurs [***], then the applicable royalty rates in effect with respect to such Licensed Product in such Region as specified in Section 6.2(a) will be reduced
by [***]. For purposes of this Section 6.5(b), a “first commercial sale” of a Generic Product in a Region means the first sale for monetary value in an arm’s length transaction for use or consumption
by an end user of such Generic Product in such Region after the marketing authorization of such Generic Product has been obtained in such Region. 

  
 33 

 (c) Lack of Patent Protection. If, at any time during the Royalty Term with respect
to a Licensed Product, there are no Valid Claims under the Licensed Patents Covering [***], then the applicable royalty rate in effect with respect to such Licensed Product in such Region as specified in Section 6.2(a) will
be reduced by [***]. 
 (d) Cumulative Deductions. Notwithstanding the foregoing, in no event will the deductions set forth in
Section 6.5(a) through Section 6.5(c) reduce the royalties otherwise payable to Company as specified in Section 6.2 with respect to a Calendar Quarter by more than [***];
provided that, in the event the foregoing limitation limits the reduction Licensee is permitted to take during a Calendar Quarter, Licensee will be entitled to carryforward the amount of the reduction Licensee was unable to take during
such Calendar Quarter and apply such amounts to future Calendar Quarters until used and applied by Licensee in full. 
 Section 6.6.
Financial Audits. 
 (a) Record Keeping. Licensee and its Affiliates will, and will cause their respective Sublicensees to,
keep complete and accurate books and records in accordance with its Accounting Standards of the items underlying (i) Net Sales and (ii) royalty payments under this Agreement. Licensee and its Affiliates will, and will cause their
respective Sublicensees to keep, such books and records for at least [***] following the Calendar Quarter to which they pertain. Company will have the right no more than [***], at its own expense, to have an internationally recognized independent,
certified public accountant, selected by Company and reasonably acceptable to Licensee (the “Auditor”), review any such records of Licensee, and its Affiliates and their respective Sublicensees in the location(s) where such records
are customarily maintained by Licensee or its applicable Affiliate(s) or their applicable Sublicensee(s) upon reasonable prior written notice, during regular business hours and under obligations of confidentiality, for the sole purpose of verifying
the basis and accuracy of payments made under this Agreement, within the prior [***] period. The records for any Calendar Year may be audited no more than [***]. 

(b) Audit Report. The report prepared by the Auditor, a copy of which will be sent or otherwise provided to each of Company and Licensee
by such Auditor at the same time, will contain the conclusions of such Auditor regarding the audit and will specify that the amounts paid pursuant thereto were correct or, if incorrect, the amount of any underpayment or overpayment, and the specific
details regarding any discrepancies. No other information will be provided to Company without the prior consent of Licensee unless disclosure is required by Laws, regulation or judicial order, and if so determined by Company, it will, if permitted,
give Licensee prior notice thereof reasonably sufficient for Licensee to seek a protective order against or limiting such disclosure. If such report shows any underpayment, then Licensee will remit to Company, within [***], (i) the amount of such
underpayment and (ii) if such underpayment exceeds [***] of the total amount owed for the period then being audited, the reasonable out-of-pocket costs incurred by
Company in conducting such review. For the avoidance of doubt, [***], subject to Section 6.10. If such report shows any overpayment, then Company will, at Company’s election, credit the overpaid amount against future
payments owed by Licensee to Company or reimburse Licensee the amount of such overpayment. Company and Licensee mutually agree that all information subject to review under this Section 6.6 is Confidential Information
of Licensee and that Company will retain and cause the accountant to retain all such information in confidence in accordance with ARTICLE VIII. 

(c) Audit Period. Upon the expiration of [***] following the end of any Calendar Year, the audit rights set forth in this
Section 6.6 will no longer apply to such Calendar Year and the calculation of amounts payable with respect to such Calendar Year will be binding and conclusive. 

  
 34 

 Section 6.7. Tax Withholding. 

(a) General. In the event any withholding, value added, or other tax (including any tax based on income to Company) (“Tax
Withholdings”) is required to be withheld and deducted from payments by Licensee (or its Affiliate paying on behalf of Licensee) pursuant to this Agreement under applicable Laws, Licensee (or its Affiliate paying on behalf of Licensee) will
make such deduction and withholding [***], and any amounts so withheld and deducted will be remitted by Licensee (or its Affiliate paying on behalf of Licensee) on a timely basis to the appropriate Governmental Authority for the account of Company
and Licensee (or its Affiliate paying on behalf of Licensee) will provide Company reasonable evidence of the remittance within [***] thereof and for the purposes of this Agreement, Licensee will be deemed to have fulfilled all of its payment
obligations to Company with respect to such payments paid to the such Governmental Authority. Licensee may satisfy its withholding, value added or other tax obligations under this Section 6.7 through its Affiliates. 

(b) Taxes Resulting From Licensee Action. Notwithstanding Section 6.7(a), if, as a result of any action by
Licensee, including assignment or transfer of this Agreement, change in the residence of Licensee for tax purposes, change in the entity making such payment, or failure on the part of Licensee to comply with applicable Laws or filing or record
retention requirements, the amount of any tax (including income tax, value added tax) that Licensee is required to deduct or withhold from a payment made by Licensee to Company under this Agreement is increased, then [***]. 

(c) Tax Cooperation. Company and Licensee will cooperate with respect to all documentation required by any taxing authority, the
preparation of any tax returns, or reasonably requested by either Company or Licensee to secure a reduction in the rate of applicable taxes. Each of Company and Licensee shall provide the other Party and its Affiliates with reasonable assistance to
enable Company and Licensee to recovery, as permitted by applicable Laws, of Tax Withholdings resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such Tax Withholdings. 

Section 6.8. Currency of Payments. All amounts payable and calculations under this Agreement will be in Dollars. As applicable,
Net Sales and any royalty reductions will be translated into Dollars using the average of the applicable daily foreign exchange rates published in the Wall Street Journal (or any other qualified source that is acceptable to both Company and
Licensee) for [***] in which such Net Sales occurred. All payments under this Agreement will be paid in Dollars by wire transfer to an account designated by the receiving Party (which account the receiving Party may update from time to time in
writing). 
 Section 6.9. Blocked Currency. If by applicable Laws or fiscal policy of a Region, conversion into Dollars or
transfer of funds of a convertible currency to the United States is restricted, forbidden or substantially delayed, then amounts accrued in such Region under this Agreement will be paid to Company in such Region in local currency by deposit in a
local bank designated by Company, unless Company and Licensee otherwise agree. 
 Section 6.10. Late Payments. Without limiting
any other rights or remedies available to a Party hereunder, any late payment by any Party will bear interest, to the extent permitted by Laws, at an annual effective rate of [***] on the date payment was due until the date the applicable Party
makes the payment. 

  
 35 

 ARTICLE VII 

INTELLECTUAL PROPERTY OWNERSHIP, 

PROTECTION AND RELATED MATTERS 

Section 7.1. Ownership of Inventions; Ownership of Data. 

(a) Ownership of Product Inventions. Subject to Section 7.1(b), any and all Inventions invented or otherwise
developed or generated [***] in connection with the use of the Product Data and Materials during the Term, including the Patent Rights claiming such Inventions, (collectively, “Product Inventions”), will be owned by [***]. For
clarity, Product Inventions shall include Inventions arising from the use of Product Data and Materials but shall exclude the Product Data and Materials themselves. The Patent Rights Controlled by Company and claiming the Product Inventions will be
included in the Licensed Patents. 
 (b) Ownership of Product Data and Materials. As between Company and Licensee, (i) any and
all biological samples obtained from trial subjects in any Clinical Study involving the Compound and/or any Licensed Product, (ii) any and all Data and Regulatory Filings and Pricing and Reimbursement Approvals relating to the Development or
Commercialization of the Compound and/or any Licensed Product in the Territory, in each case of (i) and (ii), collected, developed or generated by or on behalf of Licensee alone (including its Affiliates, or any of its or their employees,
sublicensees, independent contractors or agents) or, collected, developed or generated by or on behalf of Company with Licensee solely for the Development or Commercialization of Compound and/or Licensed Product for the Territory and transferred to
Licensee hereunder (including jointly by their Affiliates, or any of its or their employees, sublicensees, independent contractors or agents) during the Term under this Agreement, and (iii) data or information collected, developed or generated
by or on behalf of Licensee resulting from the use of the Data or such biological samples as permitted under this Agreement ((i), (ii) and (iii) collectively, “Product Data and Materials”), will be owned by Licensee.
Notwithstanding the foregoing, Licensee shall ensure that (A) no Third Party will have any access to the Product Data and Materials except as necessary for any relevant Third Party to perform its obligations hereunder for Licensee or its
Affiliates for the furtherance of the Development or Commercialization of the Compound or Licensed Product in the Field in the Territory; (B) no Product Data and Materials will be used for the benefit of any Person, other than for Licensee or
its Affiliates for the furtherance of the Development or Commercialization of the Compound or Licensed Product in the Field in the Territory; and (C) no Product Data and Materials will be used or disclosed for any purpose related to any
Competing Product. 
 (c) Assignment Obligation. [***] hereby assigns, and shall cause its Affiliates and Sublicensees to assign, all
of its rights, title and interest in Product Inventions and Patent Rights related thereto, to [***]. With respect to any activities of Licensee under this Agreement that are subcontracted to a Person that is not an employee of Licensee, its
Affiliates or Sublicensees, Licensee shall include in the applicable subcontract (i) an assignment to Licensee of all of such subcontractor’s rights, title and interest in Product Inventions, Patent Rights and Know-How made by such subcontractor resulting from such activities, and (ii) to the extent that such subcontractor uses or incorporates its pre-existing intellectual
property or improvements thereon in performing such activities, a license to Licensee that is sublicensable to Company in multiple tiers of any such pre-existing intellectual property to the extent reasonably
necessary for (A) Company to exploit Product Inventions in the Field in the Territory, (B) Company and Licensee to Develop and Commercialize the Licensed Products in the Field in the Territory, and (C) Company and Licensee to
Manufacture the Licensed Products in the Field in the Territory. Licensee hereby grants Company a non-exclusive, irrevocable, perpetual, royalty-free, fully-paid, worldwide, sublicensable license as described
in the preceding sentence to (x) exploit the Product Inventions in the Field in the Territory, (y) Develop, have Development, Commercialize and have Commercialized the Licensed Products in the Field in the Territory, and
(z) Manufacture and have Manufactured the Licensed Products in the Field in the Territory. To the extent such subcontractor uses or incorporates its pre-existing intellectual property or improvements
thereon in performing such activities, Licensee, its Affiliates, or Sublicensees, as applicable, shall notify Company and, if requested by Company, use good faith efforts to introduce Company to such subcontractor so that Company can negotiate a
license to such pre-existing intellectual property to (I) exploit Product Inventions in or outside the Territory, (II) Develop, have Developed, Commercialize and have Commercialized the Licensed
Products in or outside the Territory, and (III) Manufacture and have Manufactured the Licensed Products in or outside the Territory, each to the extent not already covered in the foregoing license. In furtherance of the foregoing, to the extent

  
 36 

 
Licensee, or any of its Affiliates or Sublicensees is required under applicable Laws to pay a reward or remuneration to any employees or contractors who conceive, reduce to practice, discover,
develop or otherwise make any Data, Patents or inventions by or on behalf of Licensee or its Affiliates under or in connection with this Agreement, Licensee shall ensure that such employees or contractors agree to and are bound by a written inventor
reward and remuneration policy or agreement that is legally sufficient under applicable Laws, including a specific waiver of pre-emption rights under the laws of the Territory, including for Affiliates or
Sublicensees incorporated in the PRC, Article 326 of the PRC Contract Law, such that all right, title and interest in and to, and such employees or contractors shall not have any additional right or claim in or to, any Data, Patents, inventions, and
other intellectual property rights derived from their work other than the reward and remuneration they are entitled to under the inventor reward and remuneration policy or agreement of Licensee, the applicable Affiliate or Sublicensee, or such
subcontractor. As between Company and Licensee, Licensee shall incur the costs associated with paying all such inventor rewards and remuneration, and shall make, and shall cause its Affiliates and Sublicensees to make, timely payments to its or
their respective employees and contractors in accordance with its or their respective inventor reward and remuneration policy or agreement with its employees for such rewards and remuneration. 

Section 7.2. Prosecution and Maintenance of the Licensed Patents. 

(a) In the Territory. [***] will have the [***] right and discretion (subject to this Section 7.2), at its
expense, to prepare, file, prosecute, maintain and defend the Licensed Patents or any Product Invention. [***] will keep [***] reasonably informed with regard to and the status of such preparation, filing, prosecution, maintenance and defense of
Licensed Patents in the Territory that claim or Cover a Compound or a Licensed Product, or their manufacture or use in the Field. Before [***] submits any material filing, including a new patent application, or response to such patent authorities
with respect to such Licensed Patents in the Territory that claim or Cover a Compound or a Licensed Product, or their manufacture or use in the Field, [***] will provide [***] with a reasonable opportunity to review and comment on such filing or
response and will take into account and consider in good faith [***]’s reasonable and timely requests and suggestions regarding the filing, prosecution, maintenance and defense of such Licensed Patents under this
Section 7.2(a). 
 (b) Patents Controlled by One Party. Except as otherwise provided under this Agreement,
as between Company and Licensee, each Party will have the sole right (but not the obligation) to file, prosecute, maintain and defend, at its own cost and expense, all Patent Rights that are owned or Controlled by such Party or its Affiliates. 

(c) Cooperation. Each of Company and Licensee will, and will cause its Affiliates, sublicensees and any other party working on its
behalf, to, reasonably cooperate, with the other Party with respect to the preparation, filing, prosecution, maintenance and defense of Licensed Patents pursuant to this Section 7.2, including but not limited to, obtaining
all paperwork necessary to perfect the ownership interests in Product Inventions (e.g., assignments or confirmatory assignments) and obtaining executed documents in connection with the preparation, filing, prosecution, maintenance and defense of
such Licensed Patents in any patent office. 
 (d) Step-In Right. If [***] finally elects not
to continue to prosecute, maintain or defend a patent application or a patent of a certain patent family in a Region, wherein such patent application or patent [***] (such patent application or patent, “Discontinued Patent Right”),
then [***] will give [***] notice thereof within a reasonable period (but not less than [***]) prior to intentionally allowing such Discontinued Patent Rights to lapse or become abandoned. [***] will have the right, but not the obligation, to assume
responsibility for continuing the prosecution of such Discontinued Patent Right to claim or Cover a Compound or Licensed Product, or their use, in the Field in such Region and paying any required fees to maintain such Discontinued Patent Right or
defending such Patent Right in the patent office of the Region, all at [***]’s sole expense, through patent counsel or agents of its choice. If [***] elects to assume responsibility for such Discontinued Patent Right, then [***] must inform
[***]’s legal department in writing no less than [***] before such Discontinued 

  
 37 

 
Patent Right lapses or becomes abandoned, and then upon such notice, such Discontinued Patent Right will be considered the responsibility of [***], unless and until [***] provides notice to [***]
that it no longer elects to assume such responsibility (“Continued Patent Right”). [***] Upon transfer of [***]’s responsibility for filing, prosecuting, maintaining and defending a Discontinued Patent Right to [***] under this
Section 7.2(d), [***] will promptly deliver to [***] copies of all official correspondence with the patent office in the Region related to such Continued Patent Right and will take all actions and execute all documents
reasonably necessary for [***] to assume such prosecution, maintenance and defense of such Continued Patent Right. For clarity purposes, [***]. 

(e) Abandonment. Except in respect of any Discontinued Patent Rights, if [***] finally elects not to continue to prosecute or maintain a
patent application or a patent included in the Licensed Patents in a Region that claims or Covers a Compound or a Licensed Product, or their manufacture or use in the Field, then [***] will give [***] notice thereof within a reasonable period (but
not less than [***]) prior to the date [***] intends to intentionally allow such Patent Rights to lapse or become abandoned in such Region, and [***] will not allow such Patent Rights to lapse or become abandoned without [***]’s prior written
consent, not to be unreasonably withheld. 
 Section 7.3. Third Party Infringement. 

(a) Notice. Each of Company and Licensee will promptly notify the other Party in writing of any (i) apparent, threatened or actual
infringement by a Third Party of any Licensed Patent or Product Mark in the Territory, or (ii) unauthorized use or misappropriation of any Licensed Know-How by a Third Party of which it becomes aware that
impacts or may impact the other Party’s rights granted hereunder, and, in each case, will provide the other Party with all evidence in such Party’s possession or control supporting such infringement or unauthorized use or misappropriation
(each, an “Infringement”). 
 (b) Enforcement of Licensed Patents in the Territory. [***] will have the first right,
but not the obligation, using counsel of its choosing and at its sole expense, to institute any Action alleging Infringement of any of the Licensed Patents or a Product Mark with respect to a Compound or a Licensed Product in the Field in the
Territory (any such Action, an “Infringement Action”). [***] will notify and keep [***] apprised in writing of any such Infringement Action and will consider [***]’s reasonable interests and requests regarding such Infringement
Action; provided that, if [***] does not intend to prosecute an Infringement Action, or ceases to diligently pursue an Infringement Action, (i) it will promptly inform [***] in writing and (ii) [***] will have the right, but not
the obligation, at its own expense to institute an Infringement Action against the applicable Third Party infringer(s) solely with respect to the Licensed Product and with [***]’s right to review and comment. 

(c) Cooperation. In any Infringement Action brought under the Licensed Patents or Product Marks pursuant to
Section 7.3(b), each of Company and Licensee will, and will cause its Affiliates to, reasonably cooperate with each other, in good faith, relative to the other Party’s efforts to protect the Licensed Patents and
Product Marks and will join such suit as a party, if requested by the other Party. The other Party will have the right, at its own expense, to be represented in any action with respect to any such Infringement Action by counsel of its own choice.
Furthermore, the Party initiating any Infringement Action pursuant to Section 7.3(b) will consider in good faith all reasonable and timely comments from the other Party on any proposed arguments asserted or to be asserted
in litigation related to the enforcement or defense of any such Patent Rights. Neither Company nor Licensee will have the right to settle any patent infringement litigation with respect to any Licensed Patent or trademark infringement litigation
with respect to any Product Mark under this Section 7.3 in a manner that diminishes the rights or interests of the other Party without the consent of such other Party (which will not be unreasonably withheld). 

  
 38 

 (d) Allocation of Recoveries. Any settlements, damages or monetary awards recovered
by either Company or Licensee pursuant to any Infringement Action with respect to the Licensed Patents will, after reimbursing Company and Licensee for their reasonable
out-of-pocket expenses in making such recovery (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses), be [***]. 

(e) Enforcement of [***] in the Territory. [***] will have the right, but not the obligation, using counsel of its choosing and at its
sole expense, to institute an Action alleging any misappropriation from [***] or its Affiliates, Sublicensees or subcontractors of [***] occurring in the Territory after the Effective Date with respect to a Compound or a Licensed Product in the
Field in the Territory. [***] will notify and keep Company apprised in writing of any such Action and will consider [***]’s reasonable interests and requests regarding such Action. [***] will not be required to join any such Action as a party
or to provide any assistance to [***] in connection with such Action. 
 Section 7.4. Claimed Infringement. Each of Company and
Licensee will promptly notify the other Party if a Third Party brings any Action alleging patent infringement by Licensee or Company or any of their respective Affiliates or sublicensees with respect to the Development, Manufacture or
Commercialization of any Licensed Product in the Field in a Region (any such Action, an “Infringement Claim”). Each Party will have the right to defend against an Infringement Claim brought against it subject to the terms of this
Section 7.4. In the case of any Infringement Claim, [***] will have the right, but not the obligation, to control the defense and response to any such Infringement Claim. Upon the request of [***], [***] will reasonably
cooperate with [***] in the reasonable defense of such Infringement Claim. [***] will have the right to consult with [***] and to participate in and be represented by independent counsel in any associated litigation. If the Infringement Claim is
brought against both Company and Licensee, then each of Company and Licensee will have the right to defend against the Infringement Claim. The Party defending an Infringement Claim under this Section 7.4 will
(a) consult with the other Party as to the strategy for the prosecution of such defense, (b) consider in good faith any comments from the other Party with respect thereto and (c) keep the other Party reasonably informed of any
material steps taken and provide copies of all material documents filed, in connection with such defense. The Party controlling the defense against an Infringement Claim will have the right to settle such Infringement Claim on terms deemed
reasonably appropriate by such Party, provided that, unless any such settlement includes a full and unconditional release from all liability of the other Party and does not adversely affect the rights of the other Party, any such
settlement will be subject to the other Party’s prior written consent. 
 ARTICLE VIII 

CONFIDENTIALITY AND PUBLICITY 

Section 8.1. Confidential Information. 

(a) Confidentiality Obligation. During the Term and for a period of [***] after any termination or expiration of this Agreement, each
Party agrees to, and will cause its Affiliates, sublicensees and contractors to, keep in confidence and not to disclose to any Third Party, or use for any purpose, except to exercise its rights or perform its obligations under this Agreement, any
Confidential Information of the other Parties. 
 (b) Permitted Disclosures. Each Party agrees that it and its Affiliates will provide
or permit access to the other Parties’ Confidential Information only to the receiving Party’s officers, directors, employees, consultants, advisors, contractors, subcontractors and sublicensees, and to the officers, directors, employees,
consultants, advisors, contractors, subcontractors and sublicensees of the receiving Party’s Affiliates, in each case, on a need to know basis who are subject to obligations of confidentiality and non-use
with respect to such Confidential Information no less stringent than the obligations of confidentiality and non-use of the receiving Party pursuant to this Section 8.1;
provided, however, that each Party will remain responsible for any failure by its Affiliates or its or their officers, directors, employees, consultants, advisors, contractors, subcontractors and sublicensees to treat such Confidential
Information as required under this Section 8.1 as if such Affiliates, officers, directors, employees, consultants, advisors, contractors, subcontractors and sublicensees were parties directly bound to the requirements of
this Section 8.1. 

  
 39 

 (c) Confidentiality Limitation. Notwithstanding anything to the contrary herein, each
Party may use and disclose the other Party’s Confidential Information as follows: (i) under appropriate written confidentiality obligations substantially equivalent to those in this Agreement, to its Affiliates, potential and actual
permitted sublicensees, contractors, subcontractors, and any other Third Parties, to the extent such use or disclosure is reasonably necessary to perform its obligations or to exercise its rights under this Agreement; (ii) to the extent such
use or disclosure is consistent with this Agreement, is not prohibited by any agreements to which Company is a party and is reasonably necessary for filing or prosecuting the Licensed Patents; (iii) to its advisors (including financial
advisors, attorneys and accountants), actual or potential acquisition partners, financing sources or investors and underwriters on a need to know basis, in each case under appropriate confidentiality obligations (which may include professional
ethical obligations) substantially equivalent to those in this Agreement; provided, however, that each Party will remain responsible for any failure by any of the foregoing individuals to treat such Confidential Information as required
under Section 8.1 as if such individuals were parties directly bound to the requirements of this Section 8.1; (iv) as required by any court or other governmental body or as otherwise required by
applicable Laws (including any such disclosures as are required by a Regulatory Authority in connection with seeking Regulatory Approval, Pricing and Reimbursement Approval, a Regulatory Filing, or import authorization for any Licensed Product in
the Territory, or the rules or regulations of the United States Securities and Exchange Commission or similar Regulatory Authority in a country other than the United States or of any stock exchange or listing entity); provided that,
notice is promptly given to the other Party and the disclosing Party cooperates with reasonable requests from the other Party to seek a protective order or other appropriate remedy to protect the Confidential Information; (v) a Party who is
responsible for the filing, prosecution or maintenance of a patent application or a patent of a Family 1 Licensed Patent in a patent office in a Region pursuant to Section 7.2(a) or Section 7.2(d)
may disclose the Confidential Information of the other Party in connection with those activities; or (vi) Company may disclose Confidential Information of the other Party in connection with the filing, prosecution, maintenance or enforcement of
patent applications and patents disclosing Product Inventions. Notwithstanding anything to the contrary contained in this ARTICLE VIII, Confidential Information that is permitted or required to be disclosed will remain otherwise subject to
the provisions of Section 8.1(b) and this Section 8.1(c). If any Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar
Regulatory Authority in a country other than the United States, then such Party will, within a reasonable time prior to any such filing, provide the other Parties with a copy of such agreement showing any provisions hereof as to which the Party
proposes to request confidential treatment, will provide the other Parties with an opportunity to comment on any such proposed redactions and to suggest additional redactions, and will take such Party’s reasonable comments into consideration
before filing such agreement and use Commercially Reasonable Efforts to have terms identified by such other Parties afforded confidential treatment by the applicable Regulatory Authority. 

(d) Secrecy of Licensed Know-How. Company will protect, and will cause its Affiliates and its
sublicensees and its and their respective officers, directors, employees, and agents to protect, the secrecy and confidentiality of the Licensed Know-How using at least the same degree of care as it uses to
prevent the disclosure of its own other confidential information of like importance. 
 Section 8.2. Publicity. 

(a) Initial Press Releases. Promptly following the Effective Date, Company and Licensee will jointly issue a mutually agreeable initial
press release announcing certain terms of this Agreement in the form attached hereto as Exhibit I. 

  
 40 

 (b) Further Publicity; Publications. The Parties acknowledge the importance of
supporting each other’s efforts to publicly disclose results and significant developments regarding the Licensed Product in the Field in a territory, and each Party may make such disclosures from time to time, subject to this Section
8.2(b). Such disclosures may include achievement of milestones, significant events in the Development process with respect to Licensed Products, Commercialization activities with respect to Licensed Products and any significant results or events
that would materially affect prospects of the Licensed Products. Except for the initial press releases described in Section 8.2(a): 

(i) Whenever any Party elects to make any such public disclosure, it will first notify the other Parties of such planned press release or
public announcement and provide a draft for review no less than [***] in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Laws, with
as much advance notice as possible under the circumstances if it is not possible to provide notice no less than [***] in advance). Each Party will have the right to review and approve any such planned press release or public announcement proposed by
the any other Party, including any oral presentation, abstract or manuscript, that contains clinical data or pertains to results of Clinical Studies or other studies with respect to Licensed Products, or that includes Confidential Information of
such other Party; provided, however, that (A) the reviewing Party will attempt to review and provide comments as soon as reasonably possible and will not unreasonably withhold such approval if any Confidential Information of such
reviewing Party is removed; (B) the reviewing Party will provide explanations of its disapproval of such press release or public announcement or presentation or publication; and (C) a Party desiring to make such public disclosure may do so
without such prior review by the other Parties if (1) the entire contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by such Party, and (2) such press release
or public announcement does not materially differ from a previously issued press release or other publicly available information; and provided, further, that the other Parties will have the right to review, but not approve, any press
release or public announcement that the proposing Party determines is required by applicable Laws based on the advice of counsel, which public disclosures are subject to Section 8.2. The Party reviewing a press release
provided under this clause (A) of this Section 8.2(b)(i) will review, provide an initial round of feedback and approve or disapprove such press release within [***] after its receipt thereof. 

(ii) The principles to be observed in such disclosures will include accuracy, compliance with applicable Laws and regulatory guidance
documents, reasonable sensitivity to potential negative reactions of Regulatory Authorities and the need to keep investors informed regarding the business of the Party making such public disclosure. Nothing in this
Section 8.2 will restrict a Party from making a disclosure required by Laws as reasonably determined by such Party’s counsel, including disclosures required by any Laws relating to the public sale of securities;
provided, however, that such disclosure will include the minimum amount of Confidential Information required by such applicable Laws, and the Parties will use reasonable efforts to seek confidential treatment of Confidential
Information to be included in such disclosures. 
 (iii) For any proposed disclosure of scientific findings related to the activities under
this Agreement, Company and Licensee will develop a mutually agreed upon publication plan for such findings in advance of such disclosure. In the event that either Party proposes to publish or present the results of Development or Commercialization
carried out on the Licensed Product, such publication or presentation will be subject to the prior review by the other Party for patentability and protection of such other Party’s Confidential Information. In addition, such publishing Party
shall agree to follow abide by the standards and guidelines, as amended from time to time, promulgated by the International Committee of Medical Journal Editors (ICMJE) and good publication practice (GPP3) with regard to scientific publications and
presentations. Each Party will provide to the other Party the opportunity to review any proposed abstracts, manuscripts or summaries of presentations that cover the results of Development or Commercialization of Licensed Products during the Term.
The other Party will respond in writing promptly and in no event later than; (a) [***] prior to the intended submission of a manuscript for publication or (b) [***] prior to the intended submission of an abstract; with either approval of the
proposed material or a specific statement of concern, based upon either the 

  
 41 

 
need to seek patent protection or concern regarding competitive disadvantage arising from the proposal. In the event of any such concern, the submitting Party agrees not to submit such
publication or to make such presentation that contains such information until the other Party is given a reasonable period of time (in any event, not to exceed [***]) to seek patent protection for any material in such publication or presentation
that it believes is patentable or to resolve any other issues, and the submitting Party will remove from such proposed publication any Confidential Information of the other Party as requested by such other Party. 

ARTICLE IX 

REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS 

Section 9.1. Mutual Representations and Warranties. Each Party represents and warrants to each other Party that, as of the
Effective Date: 
 (a) Organization. It is a corporation duly organized, validly existing, and in good standing under the Laws of the
jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. 

(b) Authority. It has full right, power and authority to enter into this Agreement and to perform its respective obligations under this
Agreement, it has the right to grant to the other the licenses and sublicenses granted pursuant to this Agreement, and this Agreement and the performance by such Party of this Agreement do not violate such Party’s charter documents, bylaws or
other organizational documents. 
 (c) Consents. Except for any Marketing Authorizations, Regulatory Approvals, Regulatory Filings,
manufacturing approvals or similar approvals necessary for the Development, Manufacture or Commercialization of Licensed Products, all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be
obtained by it in connection with the execution, delivery and performance of this Agreement have been obtained. 
 (d) No Conflict. It
is not under any obligation, contractual or otherwise, to any Person that would materially affect the diligent and complete fulfillment of obligations under this Agreement and the execution and delivery of this Agreement by such Party, and the
performance of such Party’s obligations under this Agreement (as contemplated as of the Effective Date) and the licenses and sublicenses to be granted by such Party pursuant to this Agreement (i) do not conflict with or violate any
requirement of Laws applicable to such Party, (ii) do not conflict with or violate any order, writ, judgment, injunction, decree, determination, or award of any court or Governmental Authority presently in effect applicable to such Party, and
(iii) do not conflict with, violate, breach or constitute a default under any contractual obligations of such Party or any of its Affiliates. 

(e) Enforceability. This Agreement is a legal and valid obligation binding upon it and is enforceable against it in accordance with its
terms, subject to the general principles of equity and subject to bankruptcy, insolvency, moratorium, judicial principles affecting the availability of specific performance and other similar Laws affecting the enforcement of creditors’ rights
generally. 
 (f) Compliance with Laws. Company and Licensee will, and will use Commercially Reasonable Efforts to ensure that their
respective Affiliates and sublicensees will, comply in all material respects with all applicable Laws in exercising their rights and fulfilling their obligations under this Agreement. Without limiting the generality of the foregoing, Company and
Licensee will conduct all Development and Commercialization activities relating to the Compound or Licensed Products under this Agreement in accordance with applicable Laws (including data privacy Laws, current international regulatory standards,
including, as applicable, cGMP, GLP, GCP, and other rules, regulations and requirements), and will cause all permitted collaborators and sublicensees hereunder to comply with such applicable Laws. Without limiting the generality of the foregoing,
Company and Licensee will comply with Export Control Laws, Anti-Corruption Laws and all other 

  
 42 

 
applicable Laws concerning bribery, money laundering, or corrupt practices or which in any manner prohibit the giving of anything of value to any official, agent, or employee of any government,
political party, or public international organization, candidate for public office, health care professional, or to any officer, director, employee, or representative of any other organization specifically including the U.S. Foreign Corrupt
Practices Act, in each case, in connection with the activities conducted pursuant to this Agreement. 
 Section 9.2. Additional
Representations, Warranties and Covenants of Company. Company represents and warrants, as of the Effective Date, and solely as provided in Section 9.2(m)
covenants, to Licensee that: 
 (a) Licensed Patents. All Licensed Patents as of the Effective Date are listed in Exhibit
C. Except as otherwise noted in Exhibit C, Company is the sole and exclusive owner of the Licensed Patents, all of which are free and clear of any claims, liens, charges or encumbrances. With respect to Licensed Patents not solely owned
by Company, Company licenses such Licensed Patents in a manner that permits exclusive sublicenses as provided in this Agreement. All Licensed Patents owned by Company and, [***], all other Licensed Patents, are (i) subsisting and in good
standing and (ii) being diligently prosecuted in the respective patent offices in accordance with applicable Laws, and have been filed and maintained properly and correctly and all applicable fees have been paid on or before the due date for
payment. [***], all issued Licensed Patents are valid and enforceable. 
 (b) [***]. 

(c) Licensed Technology. [***], Company has not granted to any Third Party, including any academic organization or agency, any license,
option or other rights to Develop, Manufacture (for Development or Commercialization in the Field in the Territory) or Commercialize the Compound or the Licensed Products in the Field in the Territory. [***], no Third Party has any license, option
or other rights or interest in or to the Licensed Technology in the Field in the Territory. The Licensed Technology constitutes all the Patent Rights and Know-How Controlled by Company or any of its Affiliates
that are reasonably necessary for the Development, Manufacture or Commercialization of the Compound and the Licensed Products in the Field in the Territory. 

(d) Delivery of Documentation. All material information with respect to the Development, Manufacture or Commercialization of the
Compound and the Licensed Products in Company’s or its Affiliates’ possession or control, including any Regulatory Filings relating to the Licensed Product being Developed in the United States, provided or made available to Licensee prior
to the Effective Date and described on Exhibit B attached hereto is true, correct and complete, [***]. 
 (e) Third Party
Challenges. Company has not received any written notice of any, and, [***], there are no, Actions, claims, judgments, or settlements against, or amounts with respect thereto, made against Company or any of its Affiliates relating to the Licensed
Patents or the Licensed Know-How. [***], no Action, claim or litigation has been brought or, [***], threatened by any Person (i) alleging that the Licensed Patents are invalid or unenforceable,
(ii) asserting the misuse or non-infringement or invalidity of any of the Licensed Patents, (iii) challenging Company’s Control of the Licensed Patents, or (iv) alleging misappropriation of
the Know-How used in the Development, Manufacture or Commercialization of Licensed Products by or on behalf of Company prior to the Effective Date. 

(f) Non-Infringement of Third Party IP. [***], the Development, Manufacture or Commercialization
of the Licensed Product, as conducted by Company, its Affiliates or its sublicensees prior to the Effective Date did not infringe any Patent Right or misappropriate any Know-How of any Person. [***], the
Development, Manufacture, supply, or Commercialization of Licensed Products (as single agent and not Combination Products) in the Field and in the Territory as contemplated by this Agreement does not infringe any Patent Right or misappropriate or
otherwise violate any Know-How of any Third Party. No claim of infringement of the Patent Rights or misappropriation of the Know-How of any Third Party has been made,
[***], threatened, against Company or any of its Affiliates with respect to the Development, Manufacture or Commercialization of Licensed Products. 

  
 43 

 (g) Absence of Litigation. Company has not received any written notice of any, and
[***], there are no, Actions, judgments or settlements against or owed by Company, its Affiliates or its sublicensees, or, [***], pending Actions against Company, its Affiliates, or its sublicensees or Actions threatened against Company, its
Affiliates, or its sublicensees, in each case related to Licensed Products as of the Effective Date. 
 (h) Maintenance of Regulatory
Filings, Good Laboratory and Clinical Practices. Company and its Affiliates (i) have generated, prepared, maintained, and retained all Regulatory Filings and Marketing Authorizations relevant to the Development or Commercialization of the
Licensed Products in the Field in the Territory that are required to be maintained or retained pursuant to and in compliance with applicable Laws; and (ii) have conducted in compliance with applicable Laws, including GLP and GCP, all
Development of Licensed Products in the Field conducted prior to the Effective Date; [***]. 
 (i) Confidentiality of Know-How. [***], no material breach of confidentiality has been committed by any Person with respect to the Licensed Know-How that is maintained as a trade secret and
Company has used reasonable measures to protect the confidentiality thereof. 
 (j) Assignment of Third Party Rights; Third Party
Consents. 
 (i) Company has obtained from each of its employees and agents, and from the employees and agents of its Affiliates, who
are participating in the Development, Manufacture or Commercialization of Licensed Products, rights to any and all Know-How created by such employees and agents in the course of his or her employment by or
engagement with Company that relates to Licensed Products, such that Licensee will, by virtue of this Agreement, receive from Company, without payments beyond those required by ARTICLE VI, the licenses and other rights granted to and
Controlled by Licensee under this Agreement. 
 (ii) Each Person who has or has had any ownership rights in or to any Licensed Patents
purported to be owned solely by Company, has assigned and has executed an agreement assigning its entire right, title, and interest in and to such Licensed Patents to Company; [***], no current officer, employee, agent, or consultant of Company or
any of its Affiliates is in violation of any term of any assignment or other agreement, in each case, regarding the protection of the Licensed Patents. 

(iii) Prior to the Effective Date, Company has obtained all consents from Third Parties necessary to grant Licensee the licenses and rights
Company purports to grant to Licensee under this Agreement. 
 (k) Compliance with Laws. All of the studies, tests and pre-clinical and clinical trials of Licensed Products conducted prior to, or being conducted as of, the Effective Date by or on behalf of Company that are relevant to the Development or Commercialization of the
Licensed Products in the Field in the Territory have been and are being conducted in all material respects in accordance with applicable Laws [***]. 

(l) Upstream Licenses. Neither Company nor its Affiliates are party to any agreements or contracts existing as of the Effective Date
that would constitute an Upstream License. 

  
 44 

 (m) No Conflict. During the Term, Company and its Affiliates will not grant any
interest in the Licensed Technology that is inconsistent with the terms and conditions of this Agreement. 
 Section 9.3. Covenants
of Licensee. Licensee hereby covenants to Company as follows: 
 (a) Licensee will not, in connection with the performance of its
obligations under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a public
official or entity or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, including Licensee, nor will Licensee directly or indirectly promise, offer or provide any corrupt payment,
gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a public official or entity or any other person in connection with the performance of Licensee’s obligations under this Agreement; 

(b) Licensee has in place an anti-corruption and anti-bribery policy and in connection with the performance of its obligations under this
Agreement, Licensee shall comply and shall cause its and its Affiliates’ employees to comply with Licensee’s policy; 
 (c)
Licensee shall, and shall ensure that its Affiliates and their Sublicensees and its and their respective employees and contractors will, not cause Company to be in violation of the Anti-Corruption Laws, Export Control Laws, or any other applicable
Laws, in connection with the performance of Licensee’s obligations under this Agreement; and 
 (d) Licensee shall immediately notify
Company if it has any information or suspicion that there may be a violation of the Anti-Corruption Laws, Export Control Laws, or any other Applicable Laws, including any other applicable anti-corruption and anti-bribery laws, in connection with the
performance of its obligations under this Agreement. 
 Section 9.4. No Debarment. Each of Company and Licensee represents and
warrants that neither it nor any of its or its Affiliates’ employees or agents performing under this Agreement has ever been, or is currently: (a) debarred under 21 U.S.C. § 335a or by any Regulatory Authority; (b) excluded,
debarred, suspended, or otherwise ineligible to participate in federal health care programs or in federal procurement or non-procurement programs; (c) listed on the FDA’s Disqualified and Restricted
Lists for clinical investigators; or (d) convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise
declared ineligible. Each of Company and Licensee further covenants that if, during the Term of this Agreement, it becomes aware that it or any of its or its Affiliates’ employees or agents performing under this Agreement is the subject of any
investigation or proceeding that could lead to that Party becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, such Party will promptly notify the other Party. This provision will survive
termination or expiration of this Agreement. 
 Section 9.5. No Other Warranties. EXCEPT AS EXPRESSLY STATED IN
Section 9.1, Section 9.2, OR Section 9.4, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY COMPANY HEREUNDER AND THE ASSISTANCE TO BE
PROVIDED BY COMPANY TO LICENSEE HEREUNDER ARE PROVIDED “AS IS,” AND NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WARRANTIES OF TITLE, NON-INFRINGEMENT, VALIDITY, ENFORCEABILITY, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

  
 45 

 ARTICLE X 

INDEMNIFICATION; DAMAGES 

Section 10.1. Indemnification by Company. Company will indemnify and hold harmless Licensee, its Affiliates and their
respective directors, officers, employees and agents (each, a “Licensee Indemnified Party”), from, against and in respect of any and all Third Party Losses incurred or suffered by any Licensee Indemnified Party to the extent
resulting from: (a) any breach of any representation or warranty made by Company in this Agreement, or any breach by Company of any obligation, covenant or agreement in this Agreement (including, [***]); (b) the gross negligence or intentional
misconduct of Company or any of its Affiliates, licensees, sublicensees or contractors, or any of their respective directors, officers, employees and agents, in performing Company’s obligations or exercising Company’s rights under this
Agreement; (c) activities conducted by or on behalf of Company, its Affiliates or its sublicensees or contractors related to the Development, Manufacture or Commercialization of Licensed Products anywhere in the world prior to the Effective
Date; and (d) the Development, Manufacture or Commercialization of the Licensed Products by or on behalf of Company, any of its Affiliates, Sublicensees or contractors outside the Field in the Territory or outside the Territory;
provided, however, that Company’s obligations pursuant to this Section 10.1 will not apply to the extent such Third Party Losses result from Third Party Losses for which Licensee has an obligation to
indemnify Company pursuant to Section 10.2. 
 Section 10.2. Indemnification by Licensee. Licensee
will indemnify and hold harmless Company, its Affiliates and their respective directors, officers, employees and agents (each, a “Company Indemnified Party”) from, against and in respect of any and all Third Party Losses
incurred or suffered by any Company Indemnified Party to the extent resulting from: (a) any breach of any representation or warranty made by Licensee in this Agreement, or any breach by Licensee of any covenant or agreement in this
Agreement; (b) the gross negligence or intentional misconduct of, or violation of Laws by, Licensee, any of its Affiliates, Sublicensees or contractors, or any of their respective directors, officers, employees and agents, in performing
Licensee’s obligations or exercising Licensee’s rights under this Agreement; or (c) the Development, Manufacture or Commercialization of the Licensed Product by or on behalf of Licensee, its Affiliates, Sublicensees or contractors in
the Field in the Territory (excluding, [***]); or (d) Company’s or its Affiliate’s status as an applicant or a holder of any Regulatory Approval for the Licensed Products in the Field in the Territory; provided, however,
that Licensee’s obligations pursuant to this Section 10.2 will not apply to the extent such Third Party Losses result from Third Party Losses for which Company has an obligation to indemnify Licensee pursuant to
Section 10.1. 
 Section 10.3. Claims for Indemnification. 

(a) Notice. An Indemnified Party entitled to indemnification under Section 10.1 or
Section 10.2 will give prompt written notification to the Indemnifying Party from whom indemnification is sought of the commencement of any Action by a Third Party for which indemnification may be sought (a “Third
Party Claim”) or, if earlier, upon the assertion of such Third Party Claim by a Third Party; provided, however, that failure by an Indemnified Party to give notice of a Third Party Claim as provided in this
Section 10.3(a) will not relieve the Indemnifying Party of its indemnification obligation under this Agreement, except and only to the extent that such Indemnifying Party is materially prejudiced as a result of such failure
to give notice. 
 (b) Defense. Within [***] after delivery of a notice of any Third Party Claim in accordance with
Section 10.3(a), the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Third Party Claim with counsel reasonably satisfactory to the Indemnified Party. If
the Indemnifying Party does not assume control of such defense, the Indemnified Party may control such defense. The Party not controlling such defense may participate therein at its own expense. 

  
 46 

 (c) Cooperation. The Party controlling the defense of any Third Party Claim will keep
the other Party advised of the status and material developments of such Third Party Claim and the defense thereof and will reasonably consider recommendations made by the other Party with respect thereto. The other Party will reasonably cooperate
with the Party controlling such defense and its Affiliates and agents in defense of the Third Party Claim, with all out-of-pocket costs of such cooperation to be borne
by the Party controlling such defense. 
  
 (d) Settlement. The
Indemnified Party will not agree to any settlement of such Third Party Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld. The Indemnifying Party will not, without the prior written
consent of the Indemnified Party, which will not be unreasonably withheld, agree to any settlement of such Third Party Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified
Party from all liability with respect thereto or that imposes any liability or obligation on the Indemnified Party. 
 (e) Mitigation of
Loss. Each Indemnified Party will take and will procure that its Affiliates and its and their sublicensees take all such reasonable steps and actions as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any
Third Party Claims (or potential losses or damages) under this ARTICLE X. Nothing in this Agreement will or will be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. 

Section 10.4. Insurance. Licensee, at its own expense, will maintain liability insurance (or self-insure) with respect to its
activities under this Agreement in an amount consistent with industry standards. Licensee will provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to Company upon request. Without limiting the foregoing,
during the Term and thereafter for the period of time required below, Licensee will maintain on an ongoing basis comprehensive general liability insurance policies which are consistent with normal business practices of prudent companies similar
situated in the Territory. Not later than [***] following receipt of written request from Company, Licensee will provide to Company a certificate of insurance evidencing such insurance policies. Licensee will maintain such insurance or
self-insurance coverage without interruption during the Term and for a period of [***] thereafter, and, if applicable, will provide certificates or letters evidencing such insurance coverage without interruption as reasonably requested during the
period of time for which such coverage must be maintained. Company will be provided with at least [***] prior written notice of any cancellation or material decrease in Licensee’s insurance coverage limits described above. 

ARTICLE XI 
 LIMITATION
OF LIABILITY 
 Section 11.1. No Consequential or Punitive Damages. EXCEPT AS SET FORTH IN
Section 11.2, NEITHER PARTY NOR ANY OF ITS AFFILIATES WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE OR MULTIPLE DAMAGES OR FOR ANY LOST PROFITS ARISING OUT OF THIS AGREEMENT, IN EACH
CASE HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. 

Section 11.2. EXCLUSION FROM LIABILITY LIMITATION. THE LIMITATIONS AND DISCLAIMER SET FORTH IN
Section 11.1 WILL NOT APPLY TO A CLAIM (A) FOR WILLFUL MISCONDUCT; (B) FOR A BREACH OF ARTICLE VIII; OR (C) FOR INDEMNIFIABLE LOSSES PURSUANT TO Section 10.1 OR
Section 10.2. 

  
 47 

 ARTICLE XII 

TERM AND TERMINATION 

Section 12.1. Term. Unless terminated earlier in accordance with this ARTICLE XII, this Agreement will become effective as
of the Effective Date and will continue in full force until the last to expire Royalty Term in the Territory for all Licensed Products (the “Term”).  

Section 12.2. Paid-Up License Upon Expiration. 

(a) Upon the expiration of the Royalty Term for a given Licensed Product in a given Region, the licenses and rights of reference granted to
Licensee pursuant to Section 2.1 will become perpetual, irrevocable, fully paid-up, and royalty free with respect to such Licensed Product in such Region. 

(b) Upon the expiration of this Agreement in its entirety, the licenses and rights of reference granted to Company pursuant to
Section 2.6 will become perpetual, irrevocable, fully paid-up, and royalty free. 

Section 12.3. Early Termination. 

(a) Termination for Material Breach by Licensee or Company. Subject to Section 12.3(b) with respect to
failures to achieve a Key Milestone, upon (i) any material breach of this Agreement by Company or (ii) any material breach of this Agreement by Licensee (the Party so allegedly breaching being the “Breaching Party”), the
other Party (the “Non-Breaching Party”) will have the right, but not the obligation, to terminate this Agreement in its entirety or on a Region-by-Region basis (but only if such Region is not the PRC) by providing written notice to the Breaching Party, which notice will, in each case (A) expressly reference this
Section 12.3(a), (B) reasonably describe the alleged breach which is the basis of such termination, and (C) clearly state the Non-Breaching Party’s intent to terminate this
Agreement if the alleged breach is not cured within the applicable cure period set forth in the notice, which cure period will not in any event be less than [***]. Notwithstanding the foregoing, (1) if such material breach, by its nature, is
curable, but is not reasonably curable within the applicable cure period, then such cure period will be extended if the Breaching Party provides a written plan for curing such breach to the Non-Breaching Party
and uses Commercially Reasonable Efforts to cure such breach in accordance with such written plan; provided, however, that no such extension will exceed [***] without the written consent of the
Non-Breaching Party; and (2) if the Breaching Party disputes (x) whether it has materially breached this Agreement, (y) whether such material breach is reasonably curable within the applicable
cure period, or (z) whether it has cured such material breach within the applicable cure period, the dispute will be resolved pursuant to ARTICLE XIII, and this Agreement may not be terminated and the Parties shall continue to perform
all of their respective obligations hereunder during the pendency of such dispute resolution procedure. The termination will become effective at the end of the applicable cure period unless the Breaching Party cures such breach during the applicable
cure period; provided, however, that the Non-Breaching Party may, by notice to the Breaching Party, designate a later date for such termination in order to facilitate an orderly transition of
activities relating to Licensed Products. 
 (b) Termination for Failure to Achieve a Key Milestone. In addition and without prejudice
to Company’s right to terminate this Agreement pursuant to Section 12.3(a), Company may, upon [***] prior written notice to Licensee, terminate this Agreement in its entirety or on a Region-by-Region basis in the event that (i) Licensee fails to achieve a Key Milestone by the applicable date for such Key Milestone, and (ii) if there is a Diligence Dispute, it is finally resolved
that Licensee has (I) failed to achieve a Key Milestone by the applicable date for such Key Milestone, or (II) failed to remedy such failure in accordance with the terms of the Cure Plan. Notwithstanding anything to the contrary contained
in this Agreement, Company’s right to terminate this Agreement in its entirety or on a Region-by-Region basis in accordance with this
Section 12.3(b) as a result of Licensee failing to achieve a Key Milestone by the applicable date for such Key Milestone (but not 

  
 48 

 
breach of Licensee’s general Development or Commercialization diligence obligations as set forth in Section 3.1(a) or Section 4.6(a)) will
be Company’s sole and exclusive remedy for any failure of Licensee to achieve a Key Milestone by the applicable date for such Key Milestone (but not breach of Licensee’s general Development or Commercialization diligence obligations as set
forth in Section 3.1(a) or Section 4.6(a)). 
 (c) Termination by Licensee for
Convenience. On a Region-by-Region basis, Licensee may, upon (i) [***] prior written notice to Company, if such notice is provided before the First Commercial Sale
of a Licensed Product in such Region or (ii) [***] prior written notice to Company, if such notice is provided after the First Commercial Sale of a Licensed Product in such Region, with respect to subclauses (i) and (ii), terminate this
Agreement for convenience, without cause, and for any or no reason, with respect to such Region; [***]. 
 (d) Termination for
Bankruptcy. This Agreement may be terminated in its entirety, to the extent permitted by applicable Laws, by either Company or Licensee upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or
upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy, reorganization, liquidation or receivership proceeding such
right to terminate will only become effective if the Party subject to such proceeding consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof. 

(e) Termination for Patent Challenge. Company shall have the right to terminate this Agreement in its entirety upon [***] prior written
notice to Licensee if Licensee or any of its Affiliates or Sublicensees, directly or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes
any extension of, or the grant of a supplementary protection certificate with respect to, any Licensed Patents; provided that if (i) Licensee, its Affiliates or the applicable Sublicensee withdraws such interference, opposition or
challenge within such [***] notice period or (ii) with respect to a such interference, opposition or challenge brought by a Sublicensee, if Licensee or its Affiliates, as applicable, terminates the applicable Sublicense within such [***] notice
period, then Company will not have the right to terminate this Agreement under this Section 12.3(e) as a result thereof. 

Section 12.4. Effects of Termination. 

(a) Effects of Termination Generally. Upon termination (but not expiration) of this Agreement in its entirety pursuant to
Section 12.3, the Parties’ rights and obligations under this Agreement will terminate and neither Company nor Licensee will have any further rights or obligations under this Agreement from and after the effective date
of termination, except as set forth in this Section 12.4; provided, however, that, if this Agreement is terminated with respect to a particular Region only, then such rights and obligations will terminate only
to the extent they relate solely to the terminated Region. 
 (b) Winding Down of Activities. If there are any on-going Development or Commercialization activities at termination (but not expiration) of this Agreement, Company and Licensee will negotiate in good faith and adopt a plan to wind-down such activities in an
orderly fashion or, at Company’s election, promptly transition such activities from Licensee to Company or its designee, with due regard for patient safety and the rights of any subjects that are participants in any Clinical Studies of the
Licensed Products, and take any actions it deems reasonably necessary or appropriate to avoid any human health or safety problems and in compliance with all applicable Laws. 

  
 49 

 (c) Indemnification. Following such termination, Company will indemnify, defend and
hold Licensee and Licensee Indemnified Parties harmless in the manner set forth in Section 10.2 as if Company were Licensee and Licensee Indemnified Parties were Company Indemnified Parties, mutatis mutandis, for all
Third Party Losses arising from the Development, Manufacture, Commercialization of the Licensed Products by or on behalf of Company, its Affiliates, or its or their licensees, sublicensees, or contractors after the effective date of such
termination; provided, however, that Company’s obligations pursuant to this Section 12.4(c) will not apply to the extent such Third Party Losses result from Third Party Losses for which Licensee has an
obligation to indemnify Company pursuant to Section 10.2. 
 (d) Accrued Obligations. Expiration or
termination of this Agreement for any reason will not release any Party from any obligation or liability which, on the effective date of such expiration or termination, has already accrued to any other Party or which is attributable to a period
prior to such expiration or termination. 
 (e) Survival. This Section 12.4(e), the provisions set forth in
the following Sections, as well as, to the extent applicable, any other Sections or defined terms referred to in such Sections or Articles or necessary to give them effect, will survive any expiration or termination of this Agreement in its
entirety: ARTICLE VI (solely with respect to payments payable prior to expiration or termination and as necessary to effectuate Section 12.4(i)), Section 7.1(a),
Section 7.1(b), Section 7.1(c) (solely with respect to the first, third, fifth, and sixth sentence therein), ARTICLE VIII (for the time period set forth in
Section 8.1), ARTICLE X, ARTICLE XI, Section 12.2, Section 12.4, ARTICLE XIII, and ARTICLE XIV (except that, with respect to
Section 14.1(b), only the first sentence thereof shall survive the expiration or termination). Furthermore, any other provisions required to interpret the Parties’ rights and obligations under this Agreement, including
applicable definitions in ARTICLE I, will survive to the extent required. Except as otherwise expressly provided in this Agreement, all rights and obligations of the Parties under this Agreement, including any licenses granted under this
Agreement, will terminate upon expiration or termination of this Agreement in its entirety or solely with respect to the terminated Region, as the case may be, for any reason. 

(f) Inventory. For a period of [***] after termination of this Agreement, Licensee may sell its remaining inventory of Licensed
Products; provided that it continues to make full and timely milestone payments and royalties payments owed to Company under ARTICLE VI with respect to the sale of such remaining inventory, and Licensee is otherwise not in
material breach of this Agreement. 
 (g) Transfer of Regulatory Filings and Regulatory Approvals. Following the effectiveness of any
termination of this Agreement, as promptly as practicable after Company’s written request, Licensee will, to the extent permitted under applicable Laws, and at Licensee’s sole cost and expense (unless it was terminated by Licensee pursuant
to Section 12.3(a) or Section 12.3(d), in which case such transfer will be at Company’s sole cost and expense), assign and transfer to Company all Regulatory Filings, filings for Pricing and
Reimbursement Approval and Marketing Authorizations for Licensed Products that are held by or owned by Licensee or its Affiliates or Sublicensees as of the effective date of termination, with respect to the terminated Region, as the case may be, and
will take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights under such Regulatory Filings, filings for Pricing and Reimbursement Approval and Marketing Authorizations to
Company. If applicable Laws or relevant Regulatory Authorities prevent or delay the transfer of ownership of any such Regulatory Filing, filing for Pricing and Reimbursement Approval and Marketing Authorizations to Company or if it is commercially
infeasible for Licensee to do so, then Licensee will grant, and hereby does grant, to Company an exclusive and irrevocable right of access and right of reference to such Regulatory Filing, filing for Pricing and Reimbursement Approval and Marketing
Authorizations for Licensed Products in the Territory or the terminated Region, as the case may be, and will reasonably cooperate with Company, at Licensee’s expense (unless it was terminated by Licensee pursuant to
Section 12.3(a) or Section 12.3(d), in which case such grant of access and right of reference and cooperation will be at Company’s sole cost and expense), to make the benefits of such
Regulatory Filings, filings for Pricing and Reimbursement Approval and Marketing Authorizations available to Company or its designee(s). 

  
 50 

 (h) Product Data and Materials. Upon the termination (but not expiration) of this
Agreement in its entirety: 
 (i) Licensee shall assign and hereby assigns, and shall ensure that its Affiliates and its and their
Sublicensees, and its or their employees, sublicensees, independent contractors or agents will assign, all of their rights and title and interest in Product Data and Materials to Company. Section 2.6(b), other than the
first sentence thereof, shall apply mutatis mutandis; and 
 (ii) Company shall grant and hereby grants Licensee a non-exclusive, sublicensable (only to its Affiliates), royalty-free, fully-paid license to use the Product Data and Materials in the Territory; provided that Licensee shall ensure that (A) no
Third Party will have any access to the Product Data and Materials; (B) no Product Data and Materials will be used for the benefit of any Person other than Licensee or its Affiliates; and (C) no Product Data and Materials will be used or
disclosed for any purpose related to any Competing Product. 
 (i) Reverse Royalty. [***]. 

(j) Return of Confidential Information. Within [***] after the effective date of termination (but not expiration) of this Agreement in
its entirety, each Party will, and cause its Affiliates to (i) destroy, all tangible items solely comprising, bearing or containing any Confidential Information of any other Party that are in such first Party’s or its Affiliates’
possession or Control, and provide written certification of such destruction, or (ii) prepare such tangible items of any other Party’s Confidential Information for shipment to such other Party, as such other Party may direct, at the first
Party’s expense; provided, however, that, in any event, (A) each Party may retain copies of the Confidential Information of any other Party to the extent necessary to perform its obligations or exercise its rights that
survive expiration or termination of this Agreement; and (B) each Party may retain one copy of the Confidential Information of any other Party for its legal archives. 

(k) Rights in Bankruptcy. The Parties acknowledge that this Agreement constitutes an executory contract under Section 365 of the
Code for the license of “intellectual property” as defined under Section 101 of the Code and constitutes a license of “intellectual property” for purposes of any similar laws in any other country. The Parties further
acknowledge that each of Company and Licensee will retain and may fully exercise all of its protections, rights and elections under the Code, including Section 365(n) of the Code, and any similar laws in any other country. In the event of the
commencement of a bankruptcy proceeding by or against any of Company and Licensee under the Code and any similar laws in any other country, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any such
intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon its written request
therefor, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i) above, following the rejection of this Agreement by or on behalf of the bankrupt Party upon
written request therefor by the other Party. All rights, powers and remedies of each of Company and Licensee provided for in this Section 12.4(k) are in addition to and not in substitution for any and all other rights,
powers and remedies now or hereafter existing at law or in equity (including under the Code and any similar Laws in any other country). 

(l) Termination Press Releases. In the event of termination of this Agreement for any reason and subject to the provisions of this
Section 12.4, the Parties shall cooperate in good faith to coordinate public disclosure of such termination and the reasons therefor, and shall not disclose such information without the prior approval of each other Party.
The principles to be observed in such disclosures shall be accuracy, compliance with applicable Laws and regulatory guidance documents, and reasonable sensitivity to potential negative investor reaction to such news. 

(m) Cooperation. Each Party will cause its Affiliates, sublicensees and contractors to comply with the obligations in this
Section 12.4. 

  
 51 

 ARTICLE XIII 

DISPUTE RESOLUTION 

Section 13.1. Dispute Resolution; Escalation. Company and Licensee recognize that disputes as to certain matters arising out of or
in connection with this Agreement may arise from time to time. It is the objective of Company and Licensee to establish procedures to facilitate the resolution of disputes arising out of or in connection with this Agreement in an expedited manner by
mutual cooperation. To accomplish this objective, subject to ARTICLE V and Section 13.4, any and all disputes between Company and Licensee arising out of or in connection with this Agreement will first be referred to
the JSC for resolution. Should the JSC not be able to reach agreement at a duly called meeting of the JSC within [***] after the date on which the matter is referred to the JSC, then either Company nor Licensee may refer such matter to the Senior
Officers for resolution and the Senior Officers will attempt to resolve the matter in good faith. If the Senior Officers fail to resolve such matter within [***] after the date on which the matter is first referred to the Senior Officers (unless a
longer period is agreed to by the Parties), then, subject to Section 13.4 and each Party’s final decision-making authority on matters within the purview of the JSC under Section 5.5, either
Company or Licensee may submit the dispute for final resolution by binding arbitration in accordance with Section 13.2. 

Section 13.2. Arbitration. Subject to Section 13.4 and except as set forth in this
Section 13.2, each dispute, difference, controversy or claim arising in connection with or related or incidental to, or question occurring under, this Agreement or the subject matter hereof that cannot be resolved pursuant
to ARTICLE V or Section 13.1 or Section 13.4 will be referred to and finally resolved by arbitration in accordance with the International Chamber of Commerce Rules (the
“Rules”), by an arbitral tribunal composed of three (3) arbitrators, all of whom will have previous judicial experience and significant experience in the pharmaceutical industry, with each of Company and Licensee appointing one
arbitrator and the third arbitrator to be selected by mutual agreement of the two (2) arbitrators appointed by the Parties. If the two initial arbitrators are unable to select a third arbitrator within [***], the third arbitrator will be
appointed in accordance with the Rules. The foregoing arbitration proceedings may be commenced by either Party by notice to the other Party. Unless otherwise agreed by the Parties hereto, all such arbitration proceedings will be held in [***];
provided, however, that proceedings may be conducted by telephone conference call with the consent of the Parties and the arbitrators. All arbitration proceedings and communications will be conducted in the English language. The
arbitrators will consider grants of equitable relief and orders for specific performance as co-equal remedies along with awards of monetary damages. The arbitrators will have no authority to award punitive
damages. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrators, or, in the absence of such determination, each of Company and Licensee will pay its own expenses. The Parties
hereby agree that the arbitrators have authority to issue rulings and orders regarding all procedural and evidentiary matters that the arbitrators deem reasonable and necessary with or without petition therefore by the Parties as well as the final
ruling and judgment. All rulings by the arbitrators will be final. Notwithstanding any contrary provision of this Agreement, any Party may seek equitable measures of protection in the form of attachment of assets or injunctive relief (including
specific performance and injunctive relief) in any matter relating to the proprietary rights and interests of any Party from any court of competent jurisdiction, pending a decision by the arbitral tribunal in accordance with this
Section 13.2). The Parties hereby exclude any right of appeal to any court on the merits of such matter. The provisions of this Section 13.2 may be enforced and judgment on the award (including
equitable remedies) granted in any arbitration hereunder may be entered in any court having jurisdiction over the award or any of the Parties or any of their respective assets. Except to the extent necessary to confirm an award or as may be required
by Laws, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. The Parties agree that, in the event of a dispute over the nature or quality of
performance under this Agreement, neither Company nor Licensee may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. Nothing in this Section 13.2 will
preclude any Party from seeking interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during
any arbitration if necessary to protect the interests of such Party or to 

  
 52 

 
preserve the status quo pending the arbitration proceeding. Notwithstanding the Parties’ agreement to arbitrate, unless the Parties agree in writing in any particular case, claims and
disputes between the Parties relating to or arising out of, or for which resolution depends in whole or in part on a determination of the interpretation, scope, validity, enforceability or infringement of, Patent Rights or of any Product Marks will
not be subject to arbitration under this Agreement, and the Parties may pursue whatever rights and remedies may be available to them under law or equity, including litigation in a court of competent jurisdiction, with respect to such claims and
disputes. 
 Section 13.3. Jury Waiver. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY
WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES TO ARBITRATE AS SET FORTH IN Section 13.2 (ARBITRATION). THIS
WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. 
 Section 13.4. Excluded
Matters. Notwithstanding the foregoing or anything to the contrary in this Agreement, (a) if any matter is within the scope of the JSC’s authority, the provisions of Section 5.5 will initially apply with
respect to such matter; and (b) if this Agreement expressly provides that such matter is subject to a Party’s discretion, a Party’s sole decision-making authority, a Referee’s final decision-making authority (with respect to a
Development Key Milestone Deadlock) or an Expert Panel’s final decision-making authority (with respect to a Regulatory Deadlock), such matter will not be subject to dispute resolution under this ARTICLE XIII, but may be finally
determined by such Party in accordance with the terms of this Agreement. 
 ARTICLE XIV 

MISCELLANEOUS 

Section 14.1. Assignment; Sale Transactions; Successors. 

(a) Assignment. Except as expressly set forth in this Section 14.1, this Agreement and the rights and
obligations of each Party under this Agreement will not be assignable, delegable, transferable, pledged or otherwise disposed of by any Party without the prior written consent of the other Parties. Any assignment or attempted assignment in violation
of this Section 14.1 will be null and void, and of no legal effect. 
 (b) Permitted Assignment by Licensee and
Sale Transactions. Licensee may assign or transfer this Agreement together with all of its rights and obligations hereunder, without the prior consent of Company (but with written notice to Company), (i) to an Affiliate, so long as such Person
remains an Affiliate of Licensee; or (ii) to a [***] that acquires (whether by merger, reorganization, acquisition, sale or otherwise) all or substantially all of the assets of Licensee, LianBio, or Lian Cardiovascular (a “Sale
Transaction”). If LianBio decides to seek or receives a bona fide Third Party offer that LianBio wishes to accept or commence negotiations for, a Sale Transaction of Lian Cardiovascular prior to an initial public offering of LianBio
or Lian Cardiovascular, then Licensee will promptly notify Company in writing of such decision or offer [***]. [***] 
 (c) Permitted
Assignment by Company. 
 (i) Company may assign without the prior consent of any other Party to this Agreement and its rights and
obligations hereunder in whole or in part to an Affiliate of Company or to its successor-in-interest in connection with the sale of all or substantially all of its stock
or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction. 
  

  
 53 

 (ii) Company may assign without the prior consent of any other Party its right to receive
payments under this Agreement or grant any security interest in its rights, title and interest in this Agreement, in whole or in part and in their entirety or in portions, to a financial investor in connection with a financing transaction, subject
to Licensee’s right of first negotiation set forth below. In the event that Company desires to commence negotiations with any Third Party with respect to the foregoing, Company shall promptly notify Licensee in writing of its intent to enter
into such a transaction. Within [***] after Company serving such notice to Licensee, if Licensee notifies Company in writing that it desires in good faith to negotiate an agreement with respect to such transaction, Company and Licensee shall
exclusively negotiate in good faith for up to [***] and non-exclusively negotiate in good faith thereafter for up to [***] from the date of such notice to Company regarding the terms of the definitive
agreement of such transaction. If Licensee (A) gives notice that it does not wish to negotiate for such agreement; (B) fails to timely serve a notice to Company before the expiration of the [***] notice period abovementioned; or
(C) gives a timely notice to Company but Company and Licensee fail to enter into a definitive agreement in writing before the expiration of the combined [***] period abovementioned, then Company shall be free to enter into such transaction with
any Third Party. 
 (d) Successors. Any permitted assignment of the rights and obligations of a Party under this Agreement will be
binding on, and inure to the benefit of and be enforceable by and against, the successors and permitted assigns of the assigning Party. The permitted assignee or transferee will assume all obligations of its assignor or transferor under this
Agreement. 
 Section 14.2. Guarantee by LianBio. LianBio hereby [***] guarantees to Company the full and prompt payment of all
undisputed fees and any and all other undisputed sums and charges payable by Licensee under this Agreement. LianBio hereby covenants and agrees that if default shall at any time be made by Licensee in the payment of any such fees, LianBio will pay
to Company, within [***] of written notice from Company of such default to LianBio, such fees and other sums and charges due to Company. Notwithstanding anything to the contrary contained in this Agreement, LianBio shall be a party to this Agreement
only with respect to this Section 14.2. 
 Section 14.3. Choice of Laws. This Agreement will be
governed by and interpreted under the Laws of the State of New York, without regard to the conflicts of law principles thereof. Except as otherwise expressly provided under this Agreement, any dispute, controversy, claim or difference of any kind
whatsoever arising out of or in connection with this Agreement will be resolved exclusively in accordance with Section 13.2; provided, however, that all questions concerning (a) inventorship of Patent
Rights under this Agreement will be determined in accordance with Section 7.1 and (b) the construction or effect of Patent Rights will be determined in accordance with the Laws of the country, Region or other
jurisdiction in which the particular patent within such Patent Rights has been filed or granted, as the case may be. The Parties agree to exclude the application to this Agreement of the United Nations Conventions on Contracts for the International
Sale of Goods (1980). 
 Section 14.4. Notices. Any notice or report required or permitted to be given or made under this
Agreement by one Party to any other Party will be in writing and will be deemed to have been delivered (a) upon personal delivery (upon written confirmation of receipt), (b) when received by the addressee, if sent by a reputable,
internationally recognized overnight courier that maintains records of delivery, (c) by email delivery (upon written confirmation of receipt), and (d) in the case of notices provided by telecopy (which notice will be followed immediately
by an additional notice pursuant to clause (a) or (b) above if the notice is of a default under this Agreement), upon completion of transmission, with transmission confirmed, to the addressee’s facsimile machine, as follows (or at such
other addresses or facsimile numbers as may have been furnished in writing by a Party to another Party as provided in this Section 14.4). This Section 14.4 is not intended to govern the day-to-day business communications necessary among the Parties in performing their obligations under the terms of this Agreement. 

  
 54 

			
	If to Company:	  	 MyoKardia, Inc.
 [***]

		
	With copies to:	  	[***]
		
	If to Licensee or LianBio:	  	 LianBio
 c/o Ogier Global (Cayman) Limited

89 Nexus Way
 Camana Bay

Grand Cayman
 Cayman Islands
KY1-9009
 Attention: Bing Li, Chief Executive Officer

		
	With copies to:	  	 Ropes & Gray LLP
 36F Park Place

1601 Nanjing Road West
 Shanghai, China 200040

Attention: Eric Wu
 Fax: 86-21-6157-5299
 Email: Eric.Wu@ropesgray.com

 Section 14.5. Severability. In the event that one or more provisions of this Agreement is held
invalid, illegal or unenforceable in any respect, then such provision will not render any other provision of this Agreement invalid or unenforceable, and all other provisions will remain in full force and effect and will be enforceable, unless the
provisions that have been found to be invalid or unenforceable will substantially affect the remaining rights or obligations granted or undertaken by any Party. The Parties agree to attempt to substitute for any invalid or unenforceable provision a
provision which achieves to the greatest extent possible the economic objectives of the invalid or unenforceable provision. 

Section 14.6. Integration. This Agreement, together with all schedules and exhibits attached hereto, constitutes the entire
agreement among the Parties with respect to the subject matter of this Agreement and supersedes all previous arrangements among the Parties with respect to the subject matter hereof, whether written or oral, including the Prior CDA. In the event of
a conflict between the Development Plan or any schedules or attachments to this Agreement, on the one hand, and this Agreement, on the other hand, the terms of this Agreement will govern. Each Party confirms that it is not relying on any
representations or warranties of the other Parties except as specifically set forth in this Agreement. 
 Section 14.7. Waivers and
Amendments. The failure of any Party to assert a right under this Agreement or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform
any such term or condition by any other Party. The exercise by any Party of any right or election under the terms or covenants herein will not preclude or prejudice any Party from exercising the same or any other right it may have under this
Agreement, irrespective of any previous action or proceeding taken by the Parties hereunder. Notwithstanding the authority granted to the JSC under this Agreement, (a) no waiver will be effective unless it has been given in writing and signed
by the Party giving such waiver, and (b) no provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party. 

  
 55 

 Section 14.8. Independent Contractors; No Agency. No Party will have any
responsibility for the hiring, firing or compensation of any other Party’s or such other Party’s Affiliates’ employees or for any employee benefits with respect thereto. No employee or representative of a Party or its Affiliates will
have any authority to bind or obligate any other Party for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on such other Party, without such other Party’s written approval. For all purposes, and
notwithstanding any other provision of this Agreement to the contrary, as between Company and Licensee, each Party’s legal relationship under this Agreement to the other Party will be that of independent contractor, and the relationship between
the Parties will not constitute a partnership, joint venture, or agency, including for all tax purposes, except as otherwise required by applicable Laws. 

Section 14.9. Affiliates, Sublicensees, and Contractors. To the extent that this Agreement imposes obligations on
Affiliates, sublicensees or contractors of a Party, such Party will cause its Affiliates and its sublicensees and contractors to perform such obligations, as applicable. Either Company or Licensee may use one or more of its Affiliates, sublicensees
or contractors to perform its obligations and duties or exercise its rights under this Agreement; provided, however, that (a) each such Affiliate, sublicensee or contractor will perform any such obligations delegated to it in
compliance with the applicable terms and conditions of this Agreement, (b) the performance of any obligations of a Party by its Affiliates, sublicensees or contractors will not diminish, reduce or eliminate any obligation of such Party under
this Agreement, and (c) subject to such Party’s assignment to an Affiliate pursuant to Section 14.1, such Party will remain liable under this Agreement for the prompt payment and performance of all of its
obligations under this Agreement. 
 Section 14.10. Force Majeure. Neither Party will be held liable to the other Party nor be
deemed to have defaulted under or breached this Agreement for failure or delay performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from acts of God, embargoes, war, acts of war (whether war
be declared or not), terrorism, insurrections, riots, civil commotions, strikes, lockouts, or other labor disturbances (other than strikes, lockouts, or labor disturbances involving a Party’s own employees), government actions, fire,
earthquakes, floods, epidemics, pandemics or quarantines (a “Force Majeure Event”) and for so long as such failure or delay continues to be caused by or result from such Force Majeure Event. The Parties agree the effects of the COVID-19 pandemic that is ongoing as of the Effective Date may be invoked as a Force Majeure Event for the purposes of this Agreement even though the pandemic is ongoing solely to the extent those effects are not
reasonably foreseeable by the Parties as of the Effective Date. The affected Party will notify the other Party in writing of any Force Majeure Event that may affect its performance under this Agreement as soon as reasonably practical, will provide a
good faith estimate of the period for which its failure or delay in performance under this Agreement is expected to continue based on currently available information, and will undertake reasonable efforts necessary to mitigate and overcome such
Force Majeure Event and resume normal performance of its obligations hereunder as soon a reasonably practicable under the circumstances. If the Force Majeure Event continues, then the affected Party will update such notice to the other Party on a
weekly basis to provide updated summaries of its mitigation efforts and its estimates of when normal performance under this Agreement will be able to resume. 

Section 14.11. No Third Party Beneficiary Rights. The representations, warranties, covenants and agreements set forth in this
Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they will not be construed as conferring any rights on any other Person. This Agreement is not intended to and will not be construed to give any Third
Party any interest or rights (including any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, other than, to the extent provided in ARTICLE X, the
Indemnified Parties. 
 Section 14.12. Non-exclusive Remedy. Except as expressly
provided herein, the rights and remedies provided herein are cumulative and each Party retains all remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief, with respect to any breach of this
Agreement. Neither Company nor Licensee will be required (but, for clarity, will have the right as specified in this Agreement) to terminate this Agreement due to a breach of this Agreement by the other Party. 

  
 56 

 Section 14.13. Interpretation. The Article and Section headings used herein are
for reference and convenience only, and will not enter into the interpretation of this Agreement. Except as otherwise explicitly specified to the contrary, (a) references to an Article, Section or Exhibit means an Article or Section of, or a
Schedule or Exhibit to this Agreement and all subsections thereof, unless another agreement is specified; (b) references in any Section to any clause are references to such clause of such Section; (c) references to any agreement,
instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended, replaced, or supplemented and in
effect at the relevant time of reference thereto; (d) references to a particular Laws mean such Laws as in effect as of the relevant time, including all rules and regulations thereunder and any successor Laws in effect as of the relevant time,
and including the then-current amendments thereto; (e) words in the singular or plural form include the plural and singular form, respectively; (f) unless the context requires a different interpretation, the word “or” has
the inclusive meaning that is typically associated with the phrase “and/or”; (g) the terms “including,” “include(s),” “such as,” “e.g.” and “for
example” mean including the generality of any description preceding such term and will be deemed to be followed by “without limitation”; (h) whenever this Agreement refers to a number of days, such number will refer to
calendar days unless Business Days are specified, and if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day; (i)
“monthly” means on a calendar month basis, (j) “quarter” or “quarterly” means on a Calendar Quarter basis; (k) “annual” or “annually” means on a Calendar Year
basis; (l) “year” means a 365-day period unless Calendar Year is specified; (m) references to a particular Person include such Person’s successors and assigns to the extent not
prohibited by this Agreement; (n) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa); (o) a capitalized term not
defined herein but reflecting a different part of speech than a capitalized term which is defined herein will be interpreted in a correlative manner; (p) any definition of or reference to any agreement, instrument or other document herein will
be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (q) the words
“hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement (including any Exhibits or Schedules); (r) no Party or its Affiliates will be deemed to be acting “on
behalf of” any other Party under this Agreement, except to the extent expressly otherwise provided; (s) provisions that require that a Party, or the JSC hereunder “agree”, “consent” or
“approve” or the like will be deemed to require that such agreement, consent or approval be specific and in writing in a written agreement, letter or approved minutes, but, except as expressly provided herein, excluding e-mail and instant messaging; and (t) the word “will”, when used in context to indicate an obligation, duty, or requirement of a Person, will be construed to have the same meaning and effect as the
word “shall”. 
 Section 14.14. Further Assurances. Each Party will duly execute and deliver, or cause to be duly
executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as any other Party may reasonably
request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

Section 14.15. Ambiguities; No Presumption. Each of the Parties acknowledges and agrees that this Agreement has been diligently
reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the
joint efforts of the Parties and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption will apply against any Party as being responsible for the wording or drafting of this Agreement or any such
provision, and ambiguities, if any, in this Agreement will not be construed against any Party under the rule of construction, irrespective of which Party may be deemed to have authored the ambiguous provision. 

  
 57 

 Section 14.16. Execution in Counterparts; Facsimile Signatures. This Agreement
may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if all Parties have not
executed the same counterpart. Signatures provided by facsimile transmission or in AdobeTM Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures. 

Section 14.17. Export Control. This Agreement is made subject to any restrictions required by applicable Laws concerning the
export of products or technical information from the U.S. or other countries which may be imposed upon or related to the Parties from time to time. Each of Company and Licensee agrees that it will not export, directly or indirectly, any technology
licensed to it or other technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other
governmental approval, except in compliance with U.S. export Laws and regulations. 
 Section 14.18. Language. The language of
this Agreement will be written and executed in the English language, and the English language will control its interpretation. In addition, all notices required or permitted hereunder, and all written, electronic, oral or other communication among
the Parties regarding this Agreement or any dispute or controversy arising out of it, shall be in the English language. Except as expressly otherwise provided, all communications or documents originally in a language other than the English language
shared under or in connection with this Agreement will not be required to be translated into the English language. 
 [Remainder of this
page intentionally blank.] 
  

  
 58 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative under seal, in duplicate on the Effective Date. 
  

	
	 LIANBIO LICENSING, LLC

	
	 /s/ Bing Li

	 Name: Bing Li

	 Title: Authorized Representative

	
	 LIANBIO 

	
	 /s/ Bing Li

	 Name: Bing Li

	 Title: Authorized Representative

 [Signature Page to License Agreement] 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative under seal, in duplicate on the Effective Date. 
  

	
	 MYOKARDIA, INC.

	
	 /s/ Jacob Bauer

	 Name: Jake Bauer

	 Title: Chief Business Officer

 [Signature Page to License Agreement] 

 Exhibit A 

COMPOUND 
 [***] 

  
 Exhibit A 

 Exhibit B 

LICENSED KNOW-HOW 

[***] 

  
 Exhibit B 

 Exhibit C 

LICENSED PATENTS 
 [***]

  
 Exhibit C 

 Exhibit D 

[***] 

  
 Exhibit D 

 Exhibit E 

WARRANT 

  
 Exhibit E 

 Exhibit F 

DEVELOPMENT PLAN 
 [***]

  
 Exhibit F 

 Exhibit G 

SUMMARY COMMERCIAL PLAN 

[***] 

  
 Exhibit G 

 Exhibit H 

CMO QUALIFICATIONS 
 [***]

  
 Exhibit H 

 Exhibit I 

INITIAL PRESS RELEASE 

[***] 

  
 Exhibit I

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]